<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002745.pub4" GROUP_ID="ARI" ID="780800041114324239" MERGED_FROM="" MODIFIED="2014-11-18 04:40:58 +0000" MODIFIED_BY="Liz Dooley" REVIEW_NO="A005" REVMAN_SUB_VERSION="5.3.4 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2014-11-18 04:40:58 +0000" MODIFIED_BY="Liz Dooley">
<TITLE MODIFIED="2013-04-16 06:32:54 +1000" MODIFIED_BY="[Empty name]">Amantadine and rimantadine for influenza A in children and the elderly</TITLE>
<CONTACT MODIFIED="2014-11-18 04:40:58 +0000" MODIFIED_BY="Liz Dooley"><PERSON ID="12227" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Antonio</FIRST_NAME><MIDDLE_INITIALS>JL</MIDDLE_INITIALS><LAST_NAME>Alves da Cunha</LAST_NAME><POSITION>Professor of Pediatrics</POSITION><EMAIL_1>acunha@hucff.ufrj.br</EMAIL_1><EMAIL_2>antonioledo@yahoo.com.br</EMAIL_2><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>School of Medicine, Federal University of Rio de Janeiro</ORGANISATION><ADDRESS_1>Av. Carlos Chagas Filho, 373</ADDRESS_1><ADDRESS_2>Edificio do CCS - Bloco K - 2o. andar, Sala K49</ADDRESS_2><CITY>Rio de Janeiro</CITY><ZIP>21941-902</ZIP><REGION>Rio de Janeiro</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 21 2598 9645</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-11-18 04:40:58 +0000" MODIFIED_BY="Liz Dooley"><PERSON ID="A38B70E882E26AA2013A0934B0498529" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Márcia</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Alves Galvão</LAST_NAME><POSITION>Pediatrician</POSITION><EMAIL_1>marciag@uninet.com.br</EMAIL_1><ADDRESS><ORGANISATION>Municipal Secretariat of Health</ORGANISATION><ADDRESS_1>Avenida Ayrton Senna, 250/ 205</ADDRESS_1><ADDRESS_2>Barra da Tijuca. Alfa Barra 1</ADDRESS_2><CITY>Rio de Janeiro</CITY><ZIP>22793-000</ZIP><REGION>RJ</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 21 2433 2677</PHONE_1><FAX_1>+55 21 2433 3294</FAX_1></ADDRESS></PERSON><PERSON ID="2978742482E26AA2000C5DBB81FF7E86" ROLE="AUTHOR"><FIRST_NAME>Marilene Augusta</FIRST_NAME><LAST_NAME>Rocha Crispino Santos</LAST_NAME><EMAIL_1>marilenecs@terra.com.br</EMAIL_1><ADDRESS><ORGANISATION>Municipal Secretariat of Health</ORGANISATION><ADDRESS_1>Avenida Ayrton Senna, 250/ 205</ADDRESS_1><ADDRESS_2>Barra da Tijuca, Condomínio Alfa Barra 1</ADDRESS_2><CITY>Rio de Janeiro</CITY><ZIP>22793-000</ZIP><REGION>RJ</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 21 2433 2677</PHONE_1><FAX_1>+55 21 2433 3294</FAX_1></ADDRESS></PERSON><PERSON ID="12227" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Antonio</FIRST_NAME><MIDDLE_INITIALS>JL</MIDDLE_INITIALS><LAST_NAME>Alves da Cunha</LAST_NAME><POSITION>Professor of Pediatrics</POSITION><EMAIL_1>acunha@hucff.ufrj.br</EMAIL_1><EMAIL_2>antonioledo@yahoo.com.br</EMAIL_2><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>School of Medicine, Federal University of Rio de Janeiro</ORGANISATION><ADDRESS_1>Av. Carlos Chagas Filho, 373</ADDRESS_1><ADDRESS_2>Edificio do CCS - Bloco K - 2o. andar, Sala K49</ADDRESS_2><CITY>Rio de Janeiro</CITY><ZIP>21941-902</ZIP><REGION>Rio de Janeiro</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 21 2598 9645</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-10-08 15:49:49 +1000" MODIFIED_BY="Liz Dooley">
<UP_TO_DATE>
<DATE DAY="7" MONTH="10" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="10" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="7" MONTH="10" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="11" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-10-08 15:49:41 +1000" MODIFIED_BY="Liz Dooley">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-10-08 09:30:38 +1000" MODIFIED_BY="Liz  Dooley">
<DATE DAY="7" MONTH="10" YEAR="2014"/>
<DESCRIPTION>
<P>Searches conducted. We did not identify any new trials for inclusion. We excluded 20 new trials (<LINK REF="STD-Anton-2011" TYPE="STUDY">Anton 2011</LINK>; <LINK REF="STD-Atiee-2012" TYPE="STUDY">Atiee 2012</LINK>; <LINK REF="STD-Bacosi-2002" TYPE="STUDY">Bacosi 2002</LINK>; <LINK REF="STD-Cayley-2012" TYPE="STUDY">Cayley 2012</LINK>; <LINK REF="STD-Cheng-2012" TYPE="STUDY">Cheng 2012</LINK>; <LINK REF="STD-De-Vincenzo-2012" TYPE="STUDY">De Vincenzo 2012</LINK>; <LINK REF="STD-Escuret-2012" TYPE="STUDY">Escuret 2012</LINK>; <LINK REF="STD-Gatwood-2012" TYPE="STUDY">Gatwood 2012</LINK>; <LINK REF="STD-Hayden-2012" TYPE="STUDY">Hayden 2012</LINK>; <LINK REF="STD-Hsu-2012" TYPE="STUDY">Hsu 2012</LINK>; <LINK REF="STD-Ison-2013" TYPE="STUDY">Ison 2013</LINK>; <LINK REF="STD-Jiang-2013" TYPE="STUDY">Jiang 2013</LINK>; <LINK REF="STD-Lopez_x002d_Medrano-2012" TYPE="STUDY">Lopez-Medrano 2012</LINK>; <LINK REF="STD-Louie-2012" TYPE="STUDY">Louie 2012</LINK>; <LINK REF="STD-Michiels-2013" TYPE="STUDY">Michiels 2013</LINK>; <LINK REF="STD-Sampaio-2011" TYPE="STUDY">Sampaio 2011</LINK>; <LINK REF="STD-Santesso-2013" TYPE="STUDY">Santesso 2013</LINK>; <LINK REF="STD-Shah-2012" TYPE="STUDY">Shah 2012</LINK>; <LINK REF="STD-Singer-2011" TYPE="STUDY">Singer 2011</LINK>; <LINK REF="STD-Yuen-2012" TYPE="STUDY">Yuen 2012</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-10-08 15:49:41 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="7" MONTH="10" YEAR="2014"/>
<DESCRIPTION>
<P>Our conclusions remain unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-06-26 15:25:16 +1000" MODIFIED_BY="Liz Dooley">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-05-05 16:35:26 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="27" MONTH="6" YEAR="2011"/>
<DESCRIPTION>
<P>Searches updated. No new trials fulfilled our inclusion criteria. We excluded 38 new trials (<LINK REF="STD-Bantia-2010" TYPE="STUDY">Bantia 2010</LINK>; <LINK REF="STD-Boltz-2010" TYPE="STUDY">Boltz 2010</LINK>; <LINK REF="STD-Brammer-2009" TYPE="STUDY">Brammer 2009</LINK>; <LINK REF="STD-Burch-2009" TYPE="STUDY">Burch 2009</LINK>; <LINK REF="STD-Cady-2011" TYPE="STUDY">Cady 2011</LINK>; <LINK REF="STD-Carter-2008" TYPE="STUDY">Carter 2008</LINK>; <LINK REF="STD-Cayley-2010" TYPE="STUDY">Cayley 2010</LINK>; <LINK REF="STD-Chawla-2009" TYPE="STUDY">Chawla 2009</LINK>; <LINK REF="STD-Chen-2007" TYPE="STUDY">Chen 2007</LINK>; <LINK REF="STD-Cheng-2009" TYPE="STUDY">Cheng 2009</LINK>; <LINK REF="STD-Choi-2009" TYPE="STUDY">Choi 2009</LINK>; <LINK REF="STD-Chou-2008" TYPE="STUDY">Chou 2008</LINK>; <LINK REF="STD-Cowling-2008" TYPE="STUDY">Cowling 2008</LINK>; <LINK REF="STD-Curran-2010" TYPE="STUDY">Curran 2010</LINK>; <LINK REF="STD-De-la-Camara-2007" TYPE="STUDY">De la Camara 2007</LINK>; <LINK REF="STD-DeLaney-2010" TYPE="STUDY">DeLaney 2010</LINK>; <LINK REF="STD-Falagas-2010" TYPE="STUDY">Falagas 2010</LINK>; <LINK REF="STD-Farlow-2008" TYPE="STUDY">Farlow 2008</LINK>; <LINK REF="STD-Fiore-2008" TYPE="STUDY">Fiore 2008</LINK>; <LINK REF="STD-Guo-2007" TYPE="STUDY">Guo 2007</LINK>; <LINK REF="STD-Hota-2007" TYPE="STUDY">Hota 2007</LINK>; <LINK REF="STD-Kalia-2008" TYPE="STUDY">Kalia 2008</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kirkby-2010" TYPE="STUDY">Kirkby 2010</LINK>; <LINK REF="STD-Korenke-2008" TYPE="STUDY">Korenke 2008</LINK>; <LINK REF="STD-Langlet-2009" TYPE="STUDY">Langlet 2009</LINK>; <LINK REF="STD-Matheson-2007" TYPE="STUDY">Matheson 2007</LINK>; <LINK REF="STD-Miyachi-2011" TYPE="STUDY">Miyachi 2011</LINK>; <LINK REF="STD-Moffat-2008" TYPE="STUDY">Moffat 2008</LINK>; <LINK REF="STD-Morrison-2007" TYPE="STUDY">Morrison 2007</LINK>; <LINK REF="STD-Nuesch-2007" TYPE="STUDY">Nuesch 2007</LINK>; <LINK REF="STD-Sato-2008" TYPE="STUDY">Sato 2008</LINK>; <LINK REF="STD-Simeonova-2009" TYPE="STUDY">Simeonova 2009</LINK>; <LINK REF="STD-Tappenden-2009" TYPE="STUDY">Tappenden 2009</LINK>; <LINK REF="STD-Thomas-2008" TYPE="STUDY">Thomas 2008</LINK>; <LINK REF="STD-Wailoo-2008" TYPE="STUDY">Wailoo 2008</LINK>; <LINK REF="STD-Welton-2008" TYPE="STUDY">Welton 2008</LINK>; <LINK REF="STD-Whitley-2007" TYPE="STUDY">Whitley 2007</LINK>). </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-06-26 15:25:16 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="29" MONTH="4" YEAR="2011"/>
<DESCRIPTION>
<P>Our conclusions remain unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-02-18 10:14:23 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>No changes - republished to fix technical problem.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2009-05-14 00:00:33 +1000" MODIFIED_BY="Paolo Rosati">
<DATE DAY="12" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Feedback comment added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-05-14 00:00:33 +1000" MODIFIED_BY="Paolo Rosati">
<DATE DAY="25" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-02-18 10:14:12 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="7" YEAR="2007"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-11-18 14:25:49 +1000" MODIFIED_BY="Liz  Dooley">
<SUMMARY MODIFIED="2014-11-18 14:25:49 +1000" MODIFIED_BY="Liz  Dooley">
<TITLE MODIFIED="2011-09-14 10:10:39 +1000" MODIFIED_BY="[Empty name]">Amantadine and rimantadine to prevent and treat influenza A in children and the elderly</TITLE>
<SUMMARY_BODY MODIFIED="2014-11-18 14:25:49 +1000" MODIFIED_BY="Liz  Dooley">
<P>
<B>Review question</B>
</P>
<P>As recommended by the World Health Organization (WHO), oseltamivir (Tamiflu) is currently used for people with influenza A. In previous pandemics, the virus was susceptible to amantadine and rimantadine. If they are safe and the circulating strain proves to be susceptible to these drugs, they could be an alternative for managing influenza. We therefore wanted to answer the question of whether or not amantadine and rimantadine can prevent and treat influenza A in children and the elderly.</P>
<P>
<B>Background</B>
</P>
<P>Influenza A is a respiratory infection causing cough, runny nose and fever. Most symptoms pass without treatment within three to seven days. However, hospitalisation, pneumonia and even death are rare complications of the illness, especially among children and the elderly. Pandemics are also a cause for concern.</P>
<P>
<B>Key results and quality of the evidence</B>
</P>
<P>We identified 12 trials (2494 participants: 1586 children and 908 elderly). We looked for trials that compared amantadine or rimantadine with no intervention, placebos or control drugs in children and the elderly. The most recent searches were completed in October 2014. We looked at several outcomes, including influenza A, fever duration, cough, headache, nausea/vomiting, dizziness and stimulation/insomnia.<BR/>
</P>
<P>Although amantadine was effective in preventing influenza A in children, it would be necessary to use it in up to 17 children over a period of 14 to 18 weeks to prevent one case of influenza A. Furthermore, the safety of the drug was not well established. The quality of the evidence was low.<BR/>
</P>
<P>The effectiveness of both antivirals was limited to a benefit from rimantadine in the reduction of fever by day three of treatment in children. The quality of the evidence was moderate. This benefit does not seem to justify a recommendation for using rimantadine to treat all children with influenza A.</P>
<P>Rimantadine did not show a prophylactic (preventative) effect in the elderly. The quality of evidence was very low.</P>
<P>
<B>Conclusion</B>
</P>
<P>The quality of the evidence combined with a lack of knowledge about the safety of amantadine and the limited benefits of rimantadine, do not indicate that amantadine and rimantadine compared to control (placebo or paracetamol) could be useful in preventing, treating and shortening the duration of influenza A in children and the elderly.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-11-18 14:24:42 +1000" MODIFIED_BY="Liz  Dooley">
<ABS_BACKGROUND MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Influenza is an acute respiratory illness caused by influenza A and B viruses. Complications may occur, especially among children and the elderly.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-10-07 08:49:50 +1000" MODIFIED_BY="Liz  Dooley">
<P>To assess the effectiveness and safety of amantadine and rimantadine in preventing, treating and shortening the duration of influenza A in children and the elderly.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-10-08 09:32:22 +1000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (2014, Issue 9), MEDLINE (1966 to September week 4, 2014) and EMBASE (1980 to October 2014).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-06-26 15:06:39 +1000" MODIFIED_BY="Liz Dooley">
<P>Randomised controlled trials (RCTs) or quasi-RCTs comparing amantadine and/or rimantadine with no intervention, placebo, other antivirals or different doses or schedules of amantadine or rimantadine in children and the elderly with influenza A.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed the search results. We extracted and analysed data using the standard Cochrane methodology.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-11-11 09:39:41 +1000" MODIFIED_BY="[Empty name]">
<P>We identified 12 studies (2494 participants: 1586 children and 908 elderly) comparing amantadine and rimantadine with placebo, paracetamol (one trial: 69 children) or zanamivir (two trials: 545 elderly) to treat influenza A.</P>
<P>Amantadine was effective in preventing influenza A in children (773 participants, risk ratio (RR) 0.11; 95% confidence interval (CI) 0.04 to 0.30). The assumed risk of influenza A in the control group was 10 per 100. The corresponding risk in the rimantadine group was one per 100 (95% CI 0 to 3). Nevertheless, the quality of the evidence was low and the safety of the drug was not well established.</P>
<P>For treatment, rimantadine was beneficial in abating fever on day three of treatment in children: one selected study with low risk of bias, moderate evidence quality and 69 participants (RR 0.36; 95% CI 0.14 to 0.91). The assumed risk was 38 per 100. The corresponding risk in the rimantadine group was 14 per 100 (95% CI 5 to 34).</P>
<P>Rimantadine did not show any prophylactic effect in the elderly. The quality of evidence was very low: 103 participants (RR 0.45; 95% CI 0.14 to 1.41). The assumed risk was 17 per 100. The corresponding risk in the rimantadine group was 7 per 100 (95% CI 2 to 23).</P>
<P>There was no evidence of adverse effects caused by treatment with amantadine or rimantadine.</P>
<P>We found no studies assessing amantadine in the elderly.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-11-18 14:24:42 +1000" MODIFIED_BY="Liz  Dooley">
<P>The quality of the evidence combined with a lack of knowledge about the safety of amantadine and the limited benefits of rimantadine, do not indicate that amantadine and rimantadine compared to control (placebo or paracetamol) could be useful in preventing, treating and shortening the duration of influenza A in children and the elderly.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-11-12 10:04:15 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Influenza is an acute and usually self limiting respiratory illness caused by influenza A and B viruses, which are members of the <I>Orthomyxoviridae</I> family (<LINK REF="REF-Nicholson-1992" TYPE="REFERENCE">Nicholson 1992</LINK>). Influenza may cause annual epidemics and intermittent pandemics (<LINK REF="REF-Sasaki-2011" TYPE="REFERENCE">Sasaki 2011</LINK>). Typically, seasonal influenza occurs most frequently during autumn and winter in temperate regions, but in some tropical countries it may occur throughout the year with one or two peaks during rainy seasons (<LINK REF="REF-Monto-2008" TYPE="REFERENCE">Monto 2008</LINK>; <LINK REF="REF-Yang-2010" TYPE="REFERENCE">Yang 2010</LINK>).</P>
<P>Although the natural transmission of the influenza virus predominantly occurs via aerosols dispersed by coughing or sneezing, it is also transmitted by nasal secretions and contact with contaminated surfaces. While all respiratory viruses, including influenza, use the nose as the entry channel, they can also enter through the tear ducts, draining into patients' sinuses and airways (<LINK REF="REF-Bitko-2007" TYPE="REFERENCE">Bitko 2007</LINK>). The virus particles are deactivated by the ultraviolet rays in sunlight and common disinfectants such as soap (<LINK REF="REF-Barik-2012" TYPE="REFERENCE">Barik 2012</LINK>).</P>
<P>The illness is characterised by an abrupt onset of symptoms. These symptoms include headache, fever, general aches, weakness and myalgia, accompanied by respiratory tract signs, particularly cough and sore throat. However, a wide spectrum of clinical presentations may occur, ranging from a mild, febrile upper respiratory illness, to severe prostration and respiratory and systemic signs and symptoms.</P>
<P>The most common complication that occurs during outbreaks of influenza is pneumonia (both viral and bacterial). A number of extra-pulmonary complications may also occur. These include Reye's syndrome in children (most commonly between two and 16 years of age), myocarditis, pericarditis and central nervous system (CNS) diseases. Again these include encephalitis, transverse myelitis and Guillain-Barré syndrome (<LINK REF="REF-Barik-2012" TYPE="REFERENCE">Barik 2012</LINK>; <LINK REF="REF-Wiselka-1994" TYPE="REFERENCE">Wiselka 1994</LINK>).</P>
<P>An interesting and clinically relevant aspect of pandemic and epidemic influenza that sets it apart from seasonal influenza is the induction of the so-called cytokine storm, consisting of interleukin-6, tumour necrosis factor and interferon-g. Together, these proinflammatory cytokines cause systemic inflammatory response syndrome, leading to multi-organ failure that includes airway destruction, vascular endothelial damage and plasma leakage (<LINK REF="REF-Barik-2012" TYPE="REFERENCE">Barik 2012</LINK>; <LINK REF="REF-Cheung-2002" TYPE="REFERENCE">Cheung 2002</LINK>)</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Nowadays there are two main measures for the treatment and prophylaxis of influenza viruses: immunisation using influenza vaccines directly isolated from influenza A and B viruses and antiviral agents (<LINK REF="REF-Demicheli-2000" TYPE="REFERENCE">Demicheli 2000</LINK>; <LINK REF="REF-Noah-2013" TYPE="REFERENCE">Noah 2013</LINK>). Vaccination is the primary strategy for the prevention of influenza (<LINK REF="REF-Antanova-2012" TYPE="REFERENCE">Antanova 2012</LINK>; <LINK REF="STD-Hsu-2012" TYPE="STUDY">Hsu 2012</LINK>). Nevertheless, there are a number of likely scenarios for which effective antiviral agents would be of utmost importance. For example, the available evidence on the safety, efficacy or effectiveness of influenza vaccines for people aged 65 years or older is of poor quality (<LINK REF="REF-Jefferson-2010" TYPE="REFERENCE">Jefferson 2010</LINK>; <LINK REF="REF-Thomas-2011" TYPE="REFERENCE">Thomas 2011</LINK>). Vaccination among the elderly may not be as effective as their immune systems are less responsive (<LINK REF="REF-Sasaki-2011" TYPE="REFERENCE">Sasaki 2011</LINK>). Influenza vaccines are efficacious in children older than two but little evidence is available for children under two (<LINK REF="REF-Demicheli-2012" TYPE="REFERENCE">Demicheli 2012</LINK>). During any influenza season, antigenic drift in the virus may occur after formulation of the year's vaccine. The vaccine can therefore be less protective and outbreaks can more easily occur in high-risk populations. In the course of a pandemic, vaccine supplies would be inadequate. Moreover, vaccine production by current methods cannot be carried out with the speed required to halt the progress of a new strain of influenza virus. Therefore, it is likely that vaccines would not be available for those infected by the first wave of the virus (<LINK REF="REF-Hayden-2004" TYPE="REFERENCE">Hayden 2004</LINK>). Additionally, in a study published in 2013, the author stated that vaccination-only strategies were not cost-effective for any pandemic scenario, saving few lives and incurring substantial vaccination costs (<LINK REF="REF-Kelso-2013" TYPE="REFERENCE">Kelso 2013</LINK>). Vaccination, coupled with long duration social distancing, antiviral treatment and antiviral prophylaxis, was considered to be cost-effective for moderate and extreme pandemics, as it can save lives while simultaneously reducing the total pandemic cost (<LINK REF="REF-Kelso-2013" TYPE="REFERENCE">Kelso 2013</LINK>). Antiviral agents therefore form an important part of a rational approach to influenza management (<LINK REF="REF-Kelso-2013" TYPE="REFERENCE">Kelso 2013</LINK>; <LINK REF="REF-Moscona-2005" TYPE="REFERENCE">Moscona 2005</LINK>). </P>
<P>Antiviral drugs for influenza are currently divided into two classes: M2 ion channel inhibitors and neuraminidase inhibitors. The first class includes amantadine and rimantadine and the latter zanamivir, oseltamivir, laninamivir (approved in Japan) and peramivir (approved in Japan and Korea) (<LINK REF="REF-Barik-2012" TYPE="REFERENCE">Barik 2012</LINK>). M2 ion channel inhibitors affect ion channel activity through the cell membrane and are reported to be effective by interfering with the replication cycle of type A viruses (but not type B). The neuraminidase inhibitors interfere with the release of influenza virus progeny from infected host cells and are effective against influenza A and B (<LINK REF="REF-Moscona-2005" TYPE="REFERENCE">Moscona 2005</LINK>). Both drug classes have shown partial effectiveness for the prevention and treatment of influenza A viruses, although neuraminidase inhibitors are less likely to promote the development of drug-resistant influenza (<LINK REF="REF-Moscona-2005" TYPE="REFERENCE">Moscona 2005</LINK>).</P>
<P>Resistance to M2 inhibitors remained low until 2003 (<LINK REF="REF-Bright-2005" TYPE="REFERENCE">Bright 2005</LINK>; <LINK REF="REF-Ziegler-1999" TYPE="REFERENCE">Ziegler 1999</LINK>). An epidemiological study into resistance to amantadine carried out from 1991 to 1995 described a frequency of 1% (16/2017) of resistant variants among H1N1 and H3N2 viruses (<LINK REF="REF-Ziegler-1999" TYPE="REFERENCE">Ziegler 1999</LINK>). However, there was a subsequently a dramatic increase in strains of influenza A (H3N2) with a specific mutation (Ser31Asn). An increase in resistance to amantadine was showed in communities located in Asia and North America (<LINK REF="REF-Bright-2005" TYPE="REFERENCE">Bright 2005</LINK>; <LINK REF="REF-Bright-2006" TYPE="REFERENCE">Bright 2006</LINK>). This resistance in 70% to 90% of strains occurred despite the absence of sustained selective drug pressure (<LINK REF="REF-Bright-2005" TYPE="REFERENCE">Bright 2005</LINK>; <LINK REF="REF-Bright-2006" TYPE="REFERENCE">Bright 2006</LINK>).</P>
<P>During the 2005 to 2006 season, 16% of H1N1 and 91% of H3N2 viruses were resistant around the world. Although the estimate for the proportion of resistance in H1N1 viruses was very low, an analysis conducted in China showed that the frequency of resistant H1N1 viruses had greatly increased from 28% (8/29) in the 2004 to 2005 season to 72% (33/46) in the 2005 to 2006 season. Similar studies were conducted in other countries in the 2005 to 2006 season. The following frequencies of resistance were obtained: 45% (13/29) in Europe, 24% (4/17) in Taiwan and 33% (1/3) in Canada (<LINK REF="REF-Deyde-2007" TYPE="REFERENCE">Deyde 2007</LINK>).</P>
<P>A global pandemic emerged in 2009, caused by a new influenza A strain (H1N1) (<LINK REF="REF-WHO-2010a" TYPE="REFERENCE">WHO 2010a</LINK>). All influenza A (H1N1) viruses tested in WHO Collaborating Centres to date have been shown to be resistant to amantadine and rimantadine (<LINK REF="REF-WHO-2011" TYPE="REFERENCE">WHO 2011</LINK>; <LINK REF="REF-WHO-2012" TYPE="REFERENCE">WHO 2012</LINK>).</P>
<P>When an avian influenza A (H7N9) virus was detected as the cause of human infections in China, its susceptibility to antiviral drugs was assessed. The outbreak viruses carried the established adamantine resistance marker. Once again neuraminidase inhibitors remained the only licensed treatment option (<LINK REF="REF-Li-2014" TYPE="REFERENCE">Li 2014</LINK>).</P>
<P>Influenza A resistance to amantadine and rimantadine has been frequently reported over the last few years and, as such, it may seem unnecessary to continue testing sensitivity to these drugs. However, patterns of sensitivity and resistance of influenza viruses to antiviral drugs may change over time and so we consider it necessary to continue monitoring sensitivity and resistance.</P>
</INTERVENTION>
<THEORY MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>The use of amantadine and rimantadine for the treatment and prevention of influenza A in adults has already been the topic of a review (<LINK REF="REF-Jefferson-2006b" TYPE="REFERENCE">Jefferson 2006b</LINK>). The results of that review confirmed that amantadine and rimantadine had a comparable efficacy and effectiveness in the treatment of influenza A in healthy adults, although their effectiveness in interrupting transmission was probably low. As previous pandemics proved to be susceptible to this class of drugs, it seems reasonable to review the evidence for amantadine and rimantadine for treating and preventing influenza A in children and the elderly (<LINK REF="REF-Hayden-2006b" TYPE="REFERENCE">Hayden 2006b</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Although the disease occurs in all age groups (<LINK REF="REF-Pineda-Solas-2006" TYPE="REFERENCE">Pineda Solas 2006</LINK>), the risks of complications, hospitalisations and deaths from influenza are higher among three groups of people: 1) persons older than 65 years; 2) young children; and 3) persons of any age who have medical conditions that place them at increased risk. Rates of infection are highest amongst children and they are also one of the most important links for transmission (<LINK REF="REF-Dolin-2005" TYPE="REFERENCE">Dolin 2005</LINK>).</P>
<P>Pandemics occur when influenza spreads globally, infecting 20% to 40% of the world's population in one year. This results in as many as 10 million deaths (<LINK REF="REF-WHO-2003" TYPE="REFERENCE">WHO 2003</LINK>). They usually arise in China, where pigs, ducks and humans live in close proximity to each other, and spread westward to the rest of Asia, Europe and the Americas (<LINK REF="REF-Bonn-1997" TYPE="REFERENCE">Bonn 1997</LINK>). In the past 110 years there have been five pandemics caused by different influenza A viral subtypes. The Spanish influenza pandemic (1918 to 1919) is considered to have caused an estimated 40 million deaths worldwide. Most years, typical influenza epidemics infect 5% to 20% of the population and result in anywhere between 250,000 and 500,000 deaths, according to the World Health Organization (WHO), although other estimates accounting for deaths due to complications of influenza are as high as 1 million to 1.5 million.</P>
<P>In 2009, a new influenza A strain (H1N1) caused a global pandemic. According to the WHO, as of 24 January 2010, more than 214 countries and overseas territories had reported laboratory-confirmed cases of pandemic influenza H1N1, resulting in at least 18,449 deaths (<LINK REF="REF-WHO-2010a" TYPE="REFERENCE">WHO 2010a</LINK>).</P>
<P>In an earlier version of a Cochrane review in adults, the review authors stated that neuraminidase inhibitors were effective in reducing symptoms and complications, however there are now doubts about their effectiveness against complications (<LINK REF="REF-Jefferson-2014" TYPE="REFERENCE">Jefferson 2014</LINK>).</P>
<P>In a Cochrane review published in 2007, the review authors concluded that oseltamivir may be considered for the treatment of children aged one to 12 years with influenza infection (<LINK REF="STD-Matheson-2007" TYPE="STUDY">Matheson 2007</LINK>). This antiviral is likely to shorten the duration of symptoms, hasten the return to normal activities and reduce the incidence of secondary complications. Nevertheless, the review authors also concluded that more data were needed to clarify the benefits of neuraminidase inhibitors for the treatment of influenza in asthmatic children (including addressing the potential confounder of prior vaccination).</P>
<P>Nowadays, neuraminidase inhibitors are used as a prescription drug for patients suffering from influenza on the recommendation of the WHO (<LINK REF="REF-WHO-2010b" TYPE="REFERENCE">WHO 2010b</LINK>). Governments have spent billions of dollars stockpiling neuraminidase inhibitors as a public health measure (<LINK REF="REF-WHO-2010b" TYPE="REFERENCE">WHO 2010b</LINK>). In previous pandemics, the influenza A virus was susceptible to amantadine and rimantadine. Therefore, these antivirals could be a less expensive alternative in the management of influenza if the circulating strain proves to be susceptible to amantadine and rimantadine (<LINK REF="REF-Hayden-2006b" TYPE="REFERENCE">Hayden 2006b</LINK>). However, we should emphasise the resistance patterns of the pandemic viruses in 2009. All influenza A (H1N1) viruses tested in WHO Collaborating Centres to date were sensitive to zanamivir and all were resistant to amantadine and rimantadine (<LINK REF="REF-WHO-2011" TYPE="REFERENCE">WHO 2011</LINK>).</P>
<P>These facts reinforce the importance of conducting and maintaining reviews of a variety of treatments, especially less expensive ones, for the treatment and prevention of influenza.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>To assess the effectiveness and safety of amantadine and rimantadine in preventing, treating and shortening the duration of influenza A in children and the elderly.</P>
<P>We tested the following hypotheses in comparisons between groups intended for amantadine or rimantadine prophylaxis or treatment compared with control groups:</P>
<OL>
<LI>there is no difference in the number of cases of influenza A or in the duration of influenza symptoms; and</LI>
<LI>there is no difference in the number of adverse effects.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2014-11-12 07:55:14 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) and quasi-RCTs comparing amantadine or rimantadine, or both, with placebo, control drugs, different doses or schedules of amantadine or rimantadine, or both, or no intervention, in children and the elderly.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-11-10 03:45:13 +1000" MODIFIED_BY="[Empty name]">
<P>We included studies where at least 75% of the population was up to 19 years of age, or 65 years of age or older. We also included trials with a wider age range where data by age subgroups were available.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Comparisons of amantadine or rimantadine, or both, to placebo, control drugs, other antivirals, no interventions or different doses of amantadine or rimantadine, or both, as prophylaxis and/or treatment for influenza A.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Response to treatment (measured as cases on the specified day of treatment): fever on day three of treatment, cough on day seven of treatment, malaise on day six of treatment and conjunctivitis and eye symptoms on day five of treatment.</LI>
<LI>Cases of influenza, studied in all prophylaxis comparisons, including those in which two antivirals (rimantadine and zanamivir) (<LINK REF="STD-Gravenstein-2005" TYPE="STUDY">Gravenstein 2005</LINK>; <LINK REF="STD-Schilling-1998" TYPE="STUDY">Schilling 1998</LINK>), and two different doses of rimantadine were compared (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>).</LI>
<LI>Cases of side effects in children: diarrhoea, exanthema, malaise, muscular limb pain, headache, dyspnoea, dizziness, stimulation/insomnia, nausea, vomiting, arrhythmia, gastrointestinal (GI) symptoms, CNS symptoms, change in behaviour, hyperactivity and tinnitus.</LI>
<LI>Cases of side effects in the elderly: headache, dizziness, stimulation/insomnia, nausea, vomiting, anxiety, confusion, fatigue, depression, impaired concentration, loss of appetite, rash or allergic reaction, seizures or clonic twitching, dry mouth, insomnia or sleeplessness, body weakness and debility.</LI>
</OL>
<P>We used dichotomous outcomes for all the comparisons.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>The following outcomes appeared in the protocol but in the end we did not consider them in the analysis, as they were not reported in the included trials: patients' well-being, admission to hospital, general practitioner (GP) visits and other drugs used. We could not analyse deaths. Although cited by <LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>, they were included among other causes of withdrawal.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-11-05 22:13:27 +1000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2014-11-05 22:13:27 +1000" MODIFIED_BY="[Empty name]">
<P>For this 2014 update we searched the Cochrane Central Register of Controlled Trials (CENTRAL 2014, Issue 9) (accessed 7 October 2014), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE (June 2011 to September week 4, 2014) and EMBASE (June 2011 to October 2014).</P>
<P>The search strategy for MEDLINE and CENTRAL is described in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for the EMBASE search strategy. We imposed no language or publication restrictions. We used the same search strategy for our previous update in 2011, searching the Cochrane Central Register of Controlled Trials (CENTRAL 2011, Issue 2), MEDLINE (July 2007 to June week 3, 2011) and EMBASE.com (July 2007 to June 2011). Details of the review's initial search are in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the trials registries WHO International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov for completed and ongoing trials (latest search 7 October 2014). We screened bibliographies of retrieved articles and reviews in order to identify further trials. We contacted pharmaceutical companies and researchers active in the field for unpublished trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-11-12 07:55:14 +1000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2014-05-06 09:30:23 +1000" MODIFIED_BY="Liz Dooley">
<P>Two review authors (MG and MS) independently applied the selection criteria to all retrieved articles and extracted data using a data extraction form, specifically designed for this review. We resolved disagreements by consensus. We appointed one review author (AC) as arbitrator when necessary.</P>
<P>We entered extracted data into <LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>. Combination of data was dependent on population characteristics and outcomes studied.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-11-05 22:14:54 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors (MG, MS) independently read the retrieved trials and applied the selection criteria. We independently extracted and reviewed data using the data collection form previously developed for this review. Two review authors (MG, MS) resolved disagreements on the quality of the trials by consensus. We appointed a third author (AC) as arbitrator if necessary.</P>
<P>We emailed the authors of primary studies when the complete information sought was not available in study reports. We obtained authors' contact details from the study reports, other recent publications, university directories or by searching the world wide web. We recorded the following data.</P>
<OL>
<LI>Setting: hospital, emergency, offices or clinics, primary health care, nursing homes, communities, prisons, military personnel, nursery or day care.</LI>
<LI>Participants: criteria for patients to join the trial, age, gender, diagnostic criteria and co-morbid conditions.</LI>
<LI>Interventions: placebo, other than amantadine and rimantadine antiviral controls, comparing different doses or schedules of amantadine and/or rimantadine or no intervention.</LI>
<LI>Outcome measures: global symptom improvements, relief, death, cases of influenza, malaise, fever, nausea, arthralgia, rash, headache, systemic and serious side effects, well-being, admission to hospital, GP visits, other drugs used, cough, coryza, sore throat, hoarseness, vomiting, abdominal pain, insomnia, irritability, behaviour changes and anorexia.</LI>
<LI>Adverse effects: dry mouth, drowsiness/fatigue, constipation, urinary retention, sweating, headache, diarrhoea, palpitations, irritability, blurred vision, dizziness/light headedness and nausea/vomiting and any other systemic and serious side effects.</LI>
</OL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-11-12 07:55:14 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors (MG, MS) independently screened trial quality. We resolved disagreements by discussion. We appointed a third author (AC) to act as arbitrator when necessary. We used the criteria recommended by the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> to assess the risk of bias (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We developed a form and populated it to assess the risk of bias, based on a Cochrane review (<LINK REF="REF-Ahovuo_x002d_Saloranta-2014" TYPE="REFERENCE">Ahovuo-Saloranta 2014</LINK>). We indicated if the risk of bias was low, high , or even unclear, indicating either a lack of information or uncertainty over the potential for bias.</P>
<P>
<B>1. Sequence generation: </B>was the method used to generate the allocation sequence appropriate to produce comparable groups? We considered that the risk of bias was low if the authors described a random component in the sequence generation process (for example, a random number table, a computerised random number table, coin tossing, shuffling cards or envelopes, throwing dice, drawing of lots). If there was no or insufficient information about the sequence generation process, we marked this domain 'unclear'. We considered that there was a high risk of bias if the sequence was generated by: 1) odds and evens or date of birth; 2) some rule based on date (or day) of admission; 3) some rule based on hospital or clinic record number.</P>
<P>
<B>2. Allocation sequence concealment: </B>was the method used to conceal the allocation sequence appropriate to prevent the allocation being known in advance of, or during, enrolment? We marked this domain 'low risk' of bias if the trial authors described adequate concealment (for example, by means of either central allocation, sequentially numbered drug containers of identical appearance, or sequentially numbered, opaque, sealed envelopes) and 'high risk' of bias if: 1) inadequate concealment was documented; 2) allocation concealment was not used (for example, using either an open random allocation schedule, assignment envelopes without appropriate safeguards, alternation or rotation, date of birth or case record number). We marked this domain 'unclear' if: 1) insufficient information about allocation concealment was provided; 2) the information was unclearly reported.</P>
<P>
<B>3. Blinding of participants and personnel:</B> were adequate measures used to blind study participants and personnel from knowing which intervention a participant received? We marked this domain 'low risk' of blinding if the RCT authors stated that: 1) there was no blinding; 2) there was incomplete blinding but the review authors judged that the outcome was not likely to be influenced by said incomplete blinding; 3) blinding of participants and key study personnel was ensured and it is unlikely that the blinding could have been broken. We marked this domain 'high risk' of bias, if the RCT authors described: 1) no blinding; 2) incomplete blinding and the outcome was likely to be influenced by said incomplete blinding; 3) blinding of key study participants and personnel but it was likely that the blinding could have been broken. We marked this domain 'unclear' if there was insufficient information or if the study did not address this outcome.</P>
<P>
<B>4. Blinding of outcome assessment:</B> were adequate measures used to blind outcome assessors from knowing which intervention a participant received? We marked this domain 'low risk' of bias if there was: 1) no blinding of outcome assessment but the review authors judged that the outcome measurement was not likely to be influenced by lack of blinding; 2) blinding of outcome assessors was ensured and it is unlikely that the blinding could have been broken. We marked this domain 'high risk' of bias, if: 1) no blinding of outcome assessment was stated and the outcome measurement was likely to be influenced by lack of blinding; 2) there was blinding of outcome assessors but it was likely that the blinding could have been broken. We marked this domain 'unclear' if there was insufficient information or if the study did not address this outcome.</P>
<P>
<B>5. Incomplete outcome data</B> describes how complete the data were for the clinical outcomes. Were dropout rates and reasons for withdrawals reported? Were missing data imputed appropriately? We marked this domain 'low risk' of bias if the RCT authors stated that: 1) there were no missing outcome data; 2) the reasons for missing outcome data were unlikely to be related to true outcome: 3) missing outcome data balanced out across intervention groups, with similar reasons for missing data across said groups; 4) the proportion of missing outcomes compared with the observed event risk was not enough to have a clinically relevant impact on the intervention effect estimate; 5) missing data were imputed using appropriate methods. We marked this domain 'high risk' of bias, representing a high risk of attrition bias, if: 1) the reason for missing outcome data was likely to be related to true outcome, with either an imbalance in numbers or reasons for missing data across intervention groups; 2) the proportion of missing outcomes compared with the observed event risk was enough to induce clinically relevant bias in the intervention effect estimate; 3) 'as-treated' analysis was done with substantial departure of the intervention received from that assigned at randomisation; 4) there was potentially inappropriate application of simple imputation. 'unclear risk of bias' was the expected classification of studies in which there was insufficient reporting of attrition/exclusions to permit the classification of 'low risk' or 'high risk' (e.g. number of randomised patients not stated, no reasons for missing data provided), or if the study did not address this outcome.</P>
<P>We completed a 'Risk of bias' table for each included study (see 'Risk of bias' tables in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table).  </P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-07-25 14:33:59 +1000" MODIFIED_BY="[Empty name]">
<P>We calculated risk ratios (RRs) and 95% confidence intervals (CI) for each study as all the outcomes studied were dichotomous. We tested for heterogeneity for each outcome.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-05-06 10:47:40 +1000" MODIFIED_BY="Liz Dooley">
<P>In the <LINK REF="STD-Gravenstein-2005" TYPE="STUDY">Gravenstein 2005</LINK> trial, the author stated that the study was conducted over three winter seasons and that some participants were randomised more than once. Taking into account that influenza was the outcome of interest and that in each season different influenza viruses emerge, participants that had acquired the infection in one of the seasons could not be considered to be immunologically resistant to influenza in the next season. Consequently, we decided to include all participants described by the trial authors, as this does not seem to produce bias.</P>
<P>In the <LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK> and <LINK REF="STD-Clover-1991" TYPE="STUDY">Clover 1991</LINK> studies, eligible family members were randomly assigned as a block to study rimantadine in the prevention of influenza. For the purpose of this review, we selected the children as the subgroup of interest. It could be expected that children from families in the intervention group could be more protected from influenza than children in the control group. Nevertheless, no effect was shown in either of the three trials selected for this comparison (<LINK REF="STD-Clover-1986" TYPE="STUDY">Clover 1986</LINK>; <LINK REF="STD-Clover-1991" TYPE="STUDY">Clover 1991</LINK>; <LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-11-05 22:18:59 +1000" MODIFIED_BY="[Empty name]">
<P>We contacted the trial authors to request missing data when data were not clearly provided. We analysed the available data, taking into account the relatively small number and randomness of missing data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>We stored the data extracted from primary studies in the Review Manager software (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>). All the outcomes we studied were dichotomous.<BR/>We determined whether there were sufficiently homogeneous data to combine when there were two or more selected studies for a given comparison. We grouped the previously selected articles according to the characteristics of interventions, outcomes and populations studied. We had to take into account that pooled studies may still differ from each other even though the initial application of this filter was supposed to reduce the possibility of heterogeneity.</P>
<P>We initially inspected forest plots generated by <LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK> to evaluate the possibility of heterogeneity between studies. We applied the Cochrane test for homogeneity. With this aim we set a P value of 0.1 as the limit for considering the existence of heterogeneity (<LINK REF="REF-CCI-2006" TYPE="REFERENCE">CCI 2006</LINK>). We also applied the I<SUP>2</SUP> statistic to quantify heterogeneity among the trials and to verify the impact on the meta-analysis, considering that some clinical and methodological diversity always occurs in a meta-analysis. We considered values above 50% to be representative of significant heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), and we explored the causes. We used the subgroup analysis of participants or a subgroup analysis of the studies selected for each comparison when the heterogeneity was relevant to the outcome of the meta-analysis.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-10-08 11:22:22 +1000" MODIFIED_BY="[Empty name]">
<P>We considered assessment of reporting biases to be at risk because of the small number of studies selected for each comparison. Nevertheless, we relied on extensive research and carefully examined the references of the studies found in the search results to avoid reporting biases. We analysed all trials that met the inclusion criteria, independently of the journal's impact factor, the year of publication, the language in which the article was written and the origin of both author and publication. The use of these criteria can be confirmed by checking the lists of included and excluded studies.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>We used the risk ratio (RR) and respective 95% confidence interval (CI) as a summary measure to combine data. We calculated the necessary number of patients to be treated for an individual to benefit from treatment with respect to an outcome (number needed to treat to benefit (NNTB)) and its 95% CI, when a statistical difference was found. We estimated the occurrence of an event in the population, or absolute risk (baseline risk) based on the rate of event occurrence in controls (control group rate (CGR)) for this calculation.</P>
<P>We used the random-effects model to calculate the summary measure, with the assumption that although the articles could have addressed somewhat different issues, they could be viewed as a family of studies on similar questions. We considered that the articles were a random sample of all studies that addressed the questions we were interested in. Therefore, even considering the possibility of failure of the statistical tests of homogeneity, the combination of similar studies would still be a reasonable procedure. Although it is impossible to state if the articles were really a random sample of all research on an issue, this model is more realistic and less prone to overestimate accuracy (<LINK REF="REF-Fletcher-2006" TYPE="REFERENCE">Fletcher 2006</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-07-25 14:49:27 +1000" MODIFIED_BY="[Empty name]">
<P>We pre-specified some subgroup analyses to investigate heterogeneity. We planned to take into account the drugs used for control and treatment, their doses and the previous use of anti-influenza vaccine(s). However, we stress that the subgroup analysis does not take into account the randomisation processes, so these results must be considered with caution.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>We carried out sensitivity analyses to explore heterogeneity. We conducted subgroup analyses for subsets of participants. We had planned to analyse rimantadine and amantadine separately and together. However, when we identified the use of different antivirals being used as a control, we performed a subgroup analysis. We separated the trials in which the comparison was made using different antiviral medications from those in which the control was made with placebo or other drugs. We also carried out subgroup analyses for subsets of immunised and non-immunised participants, as well as according to the dosages of antivirals tested in the trials.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-11-12 10:04:15 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-11-05 22:25:39 +1000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2014-11-03 02:29:44 +1000" MODIFIED_BY="[Empty name]">
<P>We retrieved a total of 33 records in this updated search. Out of a total of 205 abstracts, titles and studies that we retrieved through all the searches, 195 were written in English, three in Russian, two in Czech, three in German, one in French and one in Japanese. We discarded 129 studies. We assessed the remaining 78 articles in detail. It was necessary to contact 46 trial authors to verify that their studies met our selection criteria. We included 12 trials in this review. All of them are published trials and are described in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. We added another 38 trials in 2011 when we updated this review; we excluded all of them and our conclusions remain unchanged.</P>
<P>We did not identify any new trials for inclusion in this 2014 update. We excluded 20 new trials (<LINK REF="STD-Anton-2011" TYPE="STUDY">Anton 2011</LINK>; <LINK REF="STD-Atiee-2012" TYPE="STUDY">Atiee 2012</LINK>; <LINK REF="STD-Bacosi-2002" TYPE="STUDY">Bacosi 2002</LINK>; <LINK REF="STD-Cayley-2012" TYPE="STUDY">Cayley 2012</LINK>; <LINK REF="STD-Cheng-2012" TYPE="STUDY">Cheng 2012</LINK>; <LINK REF="STD-De-Vincenzo-2012" TYPE="STUDY">De Vincenzo 2012</LINK>; <LINK REF="STD-Escuret-2012" TYPE="STUDY">Escuret 2012</LINK>; <LINK REF="STD-Gatwood-2012" TYPE="STUDY">Gatwood 2012</LINK>; <LINK REF="STD-Hayden-2012" TYPE="STUDY">Hayden 2012</LINK>; <LINK REF="STD-Hsu-2012" TYPE="STUDY">Hsu 2012</LINK>; <LINK REF="STD-Ison-2013" TYPE="STUDY">Ison 2013</LINK>; <LINK REF="STD-Jiang-2013" TYPE="STUDY">Jiang 2013</LINK>; <LINK REF="STD-Lopez_x002d_Medrano-2012" TYPE="STUDY">Lopez-Medrano 2012</LINK>; <LINK REF="STD-Louie-2012" TYPE="STUDY">Louie 2012</LINK>; <LINK REF="STD-Michiels-2013" TYPE="STUDY">Michiels 2013</LINK>; <LINK REF="STD-Sampaio-2011" TYPE="STUDY">Sampaio 2011</LINK>; <LINK REF="STD-Santesso-2013" TYPE="STUDY">Santesso 2013</LINK>; <LINK REF="STD-Shah-2012" TYPE="STUDY">Shah 2012</LINK>; <LINK REF="STD-Singer-2011" TYPE="STUDY">Singer 2011</LINK>; <LINK REF="STD-Yuen-2012" TYPE="STUDY">Yuen 2012</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-11-05 22:25:39 +1000" MODIFIED_BY="[Empty name]">
<P>The 12 included studies were all randomised trials (<LINK REF="STD-Clover-1986" TYPE="STUDY">Clover 1986</LINK>; <LINK REF="STD-Clover-1991" TYPE="STUDY">Clover 1991</LINK>; <LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>; <LINK REF="STD-Finklea-1967" TYPE="STUDY">Finklea 1967</LINK>; <LINK REF="STD-Gravenstein-2005" TYPE="STUDY">Gravenstein 2005</LINK>; <LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>; <LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK>; <LINK REF="STD-Kitamoto-1971" TYPE="STUDY">Kitamoto 1971</LINK>; <LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>; <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK>; <LINK REF="STD-Payler-1984" TYPE="STUDY">Payler 1984</LINK>; <LINK REF="STD-Schilling-1998" TYPE="STUDY">Schilling 1998</LINK>); 11 were blinded and one was unblinded (<LINK REF="STD-Schilling-1998" TYPE="STUDY">Schilling 1998</LINK>). The methods of randomisation and the follow-up period were poorly described in all studies, although we could estimate that follow-up ranged from eight to 120 days. We classified the included trials into two major groups: those conducted in children and those in the elderly.</P>
<SUBSECTION>
<HEADING LEVEL="4">Trials in children</HEADING>
<P>Eight selected studies looked at the following.</P>
<OL>
<LI>Treatment with amantadine (<LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK>; <LINK REF="STD-Kitamoto-1971" TYPE="STUDY">Kitamoto 1971</LINK>) and rimantadine (<LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>).</LI>
<LI>Prophylaxis with amantadine (<LINK REF="STD-Finklea-1967" TYPE="STUDY">Finklea 1967</LINK>; <LINK REF="STD-Payler-1984" TYPE="STUDY">Payler 1984</LINK>) and rimantadine (<LINK REF="STD-Clover-1986" TYPE="STUDY">Clover 1986</LINK>; <LINK REF="STD-Clover-1991" TYPE="STUDY">Clover 1991</LINK>; <LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>).</LI>
<LI>Adverse effects due to amantadine (<LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK>; <LINK REF="STD-Kitamoto-1971" TYPE="STUDY">Kitamoto 1971</LINK>) and rimantadine (<LINK REF="STD-Clover-1986" TYPE="STUDY">Clover 1986</LINK>; <LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>; <LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>).</LI>
</OL>
<P>For treatment trials and the outcome fever on day three of treatment, the amantadine arm size was 51 and the control arm size was 53 children (<LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK>; <LINK REF="STD-Kitamoto-1971" TYPE="STUDY">Kitamoto 1971</LINK>). The rimantadine arm size was 37 and the control arm size was 32 children (<LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>). For the other outcomes, cough on day seven, malaise on day six and eye symptoms on day five, we selected just one trial (<LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>). The rimantadine arm size was 37 and control arm size was 32 children for each of these outcomes.</P>
<P>In the five prophylaxis trials, we applied wider age ranges for children than the definition stated in the protocol (participants up to 16 years of age). These trials included older participants who were adolescents by the WHO definition (<LINK REF="REF-WHO-2007" TYPE="REFERENCE">WHO 2007</LINK>). Data regarding the proportion of the subgroup which strictly fulfilled the age criterion were not available in these studies or by contacting the trial authors. The respective age ranges were one to 17 years (<LINK REF="STD-Clover-1991" TYPE="STUDY">Clover 1991</LINK>), 13 to 19 years (<LINK REF="STD-Payler-1984" TYPE="STUDY">Payler 1984</LINK>), one to 18 years (<LINK REF="STD-Clover-1986" TYPE="STUDY">Clover 1986</LINK>; <LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>), and eight to 19 years of age (<LINK REF="STD-Finklea-1967" TYPE="STUDY">Finklea 1967</LINK>). The amantadine arm size was 368 (<LINK REF="STD-Finklea-1967" TYPE="STUDY">Finklea 1967</LINK> (104); <LINK REF="STD-Payler-1984" TYPE="STUDY">Payler 1984</LINK> (264)) and the control arm size was 373 children (<LINK REF="STD-Finklea-1967" TYPE="STUDY">Finklea 1967</LINK> (133); <LINK REF="STD-Payler-1984" TYPE="STUDY">Payler 1984</LINK> (240)). The rimantadine arm size was 84 (<LINK REF="STD-Clover-1986" TYPE="STUDY">Clover 1986</LINK> (35); <LINK REF="STD-Clover-1991" TYPE="STUDY">Clover 1991</LINK> (22); <LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK> (27)) and the control arm size was 94 participants (<LINK REF="STD-Clover-1986" TYPE="STUDY">Clover 1986</LINK> (41); <LINK REF="STD-Clover-1991" TYPE="STUDY">Clover 1991</LINK> (24); <LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK> (29)).</P>
<P>Reported adverse effects of amantadine included exanthema, malaise, muscular limb pain, headache, arrhythmia and stimulation/insomnia. The antiviral arm size was 264 children (<LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK> (75); <LINK REF="STD-Kitamoto-1971" TYPE="STUDY">Kitamoto 1971</LINK> (189)) and the control arm size was 335 (<LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK> (84); <LINK REF="STD-Kitamoto-1971" TYPE="STUDY">Kitamoto 1971</LINK> (251)).</P>
<P>A reported adverse effect of amantadine was dyspnoea. The antiviral arm size was 75 and the control arm size was 84 children (<LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK>). For the adverse effects of hyperreactivity and tinnitus the rimantadine arm size was 27 and the control arm size was 29 children (<LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>).</P>
<P>Nausea/vomiting, diarrhoea and dizziness were described as possible adverse effects for both antivirals. For nausea/vomiting, the amantadine arm size was 264 children (<LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK> (75); <LINK REF="STD-Kitamoto-1971" TYPE="STUDY">Kitamoto 1971</LINK> (189)) and the control arm size was 335 (<LINK REF="STD-Kitamoto-1971" TYPE="STUDY">Kitamoto 1971</LINK> (251); <LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK> (84)). The rimantadine arm size was 38 (<LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK> (1); <LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK> (37)) and the control arm size was 61 (<LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK> (29); <LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK> (32)).</P>
<P>For diarrhoea and dizziness the amantadine arm size was 264 children (<LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK> (75); <LINK REF="STD-Kitamoto-1971" TYPE="STUDY">Kitamoto 1971</LINK> (189)) and the control arm size was 335 (<LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK> (84), <LINK REF="STD-Kitamoto-1971" TYPE="STUDY">Kitamoto 1971</LINK> (251)). The rimantadine arm size was 27 and the control arm size was 29 children for these adverse effects (<LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Trials in the elderly</HEADING>
<P>We selected three trials in this age group that reported on prophylaxis with rimantadine; we did not select any treatment trials. We studied the following outcomes.</P>
<OL>
<LI>Prophylaxis of laboratory and clinical infection (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>; <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK>).</LI>
<LI>Adverse reactions (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>; <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK>).</LI>
<LI>Different doses of rimantadine as a prophylactic antiviral (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>).</LI>
<LI>Comparison to other antivirals in the prophylaxis of influenza (<LINK REF="STD-Gravenstein-2005" TYPE="STUDY">Gravenstein 2005</LINK>; <LINK REF="STD-Schilling-1998" TYPE="STUDY">Schilling 1998</LINK>).</LI>
</OL>
<P>For prophylaxis of laboratory and clinical infection, the rimantadine (200 mg/day) arm size was 44 (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK> (26); <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK> (18)) and the placebo arm size was 31 participants (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK> (14); <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK> (17)). The trial authors stated they limited this analysis to vaccinated participants in nursing homes with confirmed influenza, as it provided an estimate of the additional protective efficacy of rimantadine. The sample studied by <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK> was made up of previously vaccinated participants, so all the participants were analysed (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>; <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK>).</P>
<P>In the adverse reaction studies focusing on stimulation/insomnia, confusion, fatigue, nausea, depression, loss of appetite and vomiting, the rimantadine (200 mg/day) arm size was 150 (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK> (132); <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK> (18)) and the placebo arm size was 83 participants (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK> (66); <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK> (17)). All randomly assigned participants were analysed.</P>
<P>In the adverse reaction study focusing on headache, impaired concentration, rash or allergic reaction, seizures or clonic twitching, the rimantadine (200 mg/day) arm size was 132 and the placebo arm size was 66 participants (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>).</P>
<P>In another adverse reaction study focusing on dizziness and anxiety, the rimantadine (200 mg/day) arm size was 18 and the placebo arm size was 17 participants (<LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK>).</P>
<P>In the unique study evaluating different doses of rimantadine as a prophylactic drug for clinical and confirmed influenza A, the rimantadine (100 mg/day) arm size was 28 and the rimantadine (200 mg/day) arm size was 26 participants (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>).</P>
<P>Only one selected study focused on adverse effects related to different doses of rimantadine. The studied effects were confusion, depression, impaired concentration, insomnia or sleeplessness, loss of appetite, rash or allergic reaction, seizure or clonic twitching, dry mouth, fatigue or drowsiness, headache, body weakness and debility. The 100 mg/day arm size was 130 and the 200 mg/day arm size was 132 participants (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>).</P>
<P>We selected two trials for the comparison of rimantadine to another antiviral and the participants were also the elderly (<LINK REF="STD-Gravenstein-2005" TYPE="STUDY">Gravenstein 2005</LINK>; <LINK REF="STD-Schilling-1998" TYPE="STUDY">Schilling 1998</LINK>). The rimantadine arm size was 254 and the zanamivir arm size was 291 participants. No study used amantadine for this kind of comparison.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-10-08 15:52:59 +1000" MODIFIED_BY="Liz Dooley">
<P>We excluded 212 studies for the following reasons.</P>
<OL>
<LI>They were carried out in different age groups.</LI>
<LI>They were not controlled trials.</LI>
<LI>They assessed other drugs.</LI>
<LI>They were non-human or laboratory studies.</LI>
</OL>
<P>We excluded 20 new trials in this 2014 update (<LINK REF="STD-Anton-2011" TYPE="STUDY">Anton 2011</LINK>; <LINK REF="STD-Atiee-2012" TYPE="STUDY">Atiee 2012</LINK>; <LINK REF="STD-Bacosi-2002" TYPE="STUDY">Bacosi 2002</LINK>; <LINK REF="STD-Cayley-2012" TYPE="STUDY">Cayley 2012</LINK>; <LINK REF="STD-Cheng-2012" TYPE="STUDY">Cheng 2012</LINK>; <LINK REF="STD-De-Vincenzo-2012" TYPE="STUDY">De Vincenzo 2012</LINK>; <LINK REF="STD-Escuret-2012" TYPE="STUDY">Escuret 2012</LINK>; <LINK REF="STD-Gatwood-2012" TYPE="STUDY">Gatwood 2012</LINK>; <LINK REF="STD-Hayden-2012" TYPE="STUDY">Hayden 2012</LINK>; <LINK REF="STD-Hsu-2012" TYPE="STUDY">Hsu 2012</LINK>; <LINK REF="STD-Ison-2013" TYPE="STUDY">Ison 2013</LINK>; <LINK REF="STD-Jiang-2013" TYPE="STUDY">Jiang 2013</LINK>; <LINK REF="STD-Lopez_x002d_Medrano-2012" TYPE="STUDY">Lopez-Medrano 2012</LINK>; <LINK REF="STD-Louie-2012" TYPE="STUDY">Louie 2012</LINK>; <LINK REF="STD-Michiels-2013" TYPE="STUDY">Michiels 2013</LINK>; <LINK REF="STD-Sampaio-2011" TYPE="STUDY">Sampaio 2011</LINK>; <LINK REF="STD-Santesso-2013" TYPE="STUDY">Santesso 2013</LINK>; <LINK REF="STD-Shah-2012" TYPE="STUDY">Shah 2012</LINK>; <LINK REF="STD-Singer-2011" TYPE="STUDY">Singer 2011</LINK>; <LINK REF="STD-Yuen-2012" TYPE="STUDY">Yuen 2012</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>The overall risk of bias is presented graphically in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and summarised in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>The trial authors of the 12 included studies stated that participants had been randomly allocated into treatment or control groups. In two of the studies we obtained the following information by contacting the trial authors (<LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>; <LINK REF="STD-Payler-1984" TYPE="STUDY">Payler 1984</LINK>). Hall reported that a computer system was used to randomise participants. The university pharmacy was chosen to allocate and store the study drugs (<LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>). In Payler's study, randomisation had been carried out by the statistical department of a pharmaceutical company, which kept the key to the randomisation and only when the study was analysed was the code broken (<LINK REF="STD-Payler-1984" TYPE="STUDY">Payler 1984</LINK>). There was no mention of any particular randomisation method in the other studies.</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Ten studies were described as double-blinded (<LINK REF="STD-Clover-1986" TYPE="STUDY">Clover 1986</LINK>; <LINK REF="STD-Clover-1991" TYPE="STUDY">Clover 1991</LINK>; <LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>; <LINK REF="STD-Finklea-1967" TYPE="STUDY">Finklea 1967</LINK>; <LINK REF="STD-Gravenstein-2005" TYPE="STUDY">Gravenstein 2005</LINK>; <LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>; <LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK>; <LINK REF="STD-Kitamoto-1971" TYPE="STUDY">Kitamoto 1971</LINK>; <LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>; <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK>). However, only in one trial were blinded people listed (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>). Although there was no blinding stated in <LINK REF="STD-Payler-1984" TYPE="STUDY">Payler 1984</LINK>, we judged that the outcome was not likely to be influenced by a lack of blinding. <LINK REF="STD-Schilling-1998" TYPE="STUDY">Schilling 1998</LINK> was described as an unblinded study; we also judged that the outcomes were unlikely to be influenced by a lack of blinding.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>There were no missing participants in either <LINK REF="STD-Kitamoto-1971" TYPE="STUDY">Kitamoto 1971</LINK>, <LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK> or <LINK REF="STD-Payler-1984" TYPE="STUDY">Payler 1984</LINK>. The review authors considered that the reasons for missing outcome data were unlikely to be related to true outcome in the following studies: <LINK REF="STD-Clover-1986" TYPE="STUDY">Clover 1986</LINK>; <LINK REF="STD-Clover-1991" TYPE="STUDY">Clover 1991</LINK>; <LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>; <LINK REF="STD-Finklea-1967" TYPE="STUDY">Finklea 1967</LINK>; <LINK REF="STD-Gravenstein-2005" TYPE="STUDY">Gravenstein 2005</LINK>. In the <LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK> trial, we considered that the proportion of missing outcomes compared with observed event risk was not enough to have a clinically relevant impact on the intervention effect estimate. On the other hand, we considered the reasons for missing outcome data likely to be related to the true outcome data in two studies (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>; <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK>). In <LINK REF="STD-Schilling-1998" TYPE="STUDY">Schilling 1998</LINK>, there was insufficient reporting of exclusion.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-06-18 03:12:43 +1000" MODIFIED_BY="[Empty name]">
<P>The review authors did not identify any possible sources of reporting biases.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2011-11-15 03:16:18 +1000" MODIFIED_BY="[Empty name]">
<P>The review authors did not identify any other possible sources of bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-11-12 10:04:15 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes in children</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Amantadine and rimantadine compared to control (placebo and acetaminophen) in the treatment of influenza A in children</HEADING>
<P>In the protocol, we originally planned to study the drug effect on reduction of fever and cough as they are considered the best predictors of influenza diagnosis. After collecting data, we verified that specific timelines for reduction of signs and symptoms were not reported in the included trials. We searched for another way to present an estimation of the response to amantadine and rimantadine in patients with influenza. For this unplanned analysis, we considered the available data and arbitrarily chose a day of antiviral use to evaluate the response to the treatment. This choice was based on the <LINK REF="REF-Eccle-2005" TYPE="REFERENCE">Eccle 2005</LINK> study in which clinical manifestations were classified into early and later symptoms. Typically fever may last four to eight days, so we chose day three of treatment as the cut-off point to which it could be considered that the response to the drug would be useful. Cough is considered a later manifestation that develops slowly and can still be present a week later (<LINK REF="REF-Eccle-2005" TYPE="REFERENCE">Eccle 2005</LINK>). In the same way, we chose day seven of treatment as the cut-off point by when the response to the drug could be considered useful.</P>
<P>We also decided to include other treatment outcomes as they were available in Hall's electronic correspondence to us. In the same way, we arbitrarily chose a day of antiviral use to evaluate the response to the treatment to make this unplanned analysis: 'malaise on day six', as it begins early but could still be present for one or two weeks (<LINK REF="REF-Eccle-2005" TYPE="REFERENCE">Eccle 2005</LINK>; <LINK REF="REF-Smith-2006" TYPE="REFERENCE">Smith 2006</LINK>), and 'eye manifestations on day five', as it can occur early on in the course of the illness (<LINK REF="REF-Treanor-2005" TYPE="REFERENCE">Treanor 2005</LINK>; <LINK REF="REF-Wright-2004" TYPE="REFERENCE">Wright 2004</LINK>)</P>
<P>Amantadine was compared to placebo: 104 participants (<LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK>; <LINK REF="STD-Kitamoto-1971" TYPE="STUDY">Kitamoto 1971</LINK>), and rimantadine to acetaminophen: 69 participants (<LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>).</P>
<P>There was a protective effect of amantadine and rimantadine in the occurrence of fever on day three of antiviral treatment, when trials using both antivirals were combined: 173 participants, risk ratio (RR) 0.39; 95% confidence interval (CI) 0.20 to 0.79 (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) (<LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>; <LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK>; <LINK REF="STD-Kitamoto-1971" TYPE="STUDY">Kitamoto 1971</LINK>).</P>
<P>The baseline risk of fever on day three of treatment was 0.28, calculated on the basis of the control group risk (CGR). The number of children needed to treat to benefit (NNTB) to prevent one case of fever on day three of treatment was six (95% CI 4 to 17) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>We also verified a protective effect of rimantadine for this outcome: RR 0.36; 95% CI 0.14 to 0.91 (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.2). The baseline risk of fever on day three of treatment was 0.38, calculated on the basis of the CGR. The NNTB was five (95% CI 3 to 25) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Just one trial with 69 participants reported this outcome (<LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>).</P>
<P>We observed no protective effect of amantadine in the occurrence of fever on day three of treatment: 104 participants, RR 0.37; 95% CI 0.08 to 1.75 (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.1) (<LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK>; <LINK REF="STD-Kitamoto-1971" TYPE="STUDY">Kitamoto 1971</LINK>).</P>
<P>We saw no protective effect of rimantadine regarding the occurrence of any of the following outcomes assessed: malaise on day six (RR 1.04; 95% CI 0.63 to 1.70) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>), cough on day seven (RR 0.83; 95% CI 0.63 to 1.10) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>), conjunctivitis on day five (RR 0.17; 95% CI 0.01 to 3.49) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>), and cases of pain on movement and visual distortion on day five (RR 0.58; 95% CI 0.10 to 3.24) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). Just one study with 69 participants reported these outcomes (<LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>).</P>
<P>No selected studies reported the use of amantadine for these latter outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Amantadine and rimantadine compared to control in the treatment of influenza A in the elderly</HEADING>
<P>There was no study selected for this comparison.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Amantadine and rimantadine compared to control (placebo and to specific treatment) in the prophylaxis of influenza A in children</HEADING>
<P>Amantadine was compared to placebo and specific treatment (<LINK REF="STD-Finklea-1967" TYPE="STUDY">Finklea 1967</LINK>; <LINK REF="STD-Payler-1984" TYPE="STUDY">Payler 1984</LINK>) and rimantadine to placebo (<LINK REF="STD-Clover-1986" TYPE="STUDY">Clover 1986</LINK>; <LINK REF="STD-Clover-1991" TYPE="STUDY">Clover 1991</LINK>; <LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>).</P>
<P>The amantadine (<LINK REF="STD-Finklea-1967" TYPE="STUDY">Finklea 1967</LINK>; <LINK REF="STD-Payler-1984" TYPE="STUDY">Payler 1984</LINK>) and rimantadine trials (<LINK REF="STD-Clover-1986" TYPE="STUDY">Clover 1986</LINK>; <LINK REF="STD-Clover-1991" TYPE="STUDY">Clover 1991</LINK>; <LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>) were heterogeneous (Chi<SUP>2</SUP> test 9.27, P value = 0.05, I<SUP>2</SUP> statistic 56.8%) and could not be combined.</P>
<P>A protective effect of amantadine was observed with 773 participants, RR 0.11; 95% CI 0.04 to 0.30 (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.1). The baseline risk of influenza was 0.10, calculated on the basis of the CGR. The NNTB was 12 (95% CI 9 to 17) for a period ranging from 14 (<LINK REF="STD-Payler-1984" TYPE="STUDY">Payler 1984</LINK>) to 18 weeks (<LINK REF="STD-Finklea-1967" TYPE="STUDY">Finklea 1967</LINK>).</P>
<P>On the other hand, no protective effect of rimantadine was seen in the prophylaxis of cases of influenza: 178 participants (RR 0.49; 95% CI 0.21 to 1.15) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.2) (<LINK REF="STD-Clover-1986" TYPE="STUDY">Clover 1986</LINK>; <LINK REF="STD-Clover-1991" TYPE="STUDY">Clover 1991</LINK>; <LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Use of different doses of amantadine and rimantadine for prophylaxis and treatment of influenza in children</HEADING>
<P>There was no selected study conducted in children for this comparison.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Amantadine and rimantadine compared to other antivirals in children</HEADING>
<P>There was no selected study conducted in children for this comparison</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Amantadine and rimantadine compared to control (placebo and zanamivir) in the prophylaxis of influenza A in the elderly</HEADING>
<P>Rimantadine was compared to placebo (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>; <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK>) and to zanamivir (<LINK REF="STD-Schilling-1998" TYPE="STUDY">Schilling 1998</LINK>). No protective effect of rimantadine was seen regarding the prophylaxis of influenza in the elderly: 191 participants, RR 0.74; 95% CI 0.13 to 4.07 (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
<P>Although care must be taken in the interpretation of the Chi<SUP>2</SUP> test due to its low power in detecting heterogeneity in meta-analyses, we should emphasise the high P value observed in this comparison, considered alongside the I<SUP>2</SUP> statistic value under 50%: Chi<SUP>2</SUP> test 3.28; P value = 0.19, I<SUP>2</SUP> statistic 39%. We decided to explore the reasons for these findings as if the studies were heterogeneous, even though it would result in smaller samples impairing the ability to reach any definitive conclusion (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>; <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK>; <LINK REF="STD-Schilling-1998" TYPE="STUDY">Schilling 1998</LINK>).</P>
<P>Monto and Patriarca analysed previously vaccinated participants in blinded trials and used a placebo as control (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>; <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK>). Schilling did not state if the participants were vaccinated, although it was stated that the majority of the studied population had been previously immunised (<LINK REF="STD-Schilling-1998" TYPE="STUDY">Schilling 1998</LINK>). This was an unblinded trial in which another antiviral (zanamivir) was used as a control drug.</P>
<P>When we excluded this study (<LINK REF="STD-Schilling-1998" TYPE="STUDY">Schilling 1998</LINK>), the remaining trials, <LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK> and <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK> were shown to be homogeneous but no protective effect of rimantadine prophylaxis in the occurrence of cases of influenza persisted (103 participants, RR 0.45; 95% CI 0.14 to 1.41) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
<P>
<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK> used two different doses of rimantadine in his trial (100 mg/day and 200 mg/day) and <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK> used the conventional dose of 200 mg/day. <LINK REF="STD-Schilling-1998" TYPE="STUDY">Schilling 1998</LINK> used a single dose of 100 mg/day. We also combined Monto's 200 mg/day subgroup with Patriarca's study in which the same dose was administered, but again no protective effect of rimantadine was observed in the prophylaxis of influenza: eight participants, RR 0.44; 95% CI 0.12 to 1.63) (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>) (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>; <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK>; <LINK REF="STD-Schilling-1998" TYPE="STUDY">Schilling 1998</LINK>).</P>
<P>Schilling's sample and Monto's 100 mg/day subgroup were heterogeneous and could not be combined (Chi<SUP>2</SUP> test 2.55, P value = 0.11, I<SUP>2</SUP> statistic 60.8%) (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>; <LINK REF="STD-Schilling-1998" TYPE="STUDY">Schilling 1998</LINK>).</P>
<P>There was no amantadine study selected for comparison.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Use of different doses of amantadine and rimantadine for prophylaxis and treatment of influenza A in the elderly</HEADING>
<P>A reduced rimantadine dose of 100 mg/day was comparable to the full dose of 200 mg daily for prophylaxis of influenza in the elderly, although a wide CI was verified (54 participants, RR 0.93; 95% CI 0.21 to 4.20) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). It should be emphasised that there were few data available for these comparisons (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>).</P>
<P>There was no selected study using different doses of rimantadine in the elderly, nor any selected trial comparing different doses of amantadine for prophylaxis and treatment of influenza in the elderly.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Amantadine and rimantadine compared to other antivirals in the elderly</HEADING>
<P>In Gravenstein's but not in Schilling's study an identical placebo was used (<LINK REF="STD-Gravenstein-2005" TYPE="STUDY">Gravenstein 2005</LINK>; <LINK REF="STD-Schilling-1998" TYPE="STUDY">Schilling 1998</LINK>). When rimantadine was compared to zanamivir it was shown that zanamivir prevented influenza A more effectively than rimantadine in the elderly (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
<P>There was no amantadine trial selected for this comparison in the elderly.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects of amantadine and rimantadine compared to control (placebo and acetaminophen) in children</HEADING>
<P>Amantadine was compared to placebo (<LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK>; <LINK REF="STD-Kitamoto-1971" TYPE="STUDY">Kitamoto 1971</LINK>). Rimantadine was compared to placebo (<LINK REF="STD-Clover-1986" TYPE="STUDY">Clover 1986</LINK>; <LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>) and to acetaminophen (<LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>).</P>
<P>Amantadine was not related to a higher risk of the following adverse effects in two trials with 599 participants: diarrhoea (RR 0.79; 95% CI 0.42 to 1.47) (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>), exanthema (RR 0.69; 95% CI 0.21 to 2.34) (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>), muscular limb pain (RR 0.85; 95% CI 0.46 to 1.59) (<LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>), headache (RR 0.73; 95% CI 0.52 to 1.03) (<LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>) and stimulation and insomnia (RR 0.46; 95% CI 0.12 to 1.74) (<LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>) (<LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK>; <LINK REF="STD-Kitamoto-1971" TYPE="STUDY">Kitamoto 1971</LINK>).</P>
<P>In the same way, amantadine was not related to the outcomes dizziness and dyspnoea. For dizziness there were 655 participants in two studies (<LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK>; <LINK REF="STD-Kitamoto-1971" TYPE="STUDY">Kitamoto 1971</LINK>). The RR was 6.63 (95% CI 0.32 to 137.33) (<LINK REF="CMP-006.06" TYPE="ANALYSIS">Analysis 6.6</LINK>.1) and for dyspnoea there were 159 participants in just one trial (<LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK>). The RR was 0.37 (95% CI 0.02 to 9.02) (<LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>).</P>
<P>The studies were heterogeneous for the outcomes malaise (Chi<SUP>2</SUP> test 3.75, P value = 0.05, I<SUP>2</SUP> statistic 73.3%) and nausea/vomiting (Chi<SUP>2</SUP> test 4.26, P value = 0.04, I<SUP>2</SUP> statistic 76.5%), although it seems that the author had used the same protocol. Nevertheless, the heterogeneity for the outcome nausea/vomiting does not seem to be relevant, as amantadine could be related either to an increase or to a reduction in the occurrence of this adverse effect (<LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK>; <LINK REF="STD-Kitamoto-1971" TYPE="STUDY">Kitamoto 1971</LINK>).</P>
<P>No cases of arrhythmia were reported in those two trials.</P>
<P>Rimantadine was not related to a higher risk of any of the following adverse effects assessed: central nervous system (CNS) symptoms: one study, 76 participants (RR 0.23; 95% CI 0.01 to 4.70) (<LINK REF="CMP-006.08" TYPE="ANALYSIS">Analysis 6.8</LINK>); change in behaviour: one study, 76 participants (RR 0.23; 95% CI 0.01 to 4.70) (<LINK REF="CMP-006.09" TYPE="ANALYSIS">Analysis 6.9</LINK>); diarrhoea: one study, 56 participants (RR 0.36; 95% CI 0.02 to 8.41) (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>.2); dizziness: one study, 56 participants (RR 3.21; 95% CI 0.14 to 75.68) (<LINK REF="CMP-006.06" TYPE="ANALYSIS">Analysis 6.6</LINK>.2); gastro-intestinal (GI) manifestations: one study, 76 participants (RR 1.17; 95% CI 0.08 to 18.05) (<LINK REF="CMP-006.10" TYPE="ANALYSIS">Analysis 6.10</LINK>); hyperactivity: one study, 56 participants (RR 0.36; 95% CI 0.02 to 8.41) (<LINK REF="CMP-006.11" TYPE="ANALYSIS">Analysis 6.11</LINK>); tinnitus: one study, 56 participants (RR 3.21; 95% CI 0.14 to 75.68) (<LINK REF="CMP-006.12" TYPE="ANALYSIS">Analysis 6.12</LINK>); cerebellar ataxia: one study, 69 participants (RR 2.61; 95% CI 0.11 to 61.80) (<LINK REF="CMP-006.13" TYPE="ANALYSIS">Analysis 6.13</LINK>) (<LINK REF="STD-Clover-1986" TYPE="STUDY">Clover 1986</LINK>; <LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>; <LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>).</P>
<P>As it was stated, each one of the adverse effects described above was studied in just one included trial, except for nausea and vomiting (<LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>; <LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>). In the same way, rimantadine was not related to a higher risk of nausea and vomiting: two studies, 125 participants (RR 0.96; 95% CI 0.10 to 9.01) (<LINK REF="CMP-006.15" TYPE="ANALYSIS">Analysis 6.15</LINK>.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects related to different doses of amantadine and rimantadine in children</HEADING>
<P>There were no selected studies conducted in children for this comparison.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects of amantadine and rimantadine compared to control (placebo) in the elderly</HEADING>
<P>There were two selected studies for these outcomes, both using rimantadine and placebo (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>; <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK>).</P>
<P>No effect of rimantadine was seen regarding any of the adverse outcomes assessed in the combined studies: stimulation and insomnia (233 participants, RR 1.61; 95% CI 0.43 to 6.02) (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>), confusion (233 participants, RR 0.79; 95% CI 95% 0.40 to 1.56) (<LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>), fatigue (233 participants, RR 0.81; 95% CI 0.41 to 1.60) (<LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK>) and vomiting (233 participants, RR 0.99; 95% CI 0.38 to 2.60) (<LINK REF="CMP-007.04" TYPE="ANALYSIS">Analysis 7.4</LINK>) (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>; <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK>).</P>
<P>In the same way, rimantadine was not related to the outcomes studied by Monto: headache (198 participants, RR 0.83; 95% CI 0.21 to 3.38) (<LINK REF="CMP-007.05" TYPE="ANALYSIS">Analysis 7.5</LINK>); impaired concentration (198 participants, RR 0.50; 95% CI 0.10 to 2.41) (<LINK REF="CMP-007.06" TYPE="ANALYSIS">Analysis 7.6</LINK>); rash or allergic reaction (198 participants, RR 3.53; 95% CI 0.18 to 67.28) (<LINK REF="CMP-007.07" TYPE="ANALYSIS">Analysis 7.7</LINK>); seizures or clonic twitching (198 participants, RR 2.00; 95% CI 0.23 to 17.54) (<LINK REF="CMP-007.08" TYPE="ANALYSIS">Analysis 7.8</LINK>) and dry mouth (198 participants, RR 0.70; 95% CI 0.23 to 2.12) (<LINK REF="CMP-007.09" TYPE="ANALYSIS">Analysis 7.9</LINK>), as well as in those studied by Patriarca: dizziness (35 participants, RR 0.94; 95% CI 0.15 to 5.97) (<LINK REF="CMP-007.10" TYPE="ANALYSIS">Analysis 7.10</LINK>) and anxiety (35 participants, RR 2.83; 95% CI 0.92 to 8.74) (<LINK REF="CMP-007.11" TYPE="ANALYSIS">Analysis 7.11</LINK>) (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>; <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK>).</P>
<P>The articles were heterogeneous just for the occurrence of nausea (test for heterogeneity: Chi<SUP>2</SUP> test 2.02; P value = 0.16; I<SUP>2</SUP> statistic 50.5%). Nevertheless, this heterogeneity does not seem to be relevant as rimantadine could be related either to an increase or to a reduction in the occurrence of nausea in each one of the studies (<LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK>: 35 participants, RR 5.67; 95% CI 0.76 to 42.32 and <LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>: 198 participants, RR 1.17; 95% CI 0.47 to 2.90) (<LINK REF="CMP-007.12" TYPE="ANALYSIS">Analysis 7.12</LINK>).</P>
<P>It is important to stress the small samples studied in both trials. There was no amantadine trial selected for comparison.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects related to different doses of amantadine and rimantadine in the elderly</HEADING>
<P>There was no protective effect of a reduced dose of rimantadine in the occurrence of the following adverse reactions in the elderly: one study with 262 participants: confusion (RR 0.82; 95% CI 0.41 to 1.65) (<LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>), depression (RR 0.44; 95% CI 0.12 to 1.65) (<LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK>), impaired concentration (RR 0.68; 95% CI 0.11 to 3.98) (<LINK REF="CMP-008.03" TYPE="ANALYSIS">Analysis 8.3</LINK>), insomnia or sleeplessness (RR 1.02; 95% CI 0.26 to 3.97) (<LINK REF="CMP-008.04" TYPE="ANALYSIS">Analysis 8.4</LINK>), loss of appetite (RR 0.62; 95% CI 0.27 to 1.46) (<LINK REF="CMP-008.05" TYPE="ANALYSIS">Analysis 8.5</LINK>), rash or allergic reaction (RR 0.34; 95% CI 0.04 to 3.21) (<LINK REF="CMP-008.06" TYPE="ANALYSIS">Analysis 8.6</LINK>), seizures or clonic twitching (RR 0.11; 95% CI 0.01 to 2.07) (<LINK REF="CMP-008.07" TYPE="ANALYSIS">Analysis 8.7</LINK>), dry mouth (RR 1.16; 95% CI 0.43 to 3.11) (<LINK REF="CMP-008.08" TYPE="ANALYSIS">Analysis 8.8</LINK>), fatigue or drowsiness (RR 1.14; 95% CI 0.45 to 2.87) (<LINK REF="CMP-008.09" TYPE="ANALYSIS">Analysis 8.9</LINK>), headache (RR 1.02; 95% CI 0.30 to 3.42) (<LINK REF="CMP-008.10" TYPE="ANALYSIS">Analysis 8.10</LINK>) and body weakness or debility (RR 0.91; 95% CI 0.38 to 2.18) (<LINK REF="CMP-008.11" TYPE="ANALYSIS">Analysis 8.11</LINK>) (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>).</P>
<P>There was no amantadine trial selected for this comparison in the elderly.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Additional outcome (children plus the elderly)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Rimantadine compared to control (placebo) in the prophylaxis of influenza A in children and the elderly</HEADING>
<P>Originally in the protocol we planned only to make the above 12 comparisons. However, whilst analysing the data we considered doing an additional comparison and put the two age groups together. As the small samples studied in rimantadine trials for prophylaxis might have influenced the observed results, we tried to overcome this limitation by combining the trials with rimantadine in children and in the elderly. Rimantadine had no proven effect in preventing influenza in either age group but could be effective when we combined the results from both groups. However, it must be stressed that extraneous characteristics between those groups, other than age or previous immunisations, may have occurred, impairing generalisation of these results. There were five studies selected for this comparison with 156 patients in the treatment group and 125 in the placebo control group (<LINK REF="STD-Clover-1986" TYPE="STUDY">Clover 1986</LINK>; <LINK REF="STD-Clover-1991" TYPE="STUDY">Clover 1991</LINK>; <LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>; <LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>; <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK>). The combination of the trials showed a protective effect of rimantadine in preventing influenza A (281 participants, RR 0.49; 95% CI 0.27 to 0.92) (<LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>).</P>
<P>The baseline risk of influenza A was 0.22, calculated on the basis of the CGR. The NNTB was 9.09 (95% CI 6.25 to 50). We should emphasise that the follow-up period ranged from 3 to 11 weeks.</P>
<P>The following secondary outcomes appeared in the protocol but in the end we did not consider them in the analysis, as they were not reported in the included trials: patients' well-being, admission to hospital, general practitioner (GP) visits and other drugs used. We could not analyse deaths. Although cited by <LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>, they were included among other causes of withdrawal.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-11-05 22:41:40 +1000" MODIFIED_BY="[Empty name]">
<P>
 
</P>
<SUMMARY_OF_RESULTS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>We used a comprehensive search strategy and made every effort to identify relevant studies. In the majority of our comparisons, drawing definitive conclusions was impaired by the small number of studies and participants. The studies demonstrated a decreased incidence of influenza A in children using amantadine during a period ranging from 14 to 18 weeks. The number needed to treat to benefit (NNTB) indicates that for every nine to 17 children receiving amantadine, one case of influenza A can be prevented.</P>
<P>Rimantadine had no proven effect in preventing influenza in either age group but could be effective when we combined the results of both groups. Nevertheless, any inferences from combining these groups must be treated with considerable caution, as they are different clinical groups combined with a small number of studies. Extraneous characteristics between those groups, other than age or previous immunisations, may also have occurred impairing generalisation of these results. Multiple comparisons should also be taken into account in the interpretation of these results.</P>
<P>When amantadine and rimantadine were combined, they appeared to prevent the occurrence of fever on day three in children. However, when analysed separately, this effect was confirmed only for rimantadine. It must be emphasised that there was just one rimantadine trial selected for this outcome (<LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>), in which the baseline risk for the occurrence of fever on day three was 38%. For every five children (ranging from three to 25) treated with rimantadine in this unique small sample, it would be possible to prevent one case of fever on day three of treatment.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>It could be suggested that amantadine is well tolerated by children, as its use was not related to an increase in the occurrence of the analysed adverse effects. Nevertheless, it may be difficult to distinguish between an adverse effect of the drug and a clinical manifestation of influenza itself. The outcomes muscular pain, headache, malaise, diarrhoea and nausea/vomiting may be adverse effects of amantadine as well as clinical manifestations of influenza in children (<LINK REF="REF-MS-2006" TYPE="REFERENCE">MS 2006</LINK>). In the same way, the outcome dyspnoea (as in <LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK>) may also occur due to other respiratory diseases, such as asthma, since an asthmatic episode may be triggered by respiratory viruses. So we must emphasise that adverse effects of the drug and clinical manifestations of influenza may had been confounded, since the selected trials were carried out in ill children.</P>
<P>Rimantadine, administered exclusively on a prophylactic basis, was not related to an increase in the occurrence of the analysed adverse effects. In contrast to amantadine studies, just nausea/vomiting could be confounded with influenza manifestations. The other adverse effects could not be confounded, as two of the three selected studies were about prophylaxis and were conducted in children without influenza (<LINK REF="STD-Clover-1986" TYPE="STUDY">Clover 1986</LINK>; <LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>). The third study was the only one carried out in children with influenza (<LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>). Cerebellar ataxia and nausea/vomiting were the studied adverse effects in this trial. Cerebellar ataxia could not be confounded as it had not been described as an influenza manifestation. Cases of nausea/vomiting, which were also cited by Crawford, could have been confounded with influenza manifestations in Hall's article. The side effects nausea/vomiting were described in two studies (<LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>; <LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>), while all the other adverse effects were mentioned in just one: diarrhoea, dizziness, hyperreactivity, tinnitus (<LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>), gastrointestinal (GI) symptoms, central nervous system (CNS) symptoms, changes in behaviour (<LINK REF="STD-Clover-1986" TYPE="STUDY">Clover 1986</LINK>), and cerebellar ataxia (<LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>). Rimantadine also was considered to be well tolerated by the elderly, since it was not related to an increase in the incidence of adverse effects in this age group. However, the studied samples were even smaller in the elderly than in the children's age group and this fact may have influenced our results (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>; <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK>).</P>
<P>When analysing the adverse reactions to the antivirals, we could not even try to overcome the limitation of the small number of articles and the small samples studied by combining the results of both age groups, as the trial authors had described different outcomes (<LINK REF="STD-Clover-1986" TYPE="STUDY">Clover 1986</LINK>; <LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>; <LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>; <LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK>; <LINK REF="STD-Kitamoto-1971" TYPE="STUDY">Kitamoto 1971</LINK>; <LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>; <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK>).</P>
<P>Comparison of different doses of antiviral drugs was available only for rimantadine and was tested in only one study related to the elderly group. There was no selected trial regarding the treatment either in children or in participants using amantadine in both age groups. Both doses were shown to be comparable in the prophylaxis of influenza as well as in the occurrence of adverse effects, with no proven efficacy (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>).</P>
<P>Data for comparison to other antivirals were available just for rimantadine and zanamivir for prophylaxis of influenza A in the elderly group. This fact allowed a comparison of drugs of the two different classes of antivirals: M2 ion channel inhibitors and neuraminidase inhibitors. Zanamivir more effectively prevented influenza A in the elderly group (<LINK REF="STD-Gravenstein-2005" TYPE="STUDY">Gravenstein 2005</LINK>; <LINK REF="STD-Schilling-1998" TYPE="STUDY">Schilling 1998</LINK>).</P>
<P>These antivirals proved to be effective prophylactics against influenza in the 1968 Hong Kong pandemic and in the 1977 pandemic-like event 'Russian influenza'. Although the same resistance marker (Ser31Asn) was present in two isolates of influenza A (H5N1) obtained from patients in China in 2003 and in one lineage of avian and human H5N1 viruses in Thailand, Vietnam and Cambodia, most tested isolates from a second lineage that had been circulating in Indonesia, China, Mongolia, Russia and Turkey appear to be sensitive to amantadine (<LINK REF="REF-Hayden-2005" TYPE="REFERENCE">Hayden 2005</LINK>; <LINK REF="REF-Li-2014" TYPE="REFERENCE">Li 2014</LINK>). Furthermore, the next pandemic virus may be one that, like H2N2, is susceptible to this class of drug. If the circulating strain were known to be susceptible to M2 inhibitors, these drugs would offer a less costly alternative to other antivirals (neuraminidase inhibitors) for prophylaxis against influenza.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>We selected a total of 12 randomised controlled trials (RCTs) (2494 participants: 1586 children and adolescents and 908 elderly participants).</P>
<P>The main factors that affect the strength of evidence are the sparsity of data and the unclear risk of selection bias (<LINK REF="STD-Clover-1986" TYPE="STUDY">Clover 1986</LINK>; <LINK REF="STD-Clover-1991" TYPE="STUDY">Clover 1991</LINK>; <LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>; <LINK REF="STD-Finklea-1967" TYPE="STUDY">Finklea 1967</LINK>; <LINK REF="STD-Gravenstein-2005" TYPE="STUDY">Gravenstein 2005</LINK>; <LINK REF="STD-Kitamoto-1968" TYPE="STUDY">Kitamoto 1968</LINK>; <LINK REF="STD-Kitamoto-1971" TYPE="STUDY">Kitamoto 1971</LINK>; <LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>; <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK>; <LINK REF="STD-Schilling-1998" TYPE="STUDY">Schilling 1998</LINK>). We classified two of these studies, both in the elderly, as high risk of bias because of incomplete outcome data (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>; <LINK REF="STD-Patriarca-1984" TYPE="STUDY">Patriarca 1984</LINK>) and a high probability of detection bias (<LINK REF="STD-Monto-1995" TYPE="STUDY">Monto 1995</LINK>). We considered two trials, both in children and adolescents, to have a low risk of bias (<LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>; <LINK REF="STD-Payler-1984" TYPE="STUDY">Payler 1984</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>The use of unpublished data, obtained in electronic correspondence with two of the 12 contact trial authors (<LINK REF="STD-Hall-1987" TYPE="STUDY">Hall 1987</LINK>; <LINK REF="STD-Payler-1984" TYPE="STUDY">Payler 1984</LINK>), was the only identified potential bias in this review process.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-11-05 22:41:40 +1000" MODIFIED_BY="[Empty name]">
<P>Although another Cochrane review carried out in adults showed that both amantadine and rimantadine are efficacious and safe in the prophylaxis and treatment of influenza A symptoms (<LINK REF="REF-Jefferson-2006b" TYPE="REFERENCE">Jefferson 2006b</LINK>), we could not reach the same conclusion in children and the elderly, except for prophylaxis with amantadine in children. This antiviral was effective in preventing influenza A in children. As in the adults review, rimantadine shortens the duration of fever in children. In 2012, the editorial team considered that the question addressed by this Cochrane review dealing with adults was no longer relevant to decision-making, as amantadine and rimantadine for influenza A in adults had been replaced by neuraminidase inhibitors and were no longer used.</P>
<P>The M2 ion channel inhibitors are increasingly subject to viral resistance (<LINK REF="REF-Goodman-2006" TYPE="REFERENCE">Goodman 2006</LINK>; 
<LINK REF="REF-Sleeman-2013" TYPE="REFERENCE">Sleeman 2013</LINK>). Nevertheless, we consider that in these two especially vulnerable age groups, we should continue to assess the susceptibility of any influenza A outbreak virus to all antiviral drugs, as they may be the first line of defence before an effective vaccine becomes available (<LINK REF="REF-Sleeman-2013" TYPE="REFERENCE">Sleeman 2013</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-11-05 22:44:16 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-11-05 22:42:09 +1000" MODIFIED_BY="[Empty name]">
<P>The quality of evidence currently available does not provide strong support for amantadine and rimantadine use to treat and prevent influenza in children and the elderly.</P>
<P>Amantadine was effective in preventing influenza A in children but the safety of the drug was not well established. Currently, rimantadine cannot be recommended as a prophylactic drug for either age group. Nevertheless, if we consider: 1) that it is a safe drug, 2) the results of the combined age groups and 3) the possibility that the next pandemic virus is susceptible to this class of drug, as indicated in former pandemics, we can still consider this 'old' drug as a less costly alternative to neuraminidase inhibitors.</P>
<P>Our conclusions regarding the effectiveness of both antivirals for the treatment of influenza A in children were limited to a proven benefit of rimantadine in the abatement of fever by day three of treatment. This benefit does not seem to justify a recommendation for using rimantadine to treat all children with influenza A. We could not reach a conclusion regarding amantadine in the elderly, or antiviral treatment in this age group, as no trials fulfilled our selection criteria.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-11-05 22:44:16 +1000" MODIFIED_BY="[Empty name]">
<P>Definitive conclusions may have been impaired by the small number of selected studies and the small sample numbers used. Further research is necessary for the following.</P>
<SUBSECTION>
<HEADING LEVEL="3">Treatment</HEADING>
<UL>
<LI>Amantadine for the treatment of influenza A in children to increase the sample numbers and the power of the studies.</LI>
<LI>Rimantadine for the treatment of influenza A in children in order to confirm the observed result from the only selected study and to see if the drug could be useful in treating other clinical manifestations of influenza.</LI>
<LI>Amantadine and rimantadine for the treatment of influenza A in the elderly, as no identified studies fulfilled our inclusion criteria.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Prophylaxis</HEADING>
<UL>
<LI>Rimantadine in children to increase the sample numbers and the power of the studies, in order to achieve more definitive conclusions.</LI>
<LI>Amantadine in the elderly, as there were no identified studies fulfilling our inclusion criteria for this age group.</LI>
<LI>Rimantadine in the elderly to increase the sample numbers and the power of the studies, in order to achieve more definitive conclusions.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<UL>
<LI>Amantadine in children without influenza to avoid confounding adverse reactions of the antiviral with clinical manifestations of influenza.</LI>
<LI>Rimantadine in the elderly to increase the sample numbers and the power of the studies.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Different doses of amantadine and rimantadine</HEADING>
<UL>
<LI>Further information is necessary on both drugs in both age groups.</LI>
</UL>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>The authors would like to thank Amanda Burls, Rebecca Mears, David Moore, Lisa Gold and Karen Elley for the use of their protocol. We also would like to thank Tom Jefferson and Richard Stubbs for comments provided on the draft protocol. We acknowledge Elizabeth Dooley from the Cochrane Acute Respiratory Infections Group for helping us in all phases of the review process; Ruth Foxlee and Sarah Thorning, for their essential help with the search strategy, the Iberoamerican Cochrane Centre and especially the kindness of Marta Roque, who helped us in the statistical and methodological aspects of the review. We also acknowledge Raimundo Santos, Vladmír Plesnik, Oleg Borisenko and Stuko Nakano for the assessment and translation of the essential topics for this review from the clinical trials published in German, French, Czech, Russian and Japanese. We also thank Jonathan Haliburton for reviewing the English version of this manuscript. The review authors wish to thank Caroline Hall, David Payler and Vladmír Plesnik, who generously provided us with unpublished trial data. Finally, we wish to thank the following referees who gave their permission to be acknowledged for commenting on this review: Maryann Napoli, Nelcy Rodriguez and Tom Jefferson.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-05-07 14:08:10 +1000" MODIFIED_BY="[Empty name]">
<P>Márcia G Alves Galvão: none known.<BR/>Marilene Augusta Rocha Crispino Santos: none known.<BR/>Antonio Ledo Alves da Cunha: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Márcia G Alves Galvão (MG) selected the trials, extracted data and was responsible of the methodological aspects of the review. <BR/>Marilene Augusta Rocha Crispino Santos (MS) selected the trials, extracted data, was responsible of the methodological aspects of the review and supervised the day-to-day work of the review.<BR/>Antonio Ledo Alves da Cunha (AC) was appointed as an arbitrator to solve disagreements between MG and MS on the selection of the trials. He supervised the work in all phases and provided his experience on the development of the review. </P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-11-05 22:45:51 +1000" MODIFIED_BY="[Empty name]">
<P>Originally in the protocol we planned to study the drug effect on reduction of fever and cough, as they are considered the best predictors of influenza diagnosis. After collecting data, we verified that specific timelines for reduction of signs and symptoms were not reported in the included trials. So, we considered the available data and arbitrarily chose a day of antiviral use to evaluate the response to the treatment. This choice was based on Eccle's study in which clinical manifestations were classified into early and later symptoms (<LINK REF="REF-Eccle-2005" TYPE="REFERENCE">Eccle 2005</LINK>).</P>
<P>We applied wider age ranges for children than the definition stated in the protocol (participants up to 16 years of age). Trials in older participants who were adolescents by the World Health Organization (WHO) definition were also included (<LINK REF="REF-WHO-2007" TYPE="REFERENCE">WHO 2007</LINK>). Data regarding the proportion of the subgroup which strictly fulfilled the age criterion in the protocol were not available in five studies or by contacting the trial authors. The respective age ranges were one to 17 years (<LINK REF="STD-Clover-1991" TYPE="STUDY">Clover 1991</LINK>), 13 to 19 years (<LINK REF="STD-Payler-1984" TYPE="STUDY">Payler 1984</LINK>), one to 18 years (<LINK REF="STD-Clover-1986" TYPE="STUDY">Clover 1986</LINK>; <LINK REF="STD-Crawford-1988" TYPE="STUDY">Crawford 1988</LINK>), and eight to 19 years of age (<LINK REF="STD-Finklea-1967" TYPE="STUDY">Finklea 1967</LINK>).</P>
<P>We planned only to make 12 comparisons. However, whilst analysing data we considered doing an additional comparison and put the two age groups together. As the small samples studied in rimantadine trials for prophylaxis might have influenced the observed results, we tried to overcome this limitation by combining the trials with rimantadine in children and in the elderly. It must be stressed that extraneous characteristics between those groups, other than age or previous immunisations, may have occurred, impairing generalisation of these results.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2008-06-23 09:17:53 +1000" MODIFIED_BY="[Empty name]">
<P> </P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-11-13 09:36:41 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-11-05 23:24:03 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Clover-1986" MODIFIED="2014-05-05 17:44:23 +1000" MODIFIED_BY="Liz Dooley" NAME="Clover 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clover RD, Crawford SA, Abell TD, Ramsey CN Jr, Glezen WP, Couch RB</AU>
<TI>Effectiveness of rimantadine prophylaxis of children within families</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1986</YR>
<VL>140</VL>
<NO>7</NO>
<PG>706-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00043175"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clover-1991" NAME="Clover 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clover RD, Warner JL, Becker L, Davis A</AU>
<TI>Effect of rimantadine on the immune response to influenza A infections</TI>
<SO>Journal of Medical Virology</SO>
<YR>1991</YR>
<VL>34</VL>
<NO>1</NO>
<PG>68-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1885945"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crawford-1988" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Crawford 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crawford SA, Clover RD, Abell TD, Ramsey CN, Glezen WP, Couch RB</AU>
<TI>Rimantadine prophylaxis in children: a follow up study</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1988</YR>
<VL>7</VL>
<NO>6</NO>
<PG>379-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="3292997"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Finklea-1967" NAME="Finklea 1967" YEAR="1967">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Finklea JF, Hennessy AV, Davenport FM</AU>
<TI>A field trial of amantadine prophylaxis in naturally-occurring acute respiratory illness</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1967</YR>
<VL>85</VL>
<PG>403-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="5337715"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gravenstein-2005" NAME="Gravenstein 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gravenstein S, Drinka P, Osterweil D, Schilling M, Krause P, Elliot M et al</AU>
<TI>Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population</TI>
<SO>Journal of the American Medical Directors Association</SO>
<YR>2005</YR>
<VL>6</VL>
<PG>359-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hall-1987" MODIFIED="2011-06-16 00:49:13 +1000" MODIFIED_BY="[Empty name]" NAME="Hall 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-06-16 00:49:13 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hall CB, Dolin R, Gala CL, Markovitz DM, Zhang YQ, Madore PH et al</AU>
<TI>Children with influenza A infection: treatment with rimantadine</TI>
<SO>Pediatrics</SO>
<YR>1987</YR>
<VL>80</VL>
<PG>275-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00049308"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kitamoto-1968" MODIFIED="2011-07-19 15:08:15 +1000" MODIFIED_BY="[Empty name]" NAME="Kitamoto 1968" YEAR="1968">
<REFERENCE MODIFIED="2011-07-19 15:08:15 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kitamoto O</AU>
<TI>Therapeutic effectiveness of amantadine hydrochloride in influenza A2-double-blind studies</TI>
<SO>Japanese Journal of Tuberculosis and Chest Diseases</SO>
<YR>1968</YR>
<VL>15</VL>
<NO>1</NO>
<PG>17-26</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00004214"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kitamoto-1971" MODIFIED="2011-07-19 15:08:23 +1000" MODIFIED_BY="[Empty name]" NAME="Kitamoto 1971" YEAR="1971">
<REFERENCE MODIFIED="2011-07-19 15:08:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kitamoto O</AU>
<TI>Therapeutic effectiveness of amantadine hydrochloride in naturally occurring Hong Kong influenza - double-blind studies</TI>
<SO>Japanese Journal of Tuberculosis and Chest Diseases</SO>
<YR>1971</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-0000725"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monto-1995" NAME="Monto 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monto AS, Ohmit SE, Hornbuckle K, Pearce CL</AU>
<TI>Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1995</YR>
<VL>39</VL>
<PG>2224-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00121619"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patriarca-1984" NAME="Patriarca 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patriarca PA, Kater NA, Kendal AP, Bregman DJ, Smith JD, Sikes RK</AU>
<TI>Safety of prolonged administration of rimantadine hydrochloride in prophylaxis of influenza A virus infections in nursing homes</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1984</YR>
<VL>26</VL>
<NO>1</NO>
<PG>101-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00035517"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Payler-1984" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Payler 1984" YEAR="1984">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Payler DK, Purdham PA</AU>
<TI>Influenza A prophylaxis with amantadine in a boarding school</TI>
<SO>Lancet</SO>
<YR>1984</YR>
<VL>1</VL>
<NO>8375</NO>
<PG>502-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schilling-1998" NAME="Schilling 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schilling M, Polvinelli L, Krause P, Gravenstein M, Ambrozaitis A, Jones HH et al</AU>
<TI>Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks</TI>
<SO>Vaccine</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>1771-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="9778755"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-11-05 23:24:03 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-AAPCID-2007" MODIFIED="2011-06-16 00:56:31 +1000" MODIFIED_BY="[Empty name]" NAME="AAPCID 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-06-16 00:56:31 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>American Academy of Pediatrics Committee on Infectious Diseases</AU>
<TI>Antiviral therapy and prophylaxis for influenza in children</TI>
<SO>Pediatrics</SO>
<YR>2007</YR>
<VL>119</VL>
<NO>4</NO>
<PG>852-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allen-2006" MODIFIED="2011-09-05 10:08:43 +1000" MODIFIED_BY="[Empty name]" NAME="Allen 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-09-05 10:08:43 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allen UD, Aoki FY, Stiver HG</AU>
<TI>The use of antiviral drugs for influenza: recommended guidelines for practitioners</TI>
<SO>Canadian Journal of infectious Diseases and Medical Microbiology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>5</NO>
<PG>273-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-2006" NAME="Anonymous 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Antiviral drugs in influenza: an adjunct to vaccination in some situations</TI>
<SO>Prescrire International</SO>
<YR>2006</YR>
<VL>15</VL>
<NO>81</NO>
<PG>21-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-2007" NAME="Anonymous 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Oseltamivir: new indication. Prevention of influenza in at-risk children: vaccination is best</TI>
<SO>Prescrire International</SO>
<YR>2007</YR>
<VL>16</VL>
<NO>87</NO>
<PG>9-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anton-2011" MODIFIED="2014-11-05 20:37:23 +1000" MODIFIED_BY="[Empty name]" NAME="Anton 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-11-05 20:37:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anton A, Pumarola T</AU>
<TI>Influenza in immunocompromised patients: Considerations for therapy</TI>
<SO>Future Virology</SO>
<YR>2011</YR>
<VL>6</VL>
<PG>855-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aoky-1985a" MODIFIED="2011-11-23 02:58:58 +1000" MODIFIED_BY="[Empty name]" NAME="Aoky 1985a" YEAR="1985">
<REFERENCE MODIFIED="2011-11-23 02:58:58 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aoky FY, Sitar DS</AU>
<TI>Amantadine kinetics in healthy elderly men: implications for influenza prevention</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1985</YR>
<VL>37</VL>
<NO>2</NO>
<PG>137-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00186271"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aoky-1985b" NAME="Aoky 1985b" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aoky FY, Silver HG, Sitar DS, Boudreault A, Ogilvie RI</AU>
<TI>Prophylactic amantadine dose and plasma concentration-effect relationships in healthy adults</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1985</YR>
<VL>37</VL>
<NO>2</NO>
<PG>128-36</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00036657"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aoky-1986" NAME="Aoky 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aoky FY, Sitar DS, Milley EV</AU>
<TI>Potential of influenza vaccine and amantadine to prevent influenza A illness in Canadian Forces personnel 1980-1983</TI>
<SO>Military Medicine</SO>
<YR>1986</YR>
<VL>151</VL>
<NO>9</NO>
<PG>459-65</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00174577"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Atiee-2012" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Atiee 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Atiee G&lt;br&gt;Lasseter K&lt;br&gt;Baughman S&lt;br&gt;McCullough A&lt;br&gt;Collis P&lt;br&gt;Hollister A&lt;br&gt;Hernandez J&lt;/p&gt;" NOTES_MODIFIED="2014-11-05 21:58:42 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Atiee G, Lasseter K, Baughman S, McCullough A, Collis P, Hollister A et al</AU>
<TI>Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>2012</YR>
<VL>52</VL>
<PG>1410-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Atmar-1990" MODIFIED="2011-11-23 02:59:43 +1000" MODIFIED_BY="[Empty name]" NAME="Atmar 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-11-23 02:59:43 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Atmar RL, Greenberg SB, Quarles JM, Wilson SZ, Tyler B, Feldman S et al</AU>
<TI>Safety and pharmacokinetics of rimantadine small-particle aerosol</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1990</YR>
<VL>34</VL>
<NO>11</NO>
<PG>2228-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00073727"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bacosi-2002" MODIFIED="2014-11-05 23:23:46 +1000" MODIFIED_BY="[Empty name]" NAME="Bacosi 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-11-05 23:23:46 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Bacosi, Marco&lt;br&gt;Russo, Francesca&lt;br&gt;D'innocenzo, Sara&lt;br&gt;Santolamazza, Mauro&lt;br&gt;Miglioresi, Lucia&lt;br&gt;Ursitti, Antonella&lt;br&gt;De Angelis, Anna&lt;br&gt;Patrizi, Franca&lt;br&gt;Ricci, Giovanni L.&lt;br&gt;Hepatol Res. 2002 Mar;22(3):231-239.&lt;/p&gt;" NOTES_MODIFIED="2014-11-05 23:23:46 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bacosi M, Russo F, D'Innocenzo S, Santolamazza M, Miglioresi L, Ursitti A et al</AU>
<TI>Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients</TI>
<SO>Hepatology Research</SO>
<YR>2002</YR>
<VL>22</VL>
<PG>231-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baker-1969" MODIFIED="2011-09-05 10:07:56 +1000" MODIFIED_BY="[Empty name]" NAME="Baker 1969" YEAR="1969">
<REFERENCE MODIFIED="2011-09-05 10:07:56 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baker LM, Shock MP, Iezzoni DG</AU>
<TI>The therapeutic efficacy of Symmetrel (amantadine hydrochloride) in naturally occurring influenza A2 respiratory illness</TI>
<SO>Journal of the American Osteopathic Association</SO>
<YR>1969</YR>
<VL>68</VL>
<NO>12</NO>
<PG>1244-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00003808"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bantia-2010" MODIFIED="2011-11-23 03:00:48 +1000" MODIFIED_BY="[Empty name]" NAME="Bantia 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-11-23 03:00:48 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bantia S, Kellogg D, Parker CD, Babu YS</AU>
<TI>Combination of peramivir and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model</TI>
<SO>Antiviral Research</SO>
<YR>2010</YR>
<VL>88</VL>
<NO>3</NO>
<PG>276-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barr-2007a" MODIFIED="2014-05-05 17:47:32 +1000" MODIFIED_BY="Liz Dooley" NAME="Barr 2007a" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barr IG, Hurt AC, Deed N, Iannello P, Tomasov C, Komadina N</AU>
<TI>The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006</TI>
<SO>Antiviral Research</SO>
<YR>2007</YR>
<VL>75</VL>
<NO>2</NO>
<PG>173-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barr-2007b" NAME="Barr 2007b" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barr IG, Hurt AC, Iannello P, Tomasov C, Deed N, Komadina N</AU>
<TI>Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005</TI>
<SO>Antiviral Research</SO>
<YR>2007</YR>
<VL>73</VL>
<NO>2</NO>
<PG>112-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bauer-2007" NAME="Bauer 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bauer K, Schrader C, Suess J, Wutzler P, Schmidtke M</AU>
<TI>Neuraminidase inhibitor susceptibility of porcine H3N2 influenza A viruses isolated in Germany between 1982 and 1999</TI>
<SO>Antiviral Research</SO>
<YR>2007</YR>
<VL>75</VL>
<NO>3</NO>
<PG>219-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belenky-1998" NAME="Belenky 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belenky S, Gentile D, Doyle W, Patel A, Hayden F, Skoner D</AU>
<TI>Rimantadine effect on specific serum hemagglutination inhibition and nasal antibodies in experimental influenza virus exposure of adults</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1998</YR>
<VL>157</VL>
<NO>3</NO>
<PG>A173</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00428220"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bloomfield-1970" NAME="Bloomfield 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bloomfield SS, Gaffney TE, Schiff GM</AU>
<TI>A design for the evaluation of antiviral drugs in human influenza</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1970</YR>
<VL>91</VL>
<NO>6</NO>
<PG>568-74</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00004457"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boltz-2010" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Boltz 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Boltz DA&lt;br&gt;Aldridge JR Jr&lt;br&gt;Webster RG&lt;br&gt;Govorkova EA&lt;br&gt;1F32AI078667 (United States NIAID NIH HHS)&lt;br&gt;HHSN 266200700005C (United States PHS HHS)&lt;/p&gt;" NOTES_MODIFIED="2014-11-05 21:58:42 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boltz DA, Aldridge JR Jr, Webster RG, Govorkova EA</AU>
<TI>Drugs in development for influenza</TI>
<SO>Drugs</SO>
<YR>2010</YR>
<VL>70</VL>
<NO>11</NO>
<PG>1349-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brady-1990" MODIFIED="2011-06-16 00:50:46 +1000" MODIFIED_BY="[Empty name]" NAME="Brady 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-06-16 00:50:46 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brady MT, Sears SD, Pacini DL, Samorodin R, DePamphilis J, Oakes M et al</AU>
<TI>Safety and prophylactic efficacy of low-dose rimantadine in adults during an influenza A epidemic</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1990</YR>
<VL>34</VL>
<NO>9</NO>
<PG>1633-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00073150"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brammer-2009" MODIFIED="2014-11-05 20:40:57 +1000" MODIFIED_BY="[Empty name]" NAME="Brammer 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-11-05 20:40:57 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Seasonal and pandemic influenza surveillance considerations for constructing multicomponent systems&lt;/p&gt;" NOTES_MODIFIED="2014-11-05 20:40:57 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brammer L, Budd A, Cox N</AU>
<TI>Seasonal and pandemic influenza surveillance considerations for constructing multi component systems</TI>
<SO>Influenza and Other Respiratory Viruses</SO>
<YR>2009</YR>
<VL>3</VL>
<NO>2</NO>
<PG>51-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bricaire-1990" MODIFIED="2011-06-16 00:51:43 +1000" MODIFIED_BY="[Empty name]" NAME="Bricaire 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-06-16 00:51:43 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bricaire F, Hannoun C, Boissel JP</AU>
<TI>Prevention of influenza A. Effectiveness and tolerance of rimantadine hydrochloride</TI>
<TO>Prevention de la grippe A. Efficacite et tolerance du chlor hydrate de rimantadine</TO>
<SO>Nouvelle Presse Médicale</SO>
<YR>1990</YR>
<VL>19</VL>
<NO>2</NO>
<PG>69-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00065369"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bryson-1990" MODIFIED="2011-07-19 15:27:13 +1000" MODIFIED_BY="[Empty name]" NAME="Bryson 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-07-19 15:27:13 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bryson YJ, Monahan C, Pollack M, Shields WD</AU>
<TI>A prospective double-blind study of side effects associated with the administration of amantadine for influenza A virus prophylaxis</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1980</YR>
<VL>141</VL>
<PG>543-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00022658"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burch-2009" MODIFIED="2011-11-23 03:01:39 +1000" MODIFIED_BY="[Empty name]" NAME="Burch 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-11-23 03:01:39 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Antiviral drugs for the treatment of influenza: A systematic review and economic evaluation&lt;/p&gt;" NOTES_MODIFIED="2011-11-23 03:01:39 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burch J, Paulden M, Conti S, Stock C, Corbett M, Welton NJ et al</AU>
<TI>Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation</TI>
<SO>Health Technology Assessment</SO>
<YR>2009</YR>
<VL>13</VL>
<NO>58</NO>
<PG>1-265</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cady-2011" MODIFIED="2011-07-19 15:28:07 +1000" MODIFIED_BY="[Empty name]" NAME="Cady 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-07-19 15:28:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cady SD, Wang J, Wu Y, Degrado WF, Hong M</AU>
<TI>Specific binding of adamantane drugs and direction of their polar amines in the pore of the influenza M2 transmembrane domain in lipid bilayers and dodecylphosphocholine micelles determined by NMR spectroscopy</TI>
<SO>Journal of the American Chemical Society</SO>
<YR>2011</YR>
<VL>133</VL>
<NO>12</NO>
<PG>4274-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Callmander-1968" MODIFIED="2014-11-05 20:42:24 +1000" MODIFIED_BY="[Empty name]" NAME="Callmander 1968" YEAR="1968">
<REFERENCE MODIFIED="2014-11-05 20:42:24 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Callmander E, Hellgren L</AU>
<TI>Amantadine hydrochloride as a prophylactic in respiratory infections. A double-blind investigation of its clinical use and serology</TI>
<SO>Journal of Clinical Pharmacology and the Journal of New Drugs</SO>
<YR>1968</YR>
<VL>8</VL>
<NO>3</NO>
<PG>186-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carter-2008" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Carter 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix(trademark)]: A review of its use as an active immunization against influenza A subtype H5N1 virus&lt;/p&gt;" NOTES_MODIFIED="2014-11-05 21:58:42 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carter NJ, Plosker GL</AU>
<TI>Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus</TI>
<SO>BioDrugs</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>5</NO>
<PG>279-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cayley-2010" MODIFIED="2011-07-19 15:29:34 +1000" MODIFIED_BY="[Empty name]" NAME="Cayley 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-07-19 15:29:34 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cayley WE Jr</AU>
<TI>Neuraminidase inhibitors for influenza treatment and prevention in healthy adults</TI>
<SO>American Family Physician</SO>
<YR>2010</YR>
<VL>82</VL>
<NO>3</NO>
<PG>242-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cayley-2012" MODIFIED="2014-05-05 17:47:48 +1000" MODIFIED_BY="Liz Dooley" NAME="Cayley 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-05-05 17:47:48 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cayley Jr WE</AU>
<TI>Are neuraminidase inhibitors effective for preventing and treating influenza in healthy adults and children?</TI>
<SO>American Family Physician</SO>
<YR>2012</YR>
<VL>86</VL>
<PG>624-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chawla-2009" MODIFIED="2011-07-19 15:29:43 +1000" MODIFIED_BY="[Empty name]" NAME="Chawla 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-07-19 15:29:43 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Influenza A (H1N1) outbreak and challenges for pharmacotherapy&lt;/p&gt;" NOTES_MODIFIED="2011-07-19 15:29:43 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chawla R, Sharma RK, Bhardwaj JR</AU>
<TI>Influenza A (H1N1) outbreak and challenges for pharmacotherapy</TI>
<SO>Indian Journal of Physiology and Pharmacology</SO>
<YR>2009</YR>
<VL>53</VL>
<NO>2</NO>
<PG>113-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chemaly-2006" NAME="Chemaly 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ el al</AU>
<TI>Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center</TI>
<SO>Medicine (Baltimore)</SO>
<YR>2006</YR>
<VL>85</VL>
<NO>5</NO>
<PG>278-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2007" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Chen 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Review17943819&lt;/p&gt;" NOTES_MODIFIED="2014-11-05 21:58:42 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="COCHRANE_REVIEW">
<AU>Chen XY, Wu TX, Liu GJ, Wang Q, Zheng J, Wei J et al</AU>
<TI>Chinese medicinal herbs for influenza</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-09-01 11:46:27 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-09-01 11:46:27 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004559.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-06-27 10:12:13 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2004" MODIFIED="2011-07-19 16:55:31 +1000" MODIFIED_BY="[Empty name]" NAME="Cheng 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-07-19 16:55:31 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng VCC, Tang BSF, Wu AKL, Chu CM, Yuen KY</AU>
<TI>Medical treatment of viral pneumonia including SARS in immunocompetent adult</TI>
<SO>Journal of Infection</SO>
<YR>2004</YR>
<VL>49</VL>
<NO>4</NO>
<PG>262-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2004434613"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2009" MODIFIED="2011-07-19 16:56:46 +1000" MODIFIED_BY="[Empty name]" NAME="Cheng 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-07-19 16:56:46 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Assessing the Quality of Evidence From Randomized, Controlled Drug and Nutritional Supplement Trials Conducted Among Nursing Home Residents Between 1968 and 2004: What Can We Learn?&lt;/p&gt;" NOTES_MODIFIED="2011-07-19 16:56:46 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng HY</AU>
<TI>Assessing the quality of evidence from randomized, controlled dug and nutritional supplement trials conducted among nursing home residents between 1968 and 2004: what can we learn?</TI>
<SO>Journal of the American Medical Directors Association</SO>
<YR>2009</YR>
<VL>10</VL>
<NO>1</NO>
<PG>28-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2012" MODIFIED="2014-05-05 17:48:16 +1000" MODIFIED_BY="Liz Dooley" NAME="Cheng 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-05-05 17:48:16 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng VCC, To KKW, Tse H, Hung IFN, Yuen KY</AU>
<TI>Two years after pandemic influenza A/2009/H1N1: What have we learned?</TI>
<SO>Clinical Microbiology Reviews</SO>
<YR>2012</YR>
<VL>25</VL>
<PG>223-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Choi-2009" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Choi 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;NovResearch Support, Non-U.S. Gov't19720085&lt;/p&gt;" NOTES_MODIFIED="2014-11-05 21:58:42 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Choi WY, Kim SJ, Lee NJ, Kwon M, Yang IS, Kim Min-Ji et al</AU>
<TI>Amantadine-resistant influenza A viruses isolated in South Korea from 2003 to 2009</TI>
<SO>Antiviral Research</SO>
<YR>2009</YR>
<VL>84</VL>
<NO>2</NO>
<PG>199-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chou-2008" MODIFIED="2011-07-19 16:57:49 +1000" MODIFIED_BY="[Empty name]" NAME="Chou 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-07-19 16:57:49 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Pegylated interferons for chronic hepatitis C virus infection: An indirect analysis of randomized trials&lt;/p&gt;" NOTES_MODIFIED="2011-07-19 16:57:49 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chou R, Carson S, Chan BKS</AU>
<TI>Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials</TI>
<SO>Journal of Viral Hepatitis</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>8</NO>
<PG>551-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1976" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Cohen 1976" YEAR="1976">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen A, Togo Y, Khakoo R, Waldman R, Sigel M</AU>
<TI>Comparative clinical and laboratory evaluation of the prophylactic capacity of ribavirin, amantadine hydrochloride, and placebo in induced human influenza type A</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1976</YR>
<VL>133</VL>
<NO>Suppl</NO>
<PG>A114-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-0014092"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-2006" MODIFIED="2014-11-05 20:44:51 +1000" MODIFIED_BY="[Empty name]" NAME="Cohen 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-11-05 20:44:51 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen J, Cairns C, Paquette C, Faden L</AU>
<TI>Comparing patient access to pharmaceuticals in the UK and US</TI>
<SO>Applied Health Economics and Health Policy</SO>
<YR>2006</YR>
<VL>5</VL>
<NO>3</NO>
<PG>177-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cowling-2008" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Cowling 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Preliminary findings of a randomized trial of non-pharmaceutical interventions to prevent influenza transmission in households&lt;/p&gt;" NOTES_MODIFIED="2014-11-05 21:58:42 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cowling BJ, Fung ROP, Cheng CKY, Fang VJ, Chan KH, Seto WH et al</AU>
<TI>Preliminary findings of a randomized trial of non-pharmaceutical interventions to prevent influenza transmission in households</TI>
<SO>PloS One</SO>
<YR>2008</YR>
<VL>3</VL>
<PG>5</PG>
<IDENTIFIERS MODIFIED="2011-06-27 10:17:45 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Curran-2010" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Curran 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Curran MP, Leroux-Roels I</AU>
<TI>Inactivated split-virion seasonal influenza vaccine (Fluarix®): a review of its use in the prevention of seasonal influenza in adults and the elderly</TI>
<SO>Drugs</SO>
<YR>2010</YR>
<VL>70</VL>
<NO>12</NO>
<PG>1519-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dawkins-1968" MODIFIED="2014-11-05 20:45:22 +1000" MODIFIED_BY="[Empty name]" NAME="Dawkins 1968" YEAR="1968">
<REFERENCE MODIFIED="2014-11-05 20:45:22 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dawkins AT Jr, Gallager LR, Togo Y, Hornick RB, Harris BA</AU>
<TI>Studies on induced influenza in man. II. Double-blind study designed to assess the prophylactic efficacy of an analogue of amantadine hydrochloride</TI>
<SO>JAMA</SO>
<YR>1968</YR>
<VL>203</VL>
<PG>1095-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00001969"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-la-Camara-2007" MODIFIED="2011-11-23 03:06:30 +1000" MODIFIED_BY="[Empty name]" NAME="De la Camara 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-11-23 03:06:30 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Update on viral infections in immunocompromised patients&lt;/p&gt;" NOTES_MODIFIED="2011-11-23 03:06:30 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De La Camara R, Lopez-Jimenez J, Vallejo C, Vazquez L, Luis Perez J, Varo E et al</AU>
<TI>Update on viral infections in immunocompromised patients</TI>
<SO>Enfermedades Infecciosas y Microbiologia Clinica</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>Suppl 1</NO>
<PG>2-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DeLaney-2010" MODIFIED="2011-11-23 03:06:22 +1000" MODIFIED_BY="[Empty name]" NAME="DeLaney 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-11-23 03:06:22 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DeLaney E, Smith MJ, Harvey BT, Pelletier KJ, Aquino MP, Stone JM et al</AU>
<TI>Extracorporeal life support for pandemic influenza: the role of extracorporeal membrane oxygenation in pandemic management</TI>
<SO>Journal of Extra-Corporeal Technology</SO>
<YR>2010</YR>
<VL>42</VL>
<NO>4</NO>
<PG>268-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Denys-1963" NAME="Denys 1963" YEAR="1963">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Denys A, Szram S, Tkaczewski W, Niedzielska H, Bochenska J, Kulawczyk M et al</AU>
<TI>Antiviral activity of rimantadine, virological, pathomorphological, and clinical studies</TI>
<SO>Acta Microbiologica Polonica. Series A: Microbiologia Generalis</SO>
<YR>1973</YR>
<VL>5</VL>
<PG>217-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00009559"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Vincenzo-2012" MODIFIED="2014-05-05 17:48:38 +1000" MODIFIED_BY="Liz Dooley" NAME="De Vincenzo 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-05-05 17:48:38 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Vincenzo JP</AU>
<TI>The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses</TI>
<SO>Antiviral Therapy</SO>
<YR>2012</YR>
<VL>17</VL>
<PG>213-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dolamore-2003" NAME="Dolamore 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dolamore MJ</AU>
<TI>Influenza prophylaxis in long-tern care facility: a case-control study of the risk factors for adverse drug reactions to amantadine</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>9</NO>
<PG>753</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2004048279"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dolin-1982" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Dolin 1982" YEAR="1982">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J</AU>
<TI>A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection</TI>
<SO>New England Journal of Medicine</SO>
<YR>1982</YR>
<VL>307</VL>
<NO>10</NO>
<PG>580-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00201667"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doyle-1998" NAME="Doyle 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doyle WJ, Skoner DP, Patel A, Hayden FG</AU>
<TI>Effect of rimantadine on induced specific serum haemagglutination-inhibiting antibody and nasal IgA titres after experimental exposure of adults to influenza A virus</TI>
<SO>Antiviral Therapy</SO>
<YR>1998</YR>
<VL>3</VL>
<NO>1</NO>
<PG>19-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00201667"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drinevskii-1998" NAME="Drinevskii 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drinevskii VP, Osidak LV, Natsina VK, Afanas'eva OI, Mil'kint KK, Danini GV et al</AU>
<TI>Chemotherapeutics for treatment of influenza and other viral respiratory tract infections in children</TI>
<TO>Khimiopreparaty v terapii grippa i drugikh respiratomykh infektsii u detei</TO>
<SO>Antibiotiki i Khimioterapiia</SO>
<YR>1998</YR>
<VL>43</VL>
<NO>9</NO>
<PG>29-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00332458"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drinka-1998" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Drinka 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drinka PJ, Gravenstein S, Schilling M, Krause P, Miller BA, Shult P</AU>
<TI>Duration of antiviral prophylaxis during nursing home outbreaks of influenza. A comparison of 2 protocols</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1998</YR>
<VL>158</VL>
<NO>19</NO>
<PG>2155-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00156407"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Enger-2004" NAME="Enger 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Enger C, Nordstrom BL, Thakrar B, Sacks S, Rothman KJ</AU>
<TI>Health outcomes among patients receiving oseltamivir</TI>
<SO>Pharmacoepidemiology and Drug Safety</SO>
<YR>2004</YR>
<VL>13</VL>
<NO>4</NO>
<PG>227-37</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2004179080"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Escuret-2012" MODIFIED="2014-11-05 23:23:56 +1000" MODIFIED_BY="[Empty name]" NAME="Escuret 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-11-05 23:23:56 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Escuret V&lt;br&gt;Cornu C&lt;br&gt;Boutitie F&lt;br&gt;Enouf V&lt;br&gt;Mosnier A&lt;br&gt;Bouscambert-Duchamp M&lt;br&gt;Gaillard S&lt;br&gt;Duval X&lt;br&gt;Blanchon T&lt;br&gt;Leport C&lt;br&gt;Gueyffier F&lt;br&gt;Van Der Werf S&lt;br&gt;Lina B&lt;br&gt;S0166-3542(12)00176-3&lt;/p&gt;" NOTES_MODIFIED="2014-11-05 23:23:56 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Escuret V, Cornu C, Boutitie F, Enouf V, Mosnier A, Bouscambert-Duchamp M et al</AU>
<TI>Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A (H1N1) virus infections</TI>
<SO>Antiviral Research</SO>
<YR>2012</YR>
<VL>96</VL>
<PG>130-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Falagas-2010" MODIFIED="2011-07-19 17:00:07 +1000" MODIFIED_BY="[Empty name]" NAME="Falagas 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-07-19 17:00:07 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Treatment options for 2009 H1N1 influenza: Evaluation of the published evidence&lt;/p&gt;" NOTES_MODIFIED="2011-07-19 17:00:07 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Falagas ME, Vouloumanou EK, Baskouta E, Rafailidis PI, Polyzos K, Rello J</AU>
<TI>Treatment options for 2009 H1N1 influenza: evaluation of the published evidence</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>2010</YR>
<VL>35</VL>
<NO>5</NO>
<PG>421-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farlow-2008" MODIFIED="2011-07-19 17:00:26 +1000" MODIFIED_BY="[Empty name]" NAME="Farlow 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-07-19 17:00:26 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Research Support, N.I.H., Extramural&lt;br&gt;Research Support, Non-U.S. Gov't18558791&lt;/p&gt;" NOTES_MODIFIED="2011-07-19 17:00:26 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farlow MR, Graham SM, Alva G</AU>
<TI>Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials</TI>
<SO>Drug Safety</SO>
<YR>2008</YR>
<VL>31</VL>
<NO>7</NO>
<PG>577-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fiore-2008" MODIFIED="2011-11-23 03:07:36 +1000" MODIFIED_BY="[Empty name]" NAME="Fiore 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-11-23 03:07:36 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Antiviral effects of Glycyrrhiza species&lt;/p&gt;" NOTES_MODIFIED="2011-11-23 03:07:36 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fiore C, Eisenhut M, Krausse R, Ragazzi E, Pellati D, Armanini D et al</AU>
<TI>Antiviral effects of Glycyrrhiza species</TI>
<SO>Phytotherapy Research</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>2</NO>
<PG>141-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Furuta-2005" NAME="Furuta 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Furuta Y, Takahashi K, Kuno-Markawa M, Sangawa H, Uehara S, Kozaki K el al</AU>
<TI>Mechanism of action of T-705 against influenza virus</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2005</YR>
<VL>49</VL>
<NO>3</NO>
<PG>981-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galabov-2006" NAME="Galabov 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galabov AS, Simeonova L, Gegova G</AU>
<TI>Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice</TI>
<SO>Antiviral Chemistry &amp; Chemotherapy</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>5</NO>
<PG>251-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galbraith-1969a" NAME="Galbraith 1969a" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galbraith AW, Oxford JS, Schild GC, Watson GI</AU>
<TI>Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections in the family environment: a controlled double-blind study</TI>
<SO>Lancet</SO>
<YR>1969</YR>
<VL>2</VL>
<NO>7629</NO>
<PG>1026-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00003903"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galbraith-1969b" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Galbraith 1969b" YEAR="1969">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galbraith AW, Oxford JS, Schild GC, Watson GI</AU>
<TI>Study of 1-adamantanamine hydrochloride used prophylactically during the Hong-Kong influenza epidemic in the family environment</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1969</YR>
<VL>41</VL>
<NO>3</NO>
<PG>677-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="00004308"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galbraith-1971" MODIFIED="2011-06-16 00:59:05 +1000" MODIFIED_BY="[Empty name]" NAME="Galbraith 1971" YEAR="1971">
<REFERENCE MODIFIED="2011-06-16 00:59:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galbraith AW, Oxford JS, Schild GC, Potter CW, Watson GI</AU>
<TI>Therapeutic effect of 1-adamantanamine hydrochloride in naturally occurring influenza A 2-Hong Kong infection. A controlled double-blind study</TI>
<SO>Lancet</SO>
<YR>1971</YR>
<VL>2</VL>
<NO>7716</NO>
<PG>113-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="00006011"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galbraith-1973" MODIFIED="2011-07-19 17:01:21 +1000" MODIFIED_BY="[Empty name]" NAME="Galbraith 1973" YEAR="1973">
<REFERENCE MODIFIED="2011-07-19 17:01:21 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galbraith AW, Schild GC, Potter CW, Watson GI</AU>
<TI>The therapeutic effect of amantadine in influenza occurring during the winter of 1971-2 assessed by double-blind study</TI>
<SO>Journal of the Royal College of General Practitioners</SO>
<YR>1973</YR>
<VL>23</VL>
<NO>126</NO>
<PG>34-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00008567"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garman-2004" NAME="Garman 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garman E, Laver G</AU>
<TI>Controlling influenza by inhibiting the virus's neuramidase</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>363</VL>
<NO>9409</NO>
<PG>617-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2004098284"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gatwood-2012" MODIFIED="2014-05-05 17:49:47 +1000" MODIFIED_BY="Liz Dooley" NAME="Gatwood 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-05-05 17:49:47 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gatwood J, Meltzer MI, Messonnier M, Ortega-Sanchez IR, Balkrishnan R, Prosser LA</AU>
<TI>Seasonal influenza vaccination of healthy working-age adults: a review of economic evaluations</TI>
<SO>Drugs</SO>
<YR>2012</YR>
<VL>72</VL>
<PG>35-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerth-1966" MODIFIED="2011-11-23 03:08:21 +1000" MODIFIED_BY="[Empty name]" NAME="Gerth 1966" YEAR="1966">
<REFERENCE MODIFIED="2011-11-23 03:08:21 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerth HJ</AU>
<TI>Influenza prevention with 1-amino-adamantan-hydrochloride.II</TI>
<TO>Grippeprophylaxe mit 1-Amino-adamantan-hydrochlorid</TO>
<SO>Die Medizinische Welt</SO>
<YR>1966</YR>
<VL>2</VL>
<PG>96-100</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00000687"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Griffin-2004" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Griffin 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Griffin SDC, Harvey R, Clarke DS, Barclay WS, Harris M, Rowlands DJ</AU>
<TI>A conserved basic loop in hepatitis C virus p7 protein is required for amantadine-sensitive ion channel activity in mammalian cells but is dispensable for localization to mitochondria</TI>
<SO>Journal of General Virology</SO>
<YR>2004</YR>
<VL>85</VL>
<NO>2</NO>
<PG>451-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2004096848"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guo-2007" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Guo 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Complementary Medicine for Treating or Preventing Influenza or Influenza-like Illness&lt;/p&gt;" NOTES_MODIFIED="2014-11-05 21:58:42 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guo R, Pittler MH, Ernst E</AU>
<TI>Complementary medicine for treating or preventing influenza or influenza-like illness</TI>
<SO>American Journal of Medicine</SO>
<YR>2007</YR>
<VL>120</VL>
<NO>11</NO>
<PG>923-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hay-1986" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Hay 1986" YEAR="1986">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hay AJ, Zambon MC, Wolstenholme AJ, Skehel JJ, Smith MH</AU>
<TI>Molecular basis of resistance of influenza A viruses to amantadine</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1986</YR>
<VL>18</VL>
<PG>19-29</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="00341317"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayden-1979" NAME="Hayden 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayden FG, Hall WJ, Douglas RGJ, Speers DM</AU>
<TI>Amantadine aerosols in normal volunteers; pharmacology and safety testing</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1979</YR>
<VL>16</VL>
<NO>5</NO>
<PG>644-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00341319"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayden-1980" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Hayden 1980" YEAR="1980">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayden FG, Hall WJ, Douglas FG Jr</AU>
<TI>Therapeutic effects of aerolized amantadine in naturally acquired infection due to influenza A virus</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1980</YR>
<VL>141</VL>
<NO>5</NO>
<PG>535-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00022657"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayden-1981" NAME="Hayden 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayden FG, Gwaltney JM Jr, Van de Castle RL, Adams KF, Giordani F</AU>
<TI>Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1981</YR>
<VL>19</VL>
<NO>2</NO>
<PG>226-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00029040"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayden-1982" NAME="Hayden 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayden FG, Zylidnikov DM, Iljenko VI, Padolka YV</AU>
<TI>Comparative therapeutic effect of aerolized and oral rimantadine HCl in experimental human influenza A virus infection</TI>
<SO>Antiviral Research</SO>
<YR>1982</YR>
<VL>2</VL>
<NO>3</NO>
<PG>147-53</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00029306"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayden-1985" NAME="Hayden 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayden FG, Minocha A, Spyker DA, Hoffman HE</AU>
<TI>Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1985</YR>
<VL>28</VL>
<NO>2</NO>
<PG>216-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00341320"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayden-1986" NAME="Hayden 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayden FG, Monto AS</AU>
<TI>Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1986</YR>
<VL>29</VL>
<NO>2</NO>
<PG>339-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-0017 4577"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayden-1989" MODIFIED="2011-11-23 03:49:13 +1000" MODIFIED_BY="[Empty name]" NAME="Hayden 1989" YEAR="1989">
<REFERENCE MODIFIED="2011-11-23 03:49:13 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayden FG, Belshe RB, Clover RB, Hay AJ, Oakes MG, Soo W</AU>
<TI>Emergence and apparent transmission of rimantadine-resistant influenza A virus in families</TI>
<SO>New England Journal of Medicine</SO>
<YR>1989</YR>
<VL>321</VL>
<NO>25</NO>
<PG>1696-702</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00064208"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayden-1991" NAME="Hayden 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S</AU>
<TI>Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1991</YR>
<VL>35</VL>
<PG>1741-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00079594"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayden-2000" MODIFIED="2011-07-19 17:02:46 +1000" MODIFIED_BY="[Empty name]" NAME="Hayden 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-07-19 17:02:46 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliott MJ, Hammond JM et al</AU>
<TI>Inhaled zanamivir for the prevention of influenza in families</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>343</VL>
<NO>18</NO>
<PG>1282-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00399563"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayden-2006" MODIFIED="2011-07-19 17:02:56 +1000" MODIFIED_BY="[Empty name]" NAME="Hayden 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-07-19 17:02:56 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayden FG, Pavia AT</AU>
<TI>Antiviral management of seasonal and pandemic influenza</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2006</YR>
<VL>194</VL>
<NO>Suppl 2</NO>
<PG>155-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayden-2012" MODIFIED="2014-05-05 17:50:11 +1000" MODIFIED_BY="Liz Dooley" NAME="Hayden 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-05-05 17:50:11 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayden FG</AU>
<TI>Experimental human influenza: Observations from studies of influenza antivirals</TI>
<SO>Antiviral Therapy</SO>
<YR>2012</YR>
<VL>17</VL>
<PG>133-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hornick-1969" NAME="Hornick 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hornick RB, Togo Y, Mahler S, Iezzoni D</AU>
<TI>Evaluation of amantadine hydrochloride in the treatment of A2 influenzal disease</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1969</YR>
<VL>41</VL>
<NO>3</NO>
<PG>671-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00004307"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hota-2007" MODIFIED="2010-11-08 10:14:08 +1000" MODIFIED_BY="[Empty name]" NAME="Hota 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-08 10:02:21 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Antivirals and the control of influenza outbreaks&lt;/p&gt;" NOTES_MODIFIED="2010-11-08 10:02:21 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hota S, McGeer A</AU>
<TI>Antivirals and the control of influenza outbreaks</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2007</YR>
<VL>45</VL>
<NO>10</NO>
<PG>1362-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hout-2006a" MODIFIED="2014-05-05 17:43:21 +1000" MODIFIED_BY="Liz Dooley" NAME="Hout 2006a" YEAR="2006">
<REFERENCE MODIFIED="2011-11-23 03:10:18 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hout DR, Gomez LM, Pacyniak E, Miller JM, Hill MS, Stephens EB</AU>
<TI>A single amino acid substitution within the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein renders simian-human immunodeficiency virus (SHIV(KU-1bMC33)) susceptible to rimantadine</TI>
<SO>Virology</SO>
<YR>2006</YR>
<VL>348</VL>
<NO>2</NO>
<PG>449-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hout-2006b" NAME="Hout 2006b" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hout DR, Gomez ML, Pacyniak E, Gomez LM, Fegley B, Mulcahy ER el al</AU>
<TI>Substitution of the transmembrane domain of Vpu in simian-human immunodeficiency virus (SHIVKU1bMC33) with that of M2 of influenza A results in a virus that is sensitive to inhibitors of the M2 ion channel and is pathogenic for pig-tailed macaques</TI>
<SO>Virology</SO>
<YR>2006</YR>
<VL>344</VL>
<NO>2</NO>
<PG>541-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hsu-2012" MODIFIED="2014-11-05 23:24:03 +1000" MODIFIED_BY="[Empty name]" NAME="Hsu 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-11-05 23:24:03 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Hsu J&lt;br&gt;Santesso N&lt;br&gt;Mustafa R&lt;br&gt;Brozek J&lt;br&gt;Chen YL&lt;br&gt;Hopkins JP&lt;br&gt;Cheung A&lt;br&gt;Hovhannisyan G&lt;br&gt;Ivanova L&lt;br&gt;Flottorp SA&lt;br&gt;Saeterdal I&lt;br&gt;Wong AD&lt;br&gt;Tian J&lt;br&gt;Uyeki TM&lt;br&gt;Akl EA&lt;br&gt;Alonso-Coello P&lt;br&gt;Smaill F&lt;br&gt;Schunemann HJ&lt;br&gt;Comment in: Ann Intern Med. 2012 Sep 4;157(5):385; author reply 386-7; PMID: 22944881&lt;br&gt;Comment in: Ann Intern Med. 2012 Sep 4;157(5):385-6; author reply 386-7; PMID: 22944882&lt;/p&gt;" NOTES_MODIFIED="2014-11-05 23:24:03 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hsu J, Santesso N, Mustafa R, Brozek J, Chen YL, Hopkins JP et al</AU>
<TI>Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2012</YR>
<VL>156</VL>
<PG>512-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hurt-2007" NAME="Hurt 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hurt AC, Selleck P, Komadina S, Shaw R, Brown L, Barr IG</AU>
<TI>Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes</TI>
<SO>Antiviral Research</SO>
<YR>2007</YR>
<VL>73</VL>
<NO>3</NO>
<PG>228-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ilyushina-2005" NAME="Ilyushina 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ilyushina NA, Govorkova EA, Webster RG</AU>
<TI>Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia</TI>
<SO>Virology</SO>
<YR>2005</YR>
<VL>341</VL>
<NO>1</NO>
<PG>102-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ilyushina-2006" NAME="Ilyushina 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>IIyushina NA, Bovin NV, Webster RG, Govorkova EA</AU>
<TI>Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants</TI>
<SO>Antiviral Research</SO>
<YR>2006</YR>
<VL>70</VL>
<NO>3</NO>
<PG>121-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ilyushina-2007a" MODIFIED="2014-05-05 17:43:27 +1000" MODIFIED_BY="Liz Dooley" NAME="Ilyushina 2007a" YEAR="2007">
<REFERENCE MODIFIED="2011-07-19 17:03:57 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ilyushina NA, Gorkova EA, Russell CJ, Hoffmann E, Webster RG</AU>
<TI>Contribution of H7 haemagglutinin to amantadine resistance and infectivity of influenza virus</TI>
<SO>Journal of General Virology</SO>
<YR>2007</YR>
<VL>88</VL>
<NO>4</NO>
<PG>1266-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ilyushina-2007b" NAME="Ilyushina 2007b" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ilyushina NA, Hoffmann E, Solomon R, Webster RG, Govorkova EA</AU>
<TI>Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice</TI>
<SO>Antiviral Therapy</SO>
<YR>2007</YR>
<VL>12</VL>
<NO>3</NO>
<PG>363-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ison-2006" MODIFIED="2011-07-19 17:06:35 +1000" MODIFIED_BY="[Empty name]" NAME="Ison 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-07-19 17:06:35 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG</AU>
<TI>Recovery of drug-resistant influenza virus from immunocompromised patients: a case series</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2006</YR>
<VL>193</VL>
<NO>6</NO>
<PG>760-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ison-2013" MODIFIED="2014-05-05 17:51:07 +1000" MODIFIED_BY="Liz Dooley" NAME="Ison 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-05-05 17:51:07 +1000" MODIFIED_BY="Liz Dooley" NOTES="&lt;p&gt;Ison MG&lt;/p&gt;" NOTES_MODIFIED="2014-05-05 17:51:07 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ison MG</AU>
<TI>Clinical use of approved influenza antivirals: therapy and prophylaxis</TI>
<SO>Influenza &amp; Other Respiratory Viruses</SO>
<YR>2013</YR>
<VL>7</VL>
<NO>Suppl 1</NO>
<PG>7-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ito-2000" MODIFIED="2011-07-19 17:06:48 +1000" MODIFIED_BY="[Empty name]" NAME="Ito 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-07-19 17:06:48 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ito S, Iijima N, Kanemaki K, Hayashi S, Hujii S, Watanabe T et al</AU>
<TI>Therapeutic efficacy of amantadine hydrochloride in patients with epidemic influenza A virus infection</TI>
<SO>Nihon Kokyuki Gakkai Zasshi [Journal of the Japanese Respiratory Society]</SO>
<YR>2000</YR>
<VL>38</VL>
<NO>12</NO>
<PG>897-902</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN: 00327106"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ito-2006" MODIFIED="2011-07-19 17:06:58 +1000" MODIFIED_BY="[Empty name]" NAME="Ito 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-07-19 17:06:58 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ito Y, Sumi H, Kato T</AU>
<TI>Evaluation of influenza vaccination in health care workers, using rapid antigen detection test</TI>
<SO>Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>2</NO>
<PG>70-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jefferson-2006a" NAME="Jefferson 2006a" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A</AU>
<TI>Antivirals for influenza in healthy adults: systematic review</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>367</VL>
<NO>9507</NO>
<PG>303-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiang-2013" MODIFIED="2014-05-05 17:52:48 +1000" MODIFIED_BY="Liz Dooley" NAME="Jiang 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-05-05 17:52:48 +1000" MODIFIED_BY="Liz Dooley" NOTES="&lt;p&gt;Jiang L&lt;br&gt;Deng L&lt;br&gt;Wu T&lt;/p&gt;" NOTES_MODIFIED="2014-05-05 17:52:48 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="COCHRANE_REVIEW">
<AU>Jiang L, Deng L, Wu T</AU>
<TI>Chinese medicinal herbs for influenza</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-05-05 17:52:48 +1000" MODIFIED_BY="Liz Dooley">
<IDENTIFIER MODIFIED="2014-05-05 17:52:48 +1000" MODIFIED_BY="Liz Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD004559.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-2006" NAME="Jones 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones JC, Turpin EA, Bultmann H, Brandt CR, Schultz-Cherry S</AU>
<TI>Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells</TI>
<SO>Journal of Virology</SO>
<YR>2006</YR>
<VL>80</VL>
<NO>24</NO>
<PG>11960-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalia-2008" MODIFIED="2011-07-19 17:09:57 +1000" MODIFIED_BY="[Empty name]" NAME="Kalia 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-07-19 17:09:57 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;NMDA receptors in clinical neurology: excitatory times ahead&lt;/p&gt;" NOTES_MODIFIED="2011-07-19 17:09:57 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalia LV, Kalia SK, Salter MW</AU>
<TI>NMDA receptors in clinical neurology: excitatory times ahead</TI>
<SO>Lancet Neurology</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>8</NO>
<PG>742-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kantor-1980" NAME="Kantor 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kantor RJ, Stevens D, Potts DW, Noble GR</AU>
<TI>Prevention of influenza A/USSR/77 (H1N1): an evaluation of the side effects and efficacy of amantadine in recruits at Fort Sam Houston</TI>
<SO>Military Medicine</SO>
<YR>1980</YR>
<VL>145</VL>
<NO>5</NO>
<PG>312-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00176323"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kawai-2005" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Kawai 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kawai N, Ikematsu H, Iwaki N, Satoh I, Kawashima T, Maeda T et al</AU>
<TI>Factors influencing the effects of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2005</YR>
<VL>40</VL>
<PG>1309-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khakoo-1981" MODIFIED="2011-07-19 17:10:58 +1000" MODIFIED_BY="[Empty name]" NAME="Khakoo 1981" YEAR="1981">
<REFERENCE MODIFIED="2011-07-19 17:10:58 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khakoo RA, Watson GW, Waldman RH, Ganguly R</AU>
<TI>Effect of inosiplex (Isoprinosine (Reg. trademark)) on induced human influenza A infection</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1981</YR>
<VL>7</VL>
<NO>4</NO>
<PG>389-97</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00192285"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2011" MODIFIED="2011-11-23 03:12:19 +1000" MODIFIED_BY="[Empty name]" NAME="Kim 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-11-23 03:12:19 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim SH, Hong SB, Yun SC, Choi WI, Ahn JJ, Lee YJ et al</AU>
<TI>Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2011</YR>
<VL>183</VL>
<NO>9</NO>
<PG>1207-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirkby-2010" MODIFIED="2010-09-22 08:48:42 +1000" MODIFIED_BY="[Empty name]" NAME="Kirkby 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-09-22 08:48:42 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Methodological considerations for future controlled influenza treatment trials in complementary and alternative medicine&lt;/p&gt;" NOTES_MODIFIED="2010-09-22 08:48:42 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirkby R, Calabrese C, Kaltman L, Monnier J, Herscu P</AU>
<TI>Methodological considerations for future controlled influenza treatment trials in complementary and alternative medicine</TI>
<SO>Journal of Alternative and Complementary Medicine</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>3</NO>
<PG>275-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kiso-2004" NAME="Kiso 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K et al</AU>
<TI>Resistant influenza A viruses in children treated with oseltamivir: descriptive study</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>364</VL>
<NO>9436</NO>
<PG>759-65</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2004375940"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kitamoto-1969" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Kitamoto 1969" YEAR="1969">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kitamoto O</AU>
<TI>Early diagnosis and treatment of influenza</TI>
<SO>Naika. Internal Medicine</SO>
<YR>1969</YR>
<VL>23</VL>
<NO>6</NO>
<PG>1271-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00003590"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knight-1969" NAME="Knight 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knight V, Fedson D, Baldini J, Douglas RG, Couch RB</AU>
<TI>Amantadine therapy of epidemic influenza A2-Hong Kong</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1969</YR>
<VL>9</VL>
<PG>370-1</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00320019"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knight-1970a" NAME="Knight 1970a" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knight V, Fedson D, Baldini J, Douglas R, Couch R</AU>
<TI>Amantadine therapy of epidemic influenza A (Hong Kong)</TI>
<SO>Infection and Immunity</SO>
<YR>1970</YR>
<VL>1</VL>
<PG>200-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="00203595"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knight-1970b" NAME="Knight 1970b" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knight V, Fedson D, Baldini J, Douglas R, Couch R</AU>
<TI>Amantadine therapy of epidemic influenza A (Hong Kong)</TI>
<SO>Infection and Immunity</SO>
<YR>1970</YR>
<VL>1</VL>
<PG>200-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knight-1981" NAME="Knight 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knight V, McClung HW, Wilson SZ, Waters BK, Quarles JM, Cameron RW et al</AU>
<TI>Ribavirin small-particle aerosol treatment of influenza</TI>
<SO>Lancet</SO>
<YR>1981</YR>
<VL>2</VL>
<NO>8253</NO>
<PG>945-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00026398"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Korenke-2008" MODIFIED="2011-07-19 17:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Korenke 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-07-19 17:12:44 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Sustained-release fampridine for symptomatic treatment of multiple sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-07-19 17:12:44 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Korenke AR, Rivey MP, Allington DR</AU>
<TI>Sustained-release fampridine for symptomatic treatment of multiple sclerosis</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2008</YR>
<VL>42</VL>
<NO>10</NO>
<PG>1458-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krylov-1978" NAME="Krylov 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krylov VF, Ketilladze ES, Smagulova EG, Alekseeva AA, Nefelova MM</AU>
<TI>Use of rimantadine in familial foci during an epidemic of influenza caused by A1 virus</TI>
<TO>Primenenie rimantadina v semeinykh ochagakh v period epidemii grippa, vyzvannogo virusom A1</TO>
<SO>Voprosy Virusologii</SO>
<YR>1978</YR>
<VL>3</VL>
<PG>277-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00018933"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kulichenko-2003" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Kulichenko 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kulichenko LL, Kireyeva LV, Malyshikina EN, Wikman G</AU>
<TI>A randomized controlled study of Kan Jang versus amantadine in the treatment of influenza in Volgograd</TI>
<SO>Journal of Herbal Pharmacotherapy</SO>
<YR>2003</YR>
<VL>3</VL>
<NO>1</NO>
<PG>77-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00473824"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Langlet-2009" MODIFIED="2014-11-05 21:13:42 +1000" MODIFIED_BY="[Empty name]" NAME="Langlet 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-11-05 21:13:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Langlet P, D'Heygere F, Henrion J, Adler M, Delwaide J, Van Vlierberghe H et al</AU>
<TI>Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naive or relapsing chronic hepatitis C patients</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2009</YR>
<VL>30</VL>
<NO>4</NO>
<PG>352-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leeming-1969" NAME="Leeming 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leeming JT</AU>
<TI>Amantadine hydrochloride and the elderly</TI>
<SO>British Medical Journal</SO>
<YR>1969</YR>
<VL>1</VL>
<NO>639</NO>
<PG>313-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00002734"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leone-2005" NAME="Leone 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leone H, Polsonetti BW</AU>
<TI>Amantadine for traumatic brain injury: does it improve cognition and reduce agitation?</TI>
<SO>Journal of Clinical Pharmacy and Therapeutics</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>2</NO>
<PG>101-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Le-Tissier-2005" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Le Tissier 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Le Tissier PR, Carmignac DF, Lilley S, Sesay AK, Phelps CJ, Houston P et al</AU>
<TI>Hypothalamic growth hormone-releasing hormone (GHRH) deficiency: target ablation pf GHRH neurons in mice using a viral ion channel transgene</TI>
<SO>Molecular Endocrinology</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>5</NO>
<PG>1251-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leung-1979" MODIFIED="2011-07-19 17:13:31 +1000" MODIFIED_BY="[Empty name]" NAME="Leung 1979" YEAR="1979">
<REFERENCE MODIFIED="2011-07-19 17:13:31 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leung P, McIntosh K, Chai H</AU>
<TI>Amantadine prophylaxis against influenza A/USSR in children with chronic asthma</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1979</YR>
<VL>63</VL>
<NO>3</NO>
<PG>140</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00353210"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lim-2007" NAME="Lim 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lim WS</AU>
<TI>Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic</TI>
<SO>Thorax</SO>
<YR>2007</YR>
<VL>62</VL>
<NO>Suppl 1</NO>
<PG>1-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2006" MODIFIED="2011-07-19 17:13:45 +1000" MODIFIED_BY="[Empty name]" NAME="Lin 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-07-19 17:13:45 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin CH, Huang YC, Chi CH, Huang CG, Tsao KC, Lin TY</AU>
<TI>Neurologic manifestations in children with influenza B virus infection</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>11</NO>
<PG>1081-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linder-2005" NAME="Linder 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linder JA, Bates DW, Platt R</AU>
<TI>Antivirals and antibiotics for influenza in the United States, 1995-2002</TI>
<SO>Pharmacoepidemiology and Drug Safety</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>8</NO>
<PG>531-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lipatov-2007" NAME="Lipatov 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lipatov AS, Evseenko VA, Yen HL, Zaykovskaya AV, Durimanov AG, Zolotykh SI et al</AU>
<TI>Influenza (H5N1) viruses in poultry, Russian Federation, 2005-2006</TI>
<SO>Emerging Infectious Diseases</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>4</NO>
<PG>539-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Little-1976" NAME="Little 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Little JW, Hall WJ, Douglas RG Jr, Hyde RW, Speers DM</AU>
<TI>Amantadine effect on peripheral airways abnormalities in influenza A study in 15 students with natural influenza A infection</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1976</YR>
<VL>85</VL>
<NO>2</NO>
<PG>177-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00014385"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Little-1978" MODIFIED="2011-11-23 03:14:44 +1000" MODIFIED_BY="[Empty name]" NAME="Little 1978" YEAR="1978">
<REFERENCE MODIFIED="2011-11-23 03:14:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Little JW, Hall WJ, Douglas RG Jr, Mudholkar GS, Speer DM, Patel K</AU>
<TI>Airway hyperreactivity and peripheral airway dysfunction in influenza A infection</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1978</YR>
<VL>118</VL>
<NO>2</NO>
<PG>295-303</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00018956"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopez_x002d_Medrano-2012" MODIFIED="2014-05-05 17:54:25 +1000" MODIFIED_BY="Liz Dooley" NAME="Lopez-Medrano 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-05-05 17:54:25 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopez-Medrano F, Carmen Farinas M, Payeras A, Pachon J</AU>
<TI>Antiviral treatment and vaccination for influenza A (H1N1) pdm09 virus: lessons learned from the pandemic</TI>
<SO>Enfermedades Infecciosas y Microbiologia Clinica</SO>
<YR>2012</YR>
<VL>30</VL>
<PG>49-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Louie-2012" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Louie 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Louie JK, Yang S, Yen C, Acosta M, Schechter R, Uyeki TM</AU>
<TI>Use of intravenous peramivir for treatment of severe influenza A (H1N1) pdm09</TI>
<SO>PloS One</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>6</NO>
<PG>e40261</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lutz-2005" NAME="Lutz 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lutz A, Dyall J, Olivo PD, Pekosz A</AU>
<TI>Virus-inducible reporter genes as a tool for detecting and quantifying influenza A virus replication</TI>
<SO>Journal of Virological Methods</SO>
<YR>2005</YR>
<VL>126</VL>
<NO>1-2</NO>
<PG>13-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lynd-2005" NAME="Lynd 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lynd LD, Goeree R, O'Brien BJ</AU>
<TI>Antiviral agents for influenza: a comparison of cost-effectiveness data</TI>
<SO>PharmacoEconomics</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>11</NO>
<PG>1083-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Machado-2004" MODIFIED="2011-11-23 03:15:43 +1000" MODIFIED_BY="[Empty name]" NAME="Machado 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-11-23 03:15:43 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Machado CM, Boas LSV, Mendes AVA, Da Rocha IF, Sturaro D, Dulley FL et al</AU>
<TI>Use of oseltamivir to control influenza complications after bone marrow transplantation</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2004</YR>
<VL>34</VL>
<NO>2</NO>
<PG>111-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2004347904"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mallia-2007" NAME="Mallia 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mallia P, Johnston SL</AU>
<TI>Influenza infection and COPD</TI>
<SO>International Journal of Chronic Obstructive Pulmonary Disease</SO>
<YR>2007</YR>
<VL>2</VL>
<NO>1</NO>
<PG>55-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maricich-2004" NAME="Maricich 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maricich SM, Neul JL, Lotze TE, Cazacu AC, Uyeki TM, Demmler GJ et al</AU>
<TI>Neurologic complications associated with influenza A in children during the 2003-2004 influenza season in Houston, Texas</TI>
<SO>Pediatrics</SO>
<YR>2004</YR>
<VL>114</VL>
<NO>5</NO>
<PG>626-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mase-2007" MODIFIED="2011-11-23 03:16:21 +1000" MODIFIED_BY="[Empty name]" NAME="Mase 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-11-23 03:16:21 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mase M, Eto M, Imai K, Tsukamoto K, Yamaguchi S</AU>
<TI>Characterization of H9N2 influenza A viruses isolated from chicken products imported into Japan from China</TI>
<SO>Epidemiology and Infection</SO>
<YR>2007</YR>
<VL>135</VL>
<NO>3</NO>
<PG>386-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mate-1970" MODIFIED="2014-11-05 21:16:07 +1000" MODIFIED_BY="[Empty name]" NAME="Mate 1970" YEAR="1970">
<REFERENCE MODIFIED="2014-11-05 21:16:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mate J, Simon M, Juvancz I, Takatsy G, Hollos I, Farkas E</AU>
<TI>Prophylactic use of amantadine during Hong Kong influenza epidemic</TI>
<SO>Acta Microbiologica Academiae Scientiarum Hungaricae</SO>
<YR>1970</YR>
<VL>17</VL>
<NO>3</NO>
<PG>285-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mate-1971" NAME="Mate 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mate J, Simon M, Juvancz I</AU>
<TI>Use of Viregyt (amantadine hydrochloride) in the treatment of epidemic influenza</TI>
<SO>Therapia Hungarica</SO>
<YR>1971</YR>
<VL>19</VL>
<NO>3</NO>
<PG>117-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00006813"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matheson-2007" MODIFIED="2011-09-01 11:57:51 +1000" MODIFIED_BY="[Empty name]" NAME="Matheson 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-09-01 11:57:51 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Neuraminidase inhibitors for preventing and treating influenza in children&lt;/p&gt;" NOTES_MODIFIED="2011-09-01 11:57:51 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="COCHRANE_REVIEW">
<AU>Matheson NJ, Harnden AR, Perera R, Sheikh A, Symmonds-Abrahams M</AU>
<TI>Neuraminidase inhibitors for preventing and treating influenza in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-09-01 11:57:51 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-09-01 11:57:51 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002744.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matsuya-2007" MODIFIED="2014-11-05 21:16:38 +1000" MODIFIED_BY="[Empty name]" NAME="Matsuya 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-11-05 21:16:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matsuya Y, Sasaki K, Ochiai H, Nemoto H</AU>
<TI>Synthesis and biological evaluation of dihydrofuran-fused perhydrophenanthrenes as a new anti-influenza agent having novel structural characteristic</TI>
<SO>Bioorganic and Medicinal Chemistry</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>1</NO>
<PG>424-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matthews-2004" NAME="Matthews 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matthews SJ, McCoy C</AU>
<TI>Peginterferon alfa-2a: a review of approved and investigational uses</TI>
<SO>Clinical Therapeutics</SO>
<YR>2004</YR>
<VL>26</VL>
<NO>7</NO>
<PG>991-1025</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2004369381"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCullers-2004" MODIFIED="2011-07-19 17:15:44 +1000" MODIFIED_BY="[Empty name]" NAME="McCullers 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-07-19 17:15:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCullers JA</AU>
<TI>Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2004</YR>
<VL>190</VL>
<NO>3</NO>
<PG>519-26</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2004322950"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McKay-2006" MODIFIED="2011-06-16 01:01:07 +1000" MODIFIED_BY="[Empty name]" NAME="McKay 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-06-16 01:01:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McKay T, Patel M, Pickles RJ, Johnson LG, Olsen JC</AU>
<TI>Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors</TI>
<SO>Gene Therapy</SO>
<YR>2006</YR>
<VL>13</VL>
<NO>8</NO>
<PG>715-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Michiels-2013" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Michiels 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Michiels B, van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S</AU>
<TI>The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews</TI>
<SO>PloS One</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>4</NO>
<PG>e60348</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mishin-2005" NAME="Mishin 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mishin VP, Hayden FG, Gubareva LV</AU>
<TI>Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2005</YR>
<VL>49</VL>
<NO>11</NO>
<PG>4515-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miyachi-2011" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Miyachi 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miyachi K, Watanabe A, Iida H, Hattori H, Ukai H, Takano T et al</AU>
<TI>Comparison of the efficacies of amantadine treatment of swine-origin influenza virus A H1N1 and seasonal influenza H1N1 and H3N2 in Japan (2008-2009)</TI>
<SO>Journal of Infection and Chemotherapy: official journal of the Japan Society of Chemotherapy</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>4</NO>
<PG>524-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moffat-2008" MODIFIED="2011-07-19 17:16:56 +1000" MODIFIED_BY="[Empty name]" NAME="Moffat 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-07-19 17:16:56 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Jan 15Research Support, N.I.H., Extramural17827230&lt;/p&gt;" NOTES_MODIFIED="2011-07-19 17:16:56 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moffat JC, Vijayvergiya V, Gao PF, Cross TA, Woodbury DJ, Busath DD</AU>
<TI>Proton transport through influenza A virus M2 protein reconstituted in vesicles</TI>
<SO>Biophysical Journal</SO>
<YR>2008</YR>
<VL>94</VL>
<NO>2</NO>
<PG>434-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monto-1979" MODIFIED="2011-11-23 03:18:32 +1000" MODIFIED_BY="[Empty name]" NAME="Monto 1979" YEAR="1979">
<REFERENCE MODIFIED="2011-11-23 03:18:32 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monto AS, Gunn RA, Bandyk MG, King CL</AU>
<TI>Prevention of Russian influenza by amantadine</TI>
<SO>JAMA</SO>
<YR>1979</YR>
<VL>241</VL>
<NO>10</NO>
<PG>1003-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morrison-2007" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Morrison 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination&lt;/p&gt;" NOTES_MODIFIED="2014-11-05 21:58:42 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morrison D, Roy S, Rayner C, Amer A, Howard D, Smith JR et al</AU>
<TI>A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination</TI>
<SO>PLoS One</SO>
<YR>2007</YR>
<VL>2</VL>
<NO>12</NO>
<PG>e1305</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muldoon-1976" MODIFIED="2014-11-05 21:18:58 +1000" MODIFIED_BY="[Empty name]" NAME="Muldoon 1976" YEAR="1976">
<REFERENCE MODIFIED="2014-11-05 21:18:58 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muldoon RL, Stanley ED, Jackson GG</AU>
<TI>Use and withdrawal of amantadine chemoprophylaxis during epidemic influenza A</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1976</YR>
<VL>113</VL>
<PG>487-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00203757"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nafta-1970" MODIFIED="2011-11-23 03:19:24 +1000" MODIFIED_BY="[Empty name]" NAME="Nafta 1970" YEAR="1970">
<REFERENCE MODIFIED="2011-11-23 03:19:24 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nafta I, Turcanu AG, Braun I, Companetz W, Simionescu A</AU>
<TI>Administration of amantadine for the prevention of Hong-Kong influenza</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1970</YR>
<VL>42</VL>
<NO>3</NO>
<PG>200-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00004499"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Natsina-1994" NAME="Natsina 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Natsina VK, Drinevskii VP, Milkint KK</AU>
<TI>Remantadine in the treatment of influenza in children</TI>
<TO>Primenenie remantadina dlia lecheniia grippa u detei</TO>
<SO>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk Vestnik</SO>
<YR>1994</YR>
<VL>9</VL>
<PG>51-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00110913"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nuesch-2007" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Nuesch 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;NovEnglish Abstract&lt;br&gt;Review18581908&lt;/p&gt;" NOTES_MODIFIED="2014-11-05 21:58:42 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nuesch R</AU>
<TI>Antiviral treatment of influenza in humans</TI>
<SO>Therapeutische Umschau</SO>
<YR>2007</YR>
<VL>64</VL>
<NO>11</NO>
<PG>635-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Donoghute-1973" MODIFIED="2011-06-16 01:01:22 +1000" MODIFIED_BY="[Empty name]" NAME="O'Donoghute 1973" YEAR="1973">
<REFERENCE MODIFIED="2011-06-16 01:01:22 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Donoghute JM, Ray CG, Terry DW Jr, Beaty HN</AU>
<TI>Prevention of nosocomial influenza infection with amantadine</TI>
<SO>American Journal of Epidemiology.</SO>
<YR>1973</YR>
<VL>97</VL>
<NO>4</NO>
<PG>276-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00008489"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Obrosova_x002d_Serova-1972" MODIFIED="2011-11-23 03:25:37 +1000" MODIFIED_BY="[Empty name]" NAME="Obrosova-Serova 1972" YEAR="1972">
<REFERENCE MODIFIED="2011-11-23 03:25:37 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Obrosova-Serova NP, Fedorova GI, Glukhov PI, Shal'nov MI, Litvinov VG</AU>
<TI>Effectiveness of midantan and interferon inducers as means of non-specific prevention of influenza</TI>
<TO>Izuchenie effektivnosti midantana i stimuliatorav interferona kak sredstv nespetsificheskoi profilaktiki grippa</TO>
<SO>Antibiotiki</SO>
<YR>1972</YR>
<VL>17</VL>
<PG>734-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00007887"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oker_x002d_Blom-1970" NAME="Oker-Blom 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oker-Blom N, Hovi T, Leinikki P, Palosuo T, Petterson R, Suni J</AU>
<TI>Protection of man from natural infection with influenza A2 Hong Kong virus by amantadine: a controlled field trial</TI>
<SO>British Medical Journal</SO>
<YR>1970</YR>
<VL>3</VL>
<NO>724</NO>
<PG>676-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00004991"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ong-2007" MODIFIED="2011-07-19 17:17:48 +1000" MODIFIED_BY="[Empty name]" NAME="Ong 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-07-19 17:17:48 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ong AK, Hayden FG</AU>
<TI>John F. Enders lecture 2006: antivirals for influenza</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2007</YR>
<VL>196</VL>
<NO>2</NO>
<PG>181-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pachucki-2004" NAME="Pachucki 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pachucki CT, Kurshid MA, Nawrocki J</AU>
<TI>Utility of reverse transcriptase PCR for rapid diagnosis of influenza A virus infection and detection of amantadine-resistant influenza A virus isolates</TI>
<SO>Journal of Clinical Microbiology</SO>
<YR>2004</YR>
<VL>42</VL>
<NO>6</NO>
<PG>2796-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2004251487"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peiris-2004" NAME="Peiris 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM et al</AU>
<TI>Re-emergence of fatal human influenza A subtype H5N1 disease</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>21</VL>
<NO>363</NO>
<PG>617-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pemberton-1986" MODIFIED="2011-07-19 17:18:06 +1000" MODIFIED_BY="[Empty name]" NAME="Pemberton 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-07-19 17:18:06 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pemberton RM, Jennings R, Potter CW, Oxford JS</AU>
<TI>Amantadine resistance in clinical influenza A (H3N2) and (H1N1) virus isolates</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1986</YR>
<VL>18</VL>
<PG>135-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00341484"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petterson-1980" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Petterson 1980" YEAR="1980">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petterson RF, Hellstrom PE, Penttinen K, Pyhala R, Tokola O, Vartio T et al</AU>
<TI>Evaluation of amantadine in the prophylaxis of influenza A (H1N1) virus infection: a controlled field trial among young adults and high-risk patients</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1980</YR>
<VL>142</VL>
<NO>3</NO>
<PG>377-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00023981"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pritchard-1989" NAME="Pritchard 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pritchard MH, Munro J</AU>
<TI>Successful treatment of juvenile chronic arthritis with a specific antiviral agent</TI>
<SO>British Journal of Rheumatology</SO>
<YR>1989</YR>
<VL>28</VL>
<NO>6</NO>
<PG>521-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00064111"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quarles-1981" NAME="Quarles 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quarles JM, Couch RB, Cate TR, Goswick CB</AU>
<TI>Comparison of amantadine and rimantadine for prevention of type A (Russian) influenza</TI>
<SO>Antiviral Research</SO>
<YR>1981</YR>
<VL>1</VL>
<NO>3</NO>
<PG>149-55</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00193509"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quilligan-1966" MODIFIED="2011-07-19 17:19:38 +1000" MODIFIED_BY="[Empty name]" NAME="Quilligan 1966" YEAR="1966">
<REFERENCE MODIFIED="2011-07-19 17:19:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quilligan JJ Jr, Hirayama H, Baernstein HD Jr</AU>
<TI>The suppression of A2 influenza in children by the chemoprophylactic use of amantadine</TI>
<SO>Journal of Pediatrics</SO>
<YR>1966</YR>
<VL>69</VL>
<NO>4</NO>
<PG>572-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00000801"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabinovich-1969" MODIFIED="2011-07-19 17:19:53 +1000" MODIFIED_BY="[Empty name]" NAME="Rabinovich 1969" YEAR="1969">
<REFERENCE MODIFIED="2011-07-19 17:19:53 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabinovich S, Baldini JT, Bannister R</AU>
<TI>Treatment of influenza. The therapeutic efficacy of rimantadine HCl in a naturally occurring influenza A2 outbreak</TI>
<SO>American Journal of the Medical Sciences</SO>
<YR>1969</YR>
<VL>257</VL>
<NO>5</NO>
<PG>328-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00003292"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reis-2006" MODIFIED="2014-11-05 21:20:40 +1000" MODIFIED_BY="[Empty name]" NAME="Reis 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-11-05 21:20:40 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reis J, John D, Heimeroth A, Mueller HH, Oertel WH, Arndt T et al</AU>
<TI>Modulation of human motor cortex excitability by single doses of amantadine</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>12</NO>
<PG>2758-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reuman-1989a" NAME="Reuman 1989a" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reuman PD, Bernstein DI, Keely SP, Young EC, Sherwood, JR, Schiff GM</AU>
<TI>Differential effect of amantadine hydrochloride on systemic and local immune response to influenza A</TI>
<SO>Journal of Medical Virology</SO>
<YR>1989</YR>
<VL>27</VL>
<NO>2</NO>
<PG>137-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00058423"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reuman-1989b" NAME="Reuman 1989b" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reuman PD, Bernstein DI, Keefer MC, Young EC, Sherwood JR, Schiff GM</AU>
<TI>Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A</TI>
<SO>Antiviral Research</SO>
<YR>1989</YR>
<VL>11</VL>
<NO>1</NO>
<PG>27-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00059636"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Risenbrough-2005" MODIFIED="2011-11-23 03:28:27 +1000" MODIFIED_BY="[Empty name]" NAME="Risenbrough 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-11-23 03:27:53 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Risenbrough NA, Bowles SK, Simor AE, McGeer A, Oh PI</AU>
<TI>Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2005</YR>
<VL>53</VL>
<NO>3</NO>
<PG>444-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rose-1980" MODIFIED="2011-07-19 17:20:33 +1000" MODIFIED_BY="[Empty name]" NAME="Rose 1980" YEAR="1980">
<REFERENCE MODIFIED="2011-07-19 17:20:33 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rose HJ</AU>
<TI>Therapeutic effects of aerosolized amantadine in naturally acquired infection due to influenza A virus</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1980</YR>
<VL>141</VL>
<NO>5</NO>
<PG>535-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00022657"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rothberg-2005" MODIFIED="2011-07-19 17:21:00 +1000" MODIFIED_BY="[Empty name]" NAME="Rothberg 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-07-19 17:21:00 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rothberg MB, Fisher D, Kelly B, Rose DN</AU>
<TI>Management of influenza symptoms in healthy children</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>2005</YR>
<VL>159</VL>
<PG>1055-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saito-2006" MODIFIED="2014-11-05 21:21:15 +1000" MODIFIED_BY="[Empty name]" NAME="Saito 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-11-05 21:21:15 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saito R, Li D, Shimomura C, Masaki H, Le MR, Nquyen HL et al</AU>
<TI>An off-seasonal amantadine-resistant H3N2 influenza outbreak in Japan</TI>
<SO>Tohoku Journal of Experimental Medicine</SO>
<YR>2006</YR>
<VL>210</VL>
<NO>1</NO>
<PG>21-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sampaio-2011" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Sampaio 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sampaio C, Bronzova J, Hauser RA, Lang AE, Rascol O, van de Witte SV et al</AU>
<TI>Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double-blind trials</TI>
<SO>Movement Disorders</SO>
<YR>2011</YR>
<VL>26</VL>
<PG>1464-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santesso-2013" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Santesso 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santesso N, Hsu J, Mustafa R, Brozek J, Chen YL, Hopkins JP et al</AU>
<TI>Antivirals for influenza: A summary of a systematic review and meta-analysis of observational studies</TI>
<SO>Influenza and other Respiratory Viruses</SO>
<YR>2013</YR>
<VL>7</VL>
<PG>76-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sato-2008" MODIFIED="2011-11-23 03:29:09 +1000" MODIFIED_BY="[Empty name]" NAME="Sato 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-11-23 03:29:09 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, Japan&lt;/p&gt;" NOTES_MODIFIED="2011-11-23 03:29:09 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sato M, Saito R, Sato I, Tanabe N, Shobugawa Y, Sasaki A et al</AU>
<TI>Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, Japan</TI>
<SO>Tohoku Journal of Experimental Medicine</SO>
<YR>2008</YR>
<VL>214</VL>
<NO>2</NO>
<PG>113-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sauerbrei-2006" NAME="Sauerbrei 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sauerbrei A, Haertl A, Brandstaedt A, Schmidtke M, Wutzler P</AU>
<TI>Utilization of the embryonated egg for in vivo evaluation of the anti-influenza virus activity of neuraminidase inhibitors</TI>
<SO>Medical Microbiology and Immunology</SO>
<YR>2006</YR>
<VL>195</VL>
<NO>2</NO>
<PG>65-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schapira-1971" NAME="Schapira 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schapira M, Oxford JS, Galbraith AW</AU>
<TI>Therapeutic effect of 1-adamantanamine hydrochloride in naturally</TI>
<SO>Journal of the Royal College of General Practitioners</SO>
<YR>1971</YR>
<VL>21</VL>
<NO>113</NO>
<PG>695-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00006890"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidt-2004" NAME="Schmidt 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt AC</AU>
<TI>Antiviral therapy for influenza: a clinical and economic comparative review</TI>
<SO>Drugs</SO>
<YR>2004</YR>
<VL>64</VL>
<NO>18</NO>
<PG>2031-46</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2004412233"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sears-1987" NAME="Sears 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sears SD, Clements ML</AU>
<TI>Protective efficacy of low dose amantadine in adults challenge with wild-type influenza A virus</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1987</YR>
<VL>31</VL>
<NO>10</NO>
<PG>1470-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00052243"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Semlitsch-1992" MODIFIED="2011-11-23 03:29:50 +1000" MODIFIED_BY="[Empty name]" NAME="Semlitsch 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-11-23 03:29:50 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Semlitsch HV, Anderer P, Saletu B</AU>
<TI>Topographic mapping of long latency "cognitive" event-related potentials (P 300): a double-blind, placebo-controlled study with amantadine in mild dementia</TI>
<SO>Journal of Neural Transmission. Parkinson's Disease and Dementia Section</SO>
<YR>1992</YR>
<VL>4</VL>
<PG>319-36</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00087210"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serkedjieva-2007" NAME="Serkedjieva 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serkedjieva J, Toshkova R, Antonova-Nikolova S, Stefanova T, Teodosieva A, Ivanova I</AU>
<TI>Effect of a plant polyphenol-rich extract on the lung protease activities of influenza-virus-infected mice</TI>
<SO>Antiviral Chemistry &amp; Chemotherapy</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>2</NO>
<PG>75-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shah-2012" MODIFIED="2014-06-25 10:56:38 +1000" MODIFIED_BY="[Empty name]" NAME="Shah 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-06-25 10:56:38 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Shah, Dimpy P&lt;br&gt;Ghantoji, Shashank S&lt;br&gt;Mulanovich, Victor E&lt;br&gt;Ariza-Heredia, Ella J&lt;br&gt;Chemaly, Roy F&lt;br&gt;United States&lt;br&gt;Am J Blood Res. 2012;2(4):203-18. Epub 2012 Nov 25.&lt;/p&gt;" NOTES_MODIFIED="2014-06-25 10:56:38 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shah DP, Ghantoji SS, Mulanovich VE, Ariza-Heredia EJ, Chemaly RF</AU>
<TI>Management of respiratory viral infections in hematopoietic cell transplant recipients</TI>
<SO>American Journal of Blood Research</SO>
<YR>2012</YR>
<VL>2</VL>
<PG>203-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shuler-2007" NAME="Shuler 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schuler CM, Iwamoto M, Bridges CB, Marin M, Neeman R, Gargiullo P et al</AU>
<TI>Vaccine effectiveness against medically attended, laboratory-confirmed influenza among children aged 6 to 59 months, 2003-2004</TI>
<SO>Pediatrics</SO>
<YR>2007</YR>
<VL>119</VL>
<NO>3</NO>
<PG>587-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shvetsova-1974" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Shvetsova 1974" YEAR="1974">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shvetsova EG, Malysheva AM, Karapats NM, Oleinikova EV, Vasil'eva RI</AU>
<TI>Comparative study of the epidemiological efficacy of specific and nonspecific influenza preventive agents</TI>
<TO>Sravnitel'noe izuchenie epidemiologicheskoi effektivnosti speisificheskikh i nespetsificheskikh sredstv profilaktiki grippa</TO>
<SO>Zhurnal Mikrobiologii Epidemiologii i Immunobiologii [Journal of Microbiology, Epidemiology and Immunobiology]</SO>
<YR>1974</YR>
<VL>51</VL>
<NO>4</NO>
<PG>47-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00010299"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simeonova-2009" MODIFIED="2011-07-19 17:21:45 +1000" MODIFIED_BY="[Empty name]" NAME="Simeonova 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-07-19 17:21:45 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Rimantadine and oseltamivir combination effects in a therapeutic course of application against influenza a (H3N2) in mice&lt;/p&gt;" NOTES_MODIFIED="2011-07-19 17:21:45 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simeonova L, Gegova G, Galabov AS</AU>
<TI>Rimantadine and oseltamivir combination effects in a therapeutic course of application against influenza a (H3N2) in mice</TI>
<SO>Antiviral Research</SO>
<YR>2009</YR>
<VL>82</VL>
<NO>2</NO>
<PG>A37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singer-2011" MODIFIED="2014-05-05 17:59:31 +1000" MODIFIED_BY="Liz Dooley" NAME="Singer 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-05-05 17:59:31 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singer B, Ross AP, Tobias K</AU>
<TI>Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2011</YR>
<VL>65</VL>
<PG>887-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skoner-1999" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Skoner 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skoner DP, Gentile DA, Patel A, Doyle WJ</AU>
<TI>Evidence for cytokine mediation of disease expression in adults experimentally infected with influenza A virus</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1999</YR>
<VL>180</VL>
<NO>1</NO>
<PG>10-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00163791"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smorodintsev-1970a" MODIFIED="2011-11-23 03:50:58 +1000" MODIFIED_BY="[Empty name]" NAME="Smorodintsev 1970a" YEAR="1970">
<REFERENCE MODIFIED="2011-11-23 03:50:58 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smorodintsev AA, Zlydnikov DM, Kiselva AM, Romanov JA, Kanantsev AP, Rumovsky VI</AU>
<TI>Evaluation of amantadine in artificially induced A2 and B influenza</TI>
<SO>JAMA</SO>
<YR>1970</YR>
<VL>213</VL>
<NO>9</NO>
<PG>1448-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00004739"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smorodintsev-1970b" MODIFIED="2011-06-16 01:02:05 +1000" MODIFIED_BY="[Empty name]" NAME="Smorodintsev 1970b" YEAR="1970">
<REFERENCE MODIFIED="2011-06-16 01:02:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smorodintsev AA, Karpuhin GI, Zlydnikov DM, Malyseva AM, Svecova EG, Burov SA et al</AU>
<TI>The prophylactic effectiveness of amantadine hydrochloride in an epidemic of Hong Kong influenza in Leningrad in 1969</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1970</YR>
<VL>42</VL>
<NO>6</NO>
<PG>865-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00005082"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smorodintsev-1970c" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Smorodintsev 1970c" YEAR="1970">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smorodintsev AA, Karpuhin GI, Zlydnikov DM</AU>
<TI>The prospect of amantadine for prevention of influenza A in humans (effectiveness of amantadine during influenza A2/Hong Kong epidemics in January-February 1969 in Leningrad)</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1970</YR>
<VL>173</VL>
<PG>44-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Somani-1991" MODIFIED="2014-11-05 21:23:41 +1000" MODIFIED_BY="[Empty name]" NAME="Somani 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-11-05 21:23:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Somani SK, Degelau J, Cooper SL, Guay DRP, Ehresman D, Zaske D</AU>
<TI>Comparison of pharmacokinetic and safety profiles of amantadine 50 and 100 mg daily doses in elderly nursing home residents</TI>
<SO>Pharmacotherapy</SO>
<YR>1991</YR>
<VL>11</VL>
<NO>6</NO>
<PG>440-66</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00441230"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tajima-2006" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Tajima 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tajima T, Kakayama E, Kondo Y, Hirai F, Ito H, Iitsuka T et al</AU>
<TI>Etiology and clinical study of community-acquired pneumonia in 157 hospitalized children</TI>
<SO>Journal of Infection and Chemotherapy: official journal of the Japan Society of Chemotherapy</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>6</NO>
<PG>372-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takemura-2005" MODIFIED="2011-07-19 17:22:34 +1000" MODIFIED_BY="[Empty name]" NAME="Takemura 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-07-19 17:22:34 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takemura Y, Ishida H, Saitoh H, Kure H, Kakoi H, Ebisawa K et al</AU>
<TI>Economic consequence of immediate testing for C-reactive protein and leukocyte count in new outpatients with acute infection</TI>
<SO>Clinica Chimica Acta: International Journal of Clinical Chemistry</SO>
<YR>2005</YR>
<VL>360</VL>
<NO>1-2</NO>
<PG>114-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tappenden-2009" MODIFIED="2011-11-23 03:32:00 +1000" MODIFIED_BY="[Empty name]" NAME="Tappenden 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-11-23 03:32:00 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): A systematic review and economic evaluation&lt;/p&gt;" NOTES_MODIFIED="2011-11-23 03:32:00 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, Read R et al</AU>
<TI>Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): A systematic review and economic evaluation</TI>
<SO>Health Technology Assessment</SO>
<YR>2009</YR>
<VL>13</VL>
<NO>11</NO>
<PG>iii-148</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terabayashi-2006" NAME="Terabayashi 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terabayashi T, Morita M, Ueno M, Nakamura T, Urashima T</AU>
<TI>Inhibition of influenza-virus-induced cytopathy by sialylglycoconjugates</TI>
<SO>Carbohydrate Research</SO>
<YR>341</YR>
<VL>13</VL>
<PG>2246-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thomas-2008" MODIFIED="2010-09-22 08:53:09 +1000" MODIFIED_BY="[Empty name]" NAME="Thomas 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-09-22 08:53:09 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Multiple sclerosis in children&lt;/p&gt;" NOTES_MODIFIED="2010-09-22 08:53:09 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomas T, Banwell B</AU>
<TI>Multiple sclerosis in children</TI>
<SO>Seminars in Neurology</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>1</NO>
<PG>69-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-1987" MODIFIED="2011-06-16 01:02:32 +1000" MODIFIED_BY="[Empty name]" NAME="Thompson 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-06-16 01:02:32 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson J, Fleet W, Lawrence E, Pierce E, Morris L, Wright P</AU>
<TI>A comparison of acetaminophen and rimantadine in the treatment of influenza A infection in children</TI>
<SO>Journal of Medical Virology</SO>
<YR>1987</YR>
<VL>21</VL>
<NO>3</NO>
<PG>249-55</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00047234"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Togo-1968" MODIFIED="2014-11-05 21:24:49 +1000" MODIFIED_BY="[Empty name]" NAME="Togo 1968" YEAR="1968">
<REFERENCE MODIFIED="2014-11-05 21:24:49 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Togo Y, Hornick RB, Dawkins AT Jr</AU>
<TI>Studies on induced influenza in man. I. Double-blind studies designed to assess prophylactic efficacy of amantadine hydrochloride against a2/Rockville/1/65 strain</TI>
<SO>JAMA</SO>
<YR>1968</YR>
<VL>203</VL>
<NO>13</NO>
<PG>1089-94</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00001827"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Togo-1970" MODIFIED="2011-11-23 03:32:34 +1000" MODIFIED_BY="[Empty name]" NAME="Togo 1970" YEAR="1970">
<REFERENCE MODIFIED="2011-11-23 03:32:34 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Togo Y, Hornick RB, Felitti VJ, Kaufman ML, Dawkins AT Jr, Kilpe VE et al</AU>
<TI>Evaluation of therapeutic efficacy of amantadine in patients with naturally occurring A2 influenza</TI>
<SO>JAMA</SO>
<YR>1970</YR>
<VL>211</VL>
<NO>7</NO>
<PG>1149-56</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00004092"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Togo-1972" MODIFIED="2011-11-23 03:32:48 +1000" MODIFIED_BY="[Empty name]" NAME="Togo 1972" YEAR="1972">
<REFERENCE MODIFIED="2011-11-23 03:32:48 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Togo Y, Schwatrz AR, Tominaga S, Hornick RB</AU>
<TI>Cyclooctylamine in the prevention of experimental human influenza</TI>
<SO>JAMA</SO>
<YR>1972</YR>
<VL>220</VL>
<NO>6</NO>
<PG>837-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00007054"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Townsend-2006" NAME="Townsend 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Townsend KA, Eiland LS</AU>
<TI>Combating influenza with antiviral therapy in the pediatric population</TI>
<SO>Pharmacotherapy</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>1</NO>
<PG>95-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-der-Wouden-2005" MODIFIED="2011-11-23 03:33:07 +1000" MODIFIED_BY="[Empty name]" NAME="Van der Wouden 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-11-23 03:33:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van der Wouden JC, Bueving HJ, Poole P</AU>
<TI>Preventing influenza: an overview of systematic reviews</TI>
<SO>Respiratory Medicine</SO>
<YR>2005</YR>
<VL>99</VL>
<NO>11</NO>
<PG>1341-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Voris-1981" MODIFIED="2011-11-23 03:51:34 +1000" MODIFIED_BY="[Empty name]" NAME="Van Voris 1981" YEAR="1981">
<REFERENCE MODIFIED="2011-11-23 03:51:34 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Voris LP, Betts RF, Hayden FG, Christmas WA, Douglas RG Jr</AU>
<TI>Successful treatment of naturally occurring influenza A/USSR/77 H1N1</TI>
<SO>JAMA</SO>
<YR>1981</YR>
<VL>245</VL>
<NO>11</NO>
<PG>1128-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00024393"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Voris-1985" NAME="Van Voris 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Voris LP, Betts RF, Menegus MA, Murphy BR, Roth FK, Douglas RG Jr</AU>
<TI>Serological diagnosis of influenza A/USSR/77 H1N1 infection: value of ELISA compared to other antibody techniques</TI>
<SO>Journal of Medical Virology</SO>
<YR>1985</YR>
<VL>16</VL>
<NO>4</NO>
<PG>315-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00039377"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wailoo-2008" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Wailoo 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Mar-AprResearch Support, Non-U.S. Gov't18380629&lt;/p&gt;" NOTES_MODIFIED="2014-11-05 21:58:42 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wailoo AJ, Sutton AJ, Cooper NJ, Turner DA, Abrams KR, Brennan A et al</AU>
<TI>Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza</TI>
<SO>Value in Health</SO>
<YR>2008</YR>
<VL>11</VL>
<NO>2</NO>
<PG>160-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Webster-1986" MODIFIED="2011-07-19 17:24:01 +1000" MODIFIED_BY="[Empty name]" NAME="Webster 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-07-19 17:24:01 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Webster R, Kawaoka Y, Bean W</AU>
<TI>Vaccination as strategy to reduce the emergence of amantadine and rimantadine-resistant strains of A/Chick/Pennsylvania/83 (H5N2) influenza virus</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1986</YR>
<VL>18</VL>
<PG>157-64</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00341633"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Welton-2008" MODIFIED="2011-07-19 17:24:14 +1000" MODIFIED_BY="[Empty name]" NAME="Welton 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-07-19 17:24:14 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Nov 29Comparative Study&lt;br&gt;Evaluation Studies&lt;br&gt;Research Support, Non-U.S. Gov't18680174&lt;/p&gt;" NOTES_MODIFIED="2011-07-19 17:24:14 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Welton NJ, Cooper NJ, Ades AE, Lu G, Sutton AJ</AU>
<TI>Mixed treatment comparison with multiple outcomes reported inconsistently across trials: evaluation of antivirals for treatment of influenza A and B</TI>
<SO>Statistics in Medicine</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>27</NO>
<PG>5620-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wendel-1966" NAME="Wendel 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wendel HA, Snyder MT, Pell P</AU>
<TI>Trial of amantadine in epidemic in influenza</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1966</YR>
<VL>7</VL>
<NO>1</NO>
<PG>38-43</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00000530"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whitley-2007" MODIFIED="2011-07-19 17:24:36 +1000" MODIFIED_BY="[Empty name]" NAME="Whitley 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-07-19 17:24:36 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;The role of oseltamivir in the treatment and prevention of influenza in children&lt;/p&gt;" NOTES_MODIFIED="2011-07-19 17:24:36 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whitley RJ</AU>
<TI>The role of oseltamivir in the treatment and prevention of influenza in children</TI>
<SO>Expert Opinion on Drug Metabolism and Toxicology</SO>
<YR>2007</YR>
<VL>3</VL>
<NO>5</NO>
<PG>755-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wingfield-1969" MODIFIED="2011-11-23 03:52:04 +1000" MODIFIED_BY="[Empty name]" NAME="Wingfield 1969" YEAR="1969">
<REFERENCE MODIFIED="2011-11-23 03:52:04 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wingfield WL, Pollack D, Grunert RR</AU>
<TI>Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man</TI>
<SO>New England Journal of Medicine</SO>
<YR>1969</YR>
<VL>281</VL>
<NO>11</NO>
<PG>579-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wong-2006" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Wong 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wong SS, Yuen KY</AU>
<TI>Avian influenza virus infections in humans</TI>
<SO>Chest</SO>
<YR>2006</YR>
<VL>129</VL>
<NO>1</NO>
<PG>156-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wright-1976" MODIFIED="2011-07-19 17:25:11 +1000" MODIFIED_BY="[Empty name]" NAME="Wright 1976" YEAR="1976">
<REFERENCE MODIFIED="2011-07-19 17:25:11 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wright PF, Khaw KT, Oxman MN, Shwachman H</AU>
<TI>Evaluation of the safety of amantadine-HCL and the role of respiratory viral infections in children with cystic fibrosis</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1976</YR>
<VL>134</VL>
<NO>2</NO>
<PG>144-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00208364"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wultzler-2004" MODIFIED="2014-11-05 21:26:28 +1000" MODIFIED_BY="[Empty name]" NAME="Wultzler 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-11-05 21:26:28 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wultzler P, Kossow KD, Lode H, Ruf BR, Scholz H, Vogel GE et al</AU>
<TI>Antiviral treatment and prophylaxis of influenza in primary care: German recommendations</TI>
<SO>Journal of Clinical Virology</SO>
<YR>2004</YR>
<VL>31</VL>
<NO>2</NO>
<PG>84-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Unique identifier: 15364262"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamaura-2003" MODIFIED="2011-11-23 03:35:19 +1000" MODIFIED_BY="[Empty name]" NAME="Yamaura 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-11-23 03:35:19 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamaura K, Yoshihara M</AU>
<TI>Investigation of the reconsultation rate and pharmacoeconomic evaluation of period of influenza treatment by oseltamivir</TI>
<SO>Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan</SO>
<YR>2003</YR>
<VL>123</VL>
<NO>10</NO>
<PG>887-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Younkin-1983" NAME="Younkin 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Younkin SW, Betts RF, Roth FK, Douglas RG Jr</AU>
<TI>Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1983</YR>
<VL>23</VL>
<NO>4</NO>
<PG>577-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00031339"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuen-2005" NAME="Yuen 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuen KY, Wong SS</AU>
<TI>Human infection by avian influenza A H5N1</TI>
<SO>Hong Kong Medical Journal</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>3</NO>
<PG>189-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuen-2012" MODIFIED="2014-05-05 18:01:20 +1000" MODIFIED_BY="Liz Dooley" NAME="Yuen 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-05-05 18:01:20 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuen C, Chan Y, Tambyah PA</AU>
<TI>Preflucel (registered trademark): a Vero-cell culture-derived trivalent influenza vaccine</TI>
<SO>Expert Review of Vaccines</SO>
<YR>2012</YR>
<VL>11</VL>
<PG>759-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zeuzem-1999" NAME="Zeuzem 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zeuzem S, Teuber G, Naumann U, Berg T, Raedle J, Hartmann S et al</AU>
<TI>Randomised, double-blind, placebo-controlled trial of interferon-alfa with and without amantadine as initial treatment for chronic hepatitis C</TI>
<SO>Hepatology</SO>
<YR>1999</YR>
<VL>30</VL>
<NO>4</NO>
<PG>200A</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00271208"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-06-26 08:10:23 +1000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2010-11-02 10:03:33 +1000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-11-13 09:36:41 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-11-13 09:36:41 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ahovuo_x002d_Saloranta-2014" MODIFIED="2014-06-25 11:07:37 +1000" MODIFIED_BY="[Empty name]" NAME="Ahovuo-Saloranta 2014" TYPE="COCHRANE_REVIEW">
<AU>Ahovuo-Saloranta A, Rautakorpi U-M, Borisenko OV, Liira H, Williams Jr JW, Mäkelä M</AU>
<TI>Antibiotics for acute maxillary sinusitis in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-06-25 11:07:36 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-25 11:07:36 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000243.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Antanova-2012" MODIFIED="2014-04-16 05:12:27 +1000" MODIFIED_BY="[Empty name]" NAME="Antanova 2012" TYPE="JOURNAL_ARTICLE">
<AU>Antonova EN, Rycroft CE, Ambrose CS, Heikkinen T, Principi N</AU>
<TI>Burden of paediatric influenza in Western Europe: a systematic review</TI>
<SO>BMC Public Health</SO>
<YR>2012</YR>
<VL>12</VL>
<PG>968-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barik-2012" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Barik 2012" TYPE="JOURNAL_ARTICLE">
<AU>Barik S</AU>
<TI>New treatments for influenza</TI>
<SO>BMC Medicine</SO>
<YR>2012</YR>
<VL>13</VL>
<NO>10</NO>
<PG>104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bitko-2007" MODIFIED="2014-05-05 18:03:40 +1000" MODIFIED_BY="Liz Dooley" NAME="Bitko 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bitko V, Musiyenko A, Barik S</AU>
<TI>Viral infection of the lungs through the eye</TI>
<SO>Journal of Virology</SO>
<YR>2007</YR>
<VL>81</VL>
<PG>783-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonn-1997" NAME="Bonn 1997" NOTES="&lt;p&gt;Bonn D. Spared an influenza pandemic for another year? Lancet. 349 (9044): 36, 1997&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Bonn D</AU>
<TI>Spared an influenza pandemic for another year?</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<NO>9044</NO>
<PG>36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bright-2005" MODIFIED="2014-11-05 23:24:09 +1000" MODIFIED_BY="[Empty name]" NAME="Bright 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM et al</AU>
<TI>Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>366</VL>
<PG>1175-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bright-2006" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Bright 2006" TYPE="JOURNAL_ARTICLE">
<AU>Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI</AU>
<TI>Adamantane resistance among influenza A viruses isolated early during the2005-2006 influenza season in the United States</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>295</VL>
<PG>891-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CCI-2006" MODIFIED="2014-11-13 09:36:41 +1000" MODIFIED_BY="[Empty name]" NAME="CCI 2006" TYPE="OTHER">
<AU>Centro Cochrane Iberoamericano</AU>
<TI>Introduction to systematic reviews</TI>
<TO>Curso de introducción a las revisiones sistemáticas</TO>
<SO>http://www.cochrane.es/</SO>
<YR>2006 (accessed 12 January 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cheung-2002" MODIFIED="2014-11-05 23:24:15 +1000" MODIFIED_BY="[Empty name]" NAME="Cheung 2002" TYPE="JOURNAL_ARTICLE">
<AU>Cheung CY, Poon LLM, Lau AS, Luk W, Lau YL, Shortridge KF et al</AU>
<TI>Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<PG>1831-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Demicheli-2000" NAME="Demicheli 2000" NOTES="&lt;p&gt;Demicheli V, Jefferson T, Rivetti D, Deeks J. Prevention and early treatment of influenza in health adults Vaccine 2000; 18: 957-1030&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Demicheli V, Jefferson T, Rivetti D, Deeks J</AU>
<TI>Prevention and early treatment of influenza in health adults</TI>
<SO>Vaccine</SO>
<YR>2000</YR>
<VL>18</VL>
<PG>957-1030</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Demicheli-2012" MODIFIED="2014-05-06 09:48:03 +1000" MODIFIED_BY="Liz Dooley" NAME="Demicheli 2012" TYPE="COCHRANE_REVIEW">
<AU>Demicheli V, Jefferson T, Al-Ansary LA, Ferroni E, Rivetti A, Di Pietrantonj C</AU>
<TI>Vaccines for preventing influenza in healthy children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2014-05-06 09:48:03 +1000" MODIFIED_BY="Liz Dooley">
<IDENTIFIER MODIFIED="2014-05-06 09:48:03 +1000" MODIFIED_BY="Liz Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD004879.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Deyde-2007" MODIFIED="2011-12-05 10:21:51 +1000" MODIFIED_BY="[Empty name]" NAME="Deyde 2007" TYPE="JOURNAL_ARTICLE">
<AU>Deyde VM, Xu X, Bright RA, Shaw M, Smith CB, Zhang Y, et al</AU>
<TI>Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2007</YR>
<VL>196</VL>
<NO>2</NO>
<PG>249-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dolin-2005" NAME="Dolin 2005" TYPE="JOURNAL_ARTICLE">
<AU>Dolin R</AU>
<TI>Influenza-interpandemic as well as pandemic disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<NO>24</NO>
<PG>2535-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eccle-2005" MODIFIED="2011-07-19 17:27:33 +1000" MODIFIED_BY="[Empty name]" NAME="Eccle 2005" TYPE="JOURNAL_ARTICLE">
<AU>Eccle R</AU>
<TI>Understanding the symptoms of the common cold and influenza</TI>
<SO>Lancet Infectious Diseases</SO>
<YR>2005</YR>
<VL>5</VL>
<PG>718-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fletcher-2006" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Fletcher 2006" TYPE="BOOK">
<AU>Fletcher RH, Fletcher SW</AU>
<SO>Epidemiologia Clínica: Elementos Essenciais</SO>
<YR>2006</YR>
<EN>4th</EN>
<PB>Artmed</PB>
<CY>Porto Alegre, Brazil</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goodman-2006" MODIFIED="2014-11-13 09:35:56 +1000" MODIFIED_BY="[Empty name]" NAME="Goodman 2006" TYPE="OTHER">
<AU>Goodman C, Mukherjee D, Faulkner E</AU>
<TI>How effective would antiviral vaccination and antiviral drug prevention and treatment strategies be for reducing the impact of the next influenza pandemic</TI>
<SO>Copenhagen, WHO Regional Office for Europe (Health Evidence Network report; http://www.euro.who.int/en/data-and-evidence/evidence-informed-policy-making/publications/pre2009/how-effective-would-antiviral-vaccination-and-antiviral-drug-prevention-and-treatment-strategies-be-for-reducing-the-impact-of-the-next-influenza-pandemic</SO>
<YR>2006 (accessed 20 October 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hayden-2004" NAME="Hayden 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hayden FG</AU>
<TI>Pandemic influenza: is an antiviral response realistic?</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>Suppl</NO>
<PG>262-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hayden-2005" MODIFIED="2014-11-05 23:24:22 +1000" MODIFIED_BY="[Empty name]" NAME="Hayden 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hayden FG, Klimov A, Tashiro M, Hay A, Monto A, McKimm-Breschkin J et al</AU>
<TI>Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses</TI>
<SO>Antiviral Therapy</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>8</NO>
<PG>873-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hayden-2006b" NAME="Hayden 2006b" TYPE="JOURNAL_ARTICLE">
<AU>Hayden FG</AU>
<TI>Antiviral resistance in influenza viruses - implications for management and pandemic response</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>354</VL>
<NO>8</NO>
<PG>785-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jefferson-2006b" MODIFIED="2014-10-07 13:01:29 +1000" MODIFIED_BY="Liz  Dooley" NAME="Jefferson 2006b" TYPE="COCHRANE_REVIEW">
<AU>Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D</AU>
<TI>Amantadine and rimantadine for influenza A in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-06-25 12:04:04 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-25 12:04:04 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001169.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jefferson-2010" MODIFIED="2014-06-24 10:20:18 +1000" MODIFIED_BY="[Empty name]" NAME="Jefferson 2010" TYPE="COCHRANE_REVIEW">
<AU>Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE</AU>
<TI>Vaccines for preventing influenza in the elderly</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-06-24 10:20:18 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-24 10:20:18 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004876.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jefferson-2014" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Jefferson 2014" TYPE="COCHRANE_REVIEW">
<AU>Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ et al</AU>
<TI>Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-06-25 11:28:41 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-25 11:28:41 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008965.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kelso-2013" MODIFIED="2014-05-06 09:40:17 +1000" MODIFIED_BY="Liz Dooley" NAME="Kelso 2013" TYPE="JOURNAL_ARTICLE">
<AU>Kelso JK, Halder N, Milne GJ</AU>
<TI>Vaccination strategies for future influenza pandemics: a severity-based cost effectiveness analysis</TI>
<SO>BMC Infectious Diseases</SO>
<YR>2013</YR>
<VL>11</VL>
<PG>1-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Li-2014" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Li 2014" TYPE="JOURNAL_ARTICLE">
<AU>Li Q, Zhou L, Zhou M, Chen Z, Li F, Wu H et al</AU>
<TI>Epidemiology of human infections with avian influenza A(H7N9) virus in China</TI>
<SO>New England Journal of Medicine</SO>
<YR>2014</YR>
<VL>370</VL>
<PG>520-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Monto-2008" MODIFIED="2011-09-05 09:41:23 +1000" MODIFIED_BY="[Empty name]" NAME="Monto 2008" TYPE="JOURNAL_ARTICLE">
<AU>Monto AS</AU>
<TI>Epidemiology of influenza</TI>
<SO>Vaccine</SO>
<YR>2008</YR>
<VL>Suppl</VL>
<NO>4</NO>
<PG>D45&#8211;8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moscona-2005" NAME="Moscona 2005" TYPE="JOURNAL_ARTICLE">
<AU>Moscona A</AU>
<TI>Neuraminidase inhibitors for Influenza</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<PG>1363-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MS-2006" NAME="MS 2006" NOTES="&lt;p&gt;Didatic CD-rom elaborated and distributed by the Brazilian Ministry of Health&lt;br&gt;Vol, iss. and pages are not available.&lt;br&gt;English title not available. Translated by the authors&lt;/p&gt;" TYPE="OTHER">
<AU>Ministério da Saúde 2006 (Brazilian Ministry of Health 2006)</AU>
<TI>Human influenza and avian influenza</TI>
<TO>Influenza humana e influenza aviária</TO>
<SO>Série F. Comunicação e Educação em Saúde</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nicholson-1992" MODIFIED="2011-08-19 11:41:19 +1000" MODIFIED_BY="[Empty name]" NAME="Nicholson 1992" NOTES="&lt;p&gt;Nicholson K. Clinical features of influenza Seminars in respiratory Infections 1992; 7(1):26-37&lt;/p&gt;" NOTES_MODIFIED="2011-08-19 11:41:19 +1000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Nicholson K</AU>
<TI>Clinical features of influenza</TI>
<SO>Seminars in Respiratory Infections</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>1</NO>
<PG>26-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Noah-2013" MODIFIED="2014-05-06 09:29:41 +1000" MODIFIED_BY="Liz Dooley" NAME="Noah 2013" TYPE="JOURNAL_ARTICLE">
<AU>Noah DL, Noah JH</AU>
<TI>Adapting global influenza management strategies to address emerging viruses</TI>
<SO>American Journal of Physiology. Lung Cellular and Molecular Physiology</SO>
<YR>2013</YR>
<VL>305</VL>
<PG>108-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pineda-Solas-2006" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Pineda Solas 2006" TYPE="JOURNAL_ARTICLE">
<AU>Pineda Solas A, Bernaola Iturbe E, Martinon-Torres F, Baca Cots M, De Juan Martin F, Gomez Campdera JA et al</AU>
<TI>Recommendations of the Vaccine Advisory Committee of the Spanish Association of Pediatrics: influenza vaccination campaign 2006-2007</TI>
<SO>Anales de Pediatría</SO>
<YR>2006</YR>
<VL>65</VL>
<NO>3</NO>
<PG>252-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sasaki-2011" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Sasaki 2011" TYPE="JOURNAL_ARTICLE">
<AU>Sasaki S, Sullivan M, Narvaez C, Holmes T, Furman D, Zheng NY et al</AU>
<TI>Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>2011</YR>
<VL>121</VL>
<NO>8</NO>
<PG>3109-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sleeman-2013" MODIFIED="2014-11-05 21:33:02 +1000" MODIFIED_BY="[Empty name]" NAME="Sleeman 2013" TYPE="JOURNAL_ARTICLE">
<AU>Sleeman K, Guo Z, Barnes J, Shaw M, Stevens J, Gubareva L</AU>
<TI>R292K Substitution and drug susceptibility of Influenza A (H7N9) viruses</TI>
<SO>Emerging Infectious Diseases</SO>
<YR>2013</YR>
<VL>9</VL>
<NO>9</NO>
<PG>1521-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2006" MODIFIED="2011-11-23 03:40:53 +1000" MODIFIED_BY="[Empty name]" NAME="Smith 2006" TYPE="JOURNAL_ARTICLE">
<AU>Smith NM, Bresee JJ, Shay DK, Uyeki TM, Cox NJ, Strikas RA</AU>
<TI>Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practice (ACIP)</TI>
<SO>Morbidity and Mortality Weekly Report: Recommendations and Reports/Centers for Disease Control</SO>
<YR>2006</YR>
<VL>55</VL>
<NO>RR10</NO>
<PG>1-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 1545-8601 (Electronic)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thomas-2011" MODIFIED="2014-06-24 10:43:31 +1000" MODIFIED_BY="[Empty name]" NAME="Thomas 2011" TYPE="COCHRANE_REVIEW">
<AU>Thomas RE, Russell M, Lorenzetti D</AU>
<TI>Interventions to increase influenza vaccination rates of those 60 years and older in the community</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2014-06-24 10:43:31 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-24 10:43:31 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005188.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Treanor-2005" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Treanor 2005" TYPE="BOOK_SECTION">
<AU>Treanor JJ</AU>
<TI>Influenza viruses</TI>
<SO>Principles and Practice of Infectious Diseases</SO>
<YR>2005</YR>
<VL>2</VL>
<PG>2060-85</PG>
<EN>6th</EN>
<ED>Mandell, Bennett, &amp; Dolin</ED>
<PB>W.B. Saunders, an imprint of Elsevier</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2003" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="WHO 2003" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Influenza. Geneva, World Health Organization, 2003 (Fact Sheet No. 211)</TI>
<SO>http://www.who.int/mediacentre/factsheets/fs211/en/print.html</SO>
<YR>2003 (accessed 20 October 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2007" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="WHO 2007" NOTES="&lt;p&gt;avaiable in www.who.int/child-adolescent-health/over.htm on January 20th, 2007&lt;/p&gt;" NOTES_MODIFIED="2014-11-05 21:58:42 +1000" NOTES_MODIFIED_BY="[Empty name]" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Child and adolescent health and development</TI>
<SO>http://www.who.int/child-adolescent-health/over.htm</SO>
<YR>2007 (20 accessed January 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2010a" MODIFIED="2014-11-13 09:13:21 +1000" MODIFIED_BY="[Empty name]" NAME="WHO 2010a" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Pandemic (H1N1) 2009 - update 112</TI>
<SO>http://www.who.int/csr/don/2010_08_06/en/</SO>
<YR>2010 (accessed 14 August 2011)</YR>
<IDENTIFIERS MODIFIED="2014-11-05 21:34:42 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2010b" MODIFIED="2014-11-13 09:33:31 +1000" MODIFIED_BY="[Empty name]" NAME="WHO 2010b" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Essential medicines selection. Unedited report of the supplementary meeting of the expert committee on the selection and use of essential medicines</TI>
<SO>http://www.who.int/selection_medicines/committees/expert/emergency_session/unedited_Emergency_report.pdf</SO>
<YR>2010 (accessed 14 August 2011)</YR>
<IDENTIFIERS MODIFIED="2011-09-01 11:31:18 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2011" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="WHO 2011" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Global Influenza Surveillance and Response System (GISRS)</TI>
<SO>http://www.who.int/influenza/gisrs_laboratory/en</SO>
<YR>2011 (accessed in 3 December 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2012" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="WHO 2012" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Laboratory methodologies for testing the antiviral susceptibility of influenza viruses</TI>
<SO>http://www.who.int/influenza/gisrs_laboratory/antiviral_susceptibility/en/</SO>
<YR>2012 (accessed 20 August 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiselka-1994" NAME="Wiselka 1994" NOTES="&lt;p&gt;Wiselka M. Influenza: diagnosis, management and prophylaxis. BMJ, 1994; 308: 1341-5&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Wiselka M</AU>
<TI>Influenza: diagnosis, management and prophylaxis</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>308</VL>
<PG>1341-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wright-2004" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Wright 2004" TYPE="BOOK_SECTION">
<AU>Wright P</AU>
<TI>Influenza viruses</TI>
<SO>Nelson Textbook of Pediatrics of Pediatrics</SO>
<YR>2004</YR>
<PG>1072-5</PG>
<EN>17th</EN>
<ED>Behrman RE, Kliegman RM, Hall BJ</ED>
<PB>Saunders (an imprint of Elsevier)</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yang-2010" MODIFIED="2011-09-01 11:19:58 +1000" MODIFIED_BY="[Empty name]" NAME="Yang 2010" TYPE="COCHRANE_PROTOCOL">
<AU>Yang M, Dong BR, Wu HM, Li T, Liu GJ</AU>
<TI>Interventions for treating influenza: an overview of Cochrane systematic reviews</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2011-09-01 11:19:58 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-09-01 11:19:58 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008799"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ziegler-1999" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NAME="Ziegler 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ziegler T, Hemphill ML, Ziegler ML, Perez-Oronoz G, Klimov AI, Hampson AW et al</AU>
<TI>Low incidence of rimantadine resistance infield isolates of influenza A viruses</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1999</YR>
<VL>4</VL>
<PG>935&#8211;9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-05-05 17:42:54 +1000" MODIFIED_BY="Liz Dooley">
<REFERENCE ID="REF-Alves-Galv_x00e3_o-2008" MODIFIED="2011-07-19 17:35:31 +1000" MODIFIED_BY="[Empty name]" NAME="Alves Galvão 2008" NOTES="&lt;p&gt;Meta-Analysis&lt;br&gt;Review18254006&lt;/p&gt;" NOTES_MODIFIED="2011-07-19 17:35:31 +1000" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Alves Galvão MG, Rocha Crispino Santos MA, Alves da Cunha AJL</AU>
<TI>Amantadine and rimantadine for influenza A in children and the elderly</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-07-19 17:35:31 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-19 17:35:31 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002745.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Alves-Galv_x00e3_o-2012" MODIFIED="2014-05-05 17:42:54 +1000" MODIFIED_BY="Liz Dooley" NAME="Alves Galvão 2012" NOTES="&lt;p&gt;Meta-Analysis&lt;br&gt;Review18254006&lt;/p&gt;" NOTES_MODIFIED="2014-05-05 17:42:54 +1000" NOTES_MODIFIED_BY="Liz Dooley" TYPE="COCHRANE_REVIEW">
<AU>Alves Galvão MG, Rocha Crispino Santos MA, Alves da Cunha AJL</AU>
<TI>Amantadine and rimantadine for influenza A in children and the elderly</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-05-05 17:42:54 +1000" MODIFIED_BY="Liz Dooley">
<IDENTIFIER MODIFIED="2014-05-05 17:42:54 +1000" MODIFIED_BY="Liz Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD002745.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2014-06-26 15:22:55 +1000" MODIFIED_BY="Liz Dooley">
<REFERENCE ID="REF-Ison-2013a" MODIFIED="2014-06-26 15:22:45 +1000" MODIFIED_BY="Liz Dooley" NAME="Ison 2013a" TYPE="JOURNAL_ARTICLE">
<AU>Ison M G</AU>
<TI>Influenza prevention and treatment in transplant recipients and immunocompromised hosts</TI>
<SO>Influenza and other Respiratory Viruses</SO>
<YR>2013</YR>
<VL>7</VL>
<PG>60-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ison-2013b" MODIFIED="2014-06-26 15:22:40 +1000" MODIFIED_BY="Liz Dooley" NAME="Ison 2013b" TYPE="JOURNAL_ARTICLE">
<AU>Ison M G</AU>
<TI>Influenza prevention and treatment in transplant recipients and immunocompromised hosts</TI>
<SO>Influenza and other Respiratory Viruses</SO>
<YR>2013</YR>
<VL>7</VL>
<PG>60-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Munier-2013a" MODIFIED="2014-06-26 15:22:55 +1000" MODIFIED_BY="Liz Dooley" NAME="Munier 2013a" TYPE="JOURNAL_ARTICLE">
<AU>Munier S, Rolland T, Diot C, Jacob Y, Naffakh N</AU>
<TI>Exploration of binary virus-host interactions using an infectious protein complementation assay</TI>
<SO>Molecular and Cellular Proteomics</SO>
<YR>2013</YR>
<VL>12</VL>
<PG>2845-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Munier-2013b" MODIFIED="2014-06-26 15:22:51 +1000" MODIFIED_BY="Liz Dooley" NAME="Munier 2013b" TYPE="JOURNAL_ARTICLE">
<AU>Munier S, Rolland T, Diot C, Jacob Y, Naffakh N</AU>
<TI>Exploration of binary virus-host interactions using an infectious protein complementation assay</TI>
<SO>Molecular and Cellular Proteomics</SO>
<YR>2013</YR>
<VL>12</VL>
<PG>2845-55</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-11-05 23:34:30 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-11-05 23:32:24 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clover-1986">
<CHAR_METHODS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel, double-blind comparison of rimantadine with PB. The trial took place during an outbreak of influenza A/H1N1 in Oklahoma<BR/>Study duration: 5 weeks<BR/>Patients and providers were blinded. Outcome assessor method of blinding was unclear<BR/>Dropouts: 3 families who moved outside the study area, 1 in the placebo group whose parents attributed the 'medication' to the reducing of the child's performance at school and 1 in the rimantadine group due to a non-influenza illness in a 4-year-old child<BR/>Co-interventions and other potential confounders were not observed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>There was a total of 146 participants, including 76 children, which was our subgroup of interest<BR/>Inclusion criteria: children within 35 families during a naturally occurring outbreak of influenza A<BR/>Exclusion criteria: if any family member was known to have cardiac, pulmonary, or neurologic disease; if a female family member was pregnant or actively trying to become pregnant; if any family member had received the influenza vaccine during the past year; if any member was taking medications that might interfere with the study<BR/>Gender: both females and males were included (proportion not specified)<BR/>Disease stage: rimantadine was administered as a prophylactic when influenza A was identified within community</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Rimantadine: 5 mg/kg/d, max: 100 mg/ d (&lt; 10 years) or 200 mg/ d (&gt; 10 years). Oral route. Duration: 5 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Laboratory-proven infection cases and reported adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1 to 18 years old</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clover-1991">
<CHAR_METHODS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel, comparison of rimantadine with PB. Multicentre trial that took place during an influenza season for 3 to 4 weeks after the start of treatment<BR/>Patients were blinded. Outcome assessor blinding was unclear<BR/>Dropouts: none (in the subgroup of interest)<BR/>Co-interventions and other potential confounders were not observed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>There was a total of 84 participants, including 46 children, which was our subgroup of interest<BR/>Inclusion criteria: children within families consisting of 2 to 5 members with at least 1 adult (ranging in age from 18 to 75 years and 1 child aged between 1 to 17 years during a naturally occurring outbreak of influenza A<BR/>Exclusion criteria: participants who had a history of amantadine hypersensitivity, chronic respiratory disease, severe medical illness, neuropsychiatric disorder; were pregnant or lactating; had a recently documented influenza A virus infection; required long-term drug therapy with amantadine or drugs that could interfere with rimantadine or with clinical assessments (e.g. aspirin, tranquillisers, antihistamines and decongestants<BR/>Gender: unclear<BR/>Disease stage: all the eligible participants were given the assigned drug as soon as influenza was first recognised in family members (the index patient) and after the member had been evaluated by a study nurse</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Rimantadine: 5 mg/kg/d, max: 150 mg/d (= or &lt; 10 years or weighing less than 30 kg) or 200 mg/d (&gt; 9 years who weighed more than 30 kg). Oral route. Duration: 10 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>The outcome of interest was laboratory-proven infection cases</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1 to 17 years old</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-05 22:46:12 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Crawford-1988">
<CHAR_METHODS MODIFIED="2014-11-05 22:46:12 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel, double-blind trial in which prophylactic efficacy of rimantadine against influenza A infection in children was evaluated. Rimantadine was compared to PB. The trial took place during a naturally occurring outbreak of influenza A (H3N2) in Oklahoma City, USA, from November, 1984 to March, 1985<BR/>Study duration: 5 weeks<BR/>Withdrawal: 3 children in the rimantadine group were found post-study to have had documented influenza A infection before or on the day of institution of prophylaxis and were excluded from the analysis. 17 people from 5 families withdrew because of relocation or refusal to have a second blood specimen drawn. Their age group was not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>There was a total of 110 participants from 29 families, including 56 children, which was our subgroup of interest<BR/>Inclusion criteria: children within 29 families during a naturally occurring outbreak of influenza A infection<BR/>Exclusion criteria: if any family member was known to have cardiac, pulmonary or neurologic disease; if a female family member was pregnant or actively trying to become pregnant; if any family member had received the influenza vaccine during the past year; if any member was taking medications that might interfere with the study<BR/>Gender: both females and males were included (proportion not specified)<BR/>Disease stage: rimantadine was administered as a prophylactic when influenza A was identified within community</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Rimantadine: 5 mg/kg/d, max: 100 mg/d (&lt; 10 years) or 200 mg/d (&gt; 10 years). Oral route</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Laboratory-proven infection cases. Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-22 03:31:36 +1000" MODIFIED_BY="[Empty name]">
<P>1 to 18 years old</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Finklea-1967">
<CHAR_METHODS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel, double-blind, trial in which amantadine was used as prophylaxis in naturally occurring acute respiratory illness. Amantadine was compared to PB. The trial took place between February 1965 to June 1965<BR/>The method of blinding is unclear<BR/>Study duration: 18 weeks<BR/>Withdrawal was the same for the 2 groups - discharge from school (19%). The proportion was not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>There were 293 participants from both sexes (proportion not stated), from 8 to 19 years of age. The participants were volunteers at a school for intellectually handicapped but educable children. Sera pairs tests were obtained in 237 children. Exclusion criteria: children receiving tranquillisers, sympathomimetic amines or anticonvulsives<BR/>Co-morbid conditions: intellectually handicapped children</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Amantadine: 1 to 2.5 mg/kg (pre-puberal: 60 mg/dose, 2 x/d, during the first week and 1 x/d during the rest of the period of the study. Older children: 100 mg/dose, 2 x/d, during the first week and 1 x/d during the rest of the period of the study</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>4-fold rises in CF and/or HI tilter against A2/AA/1/65</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>8 to 19 years old</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gravenstein-2005">
<CHAR_METHODS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel, double-blind comparison of rimantadine with zanamivir. Identical PB (inhaled or tablets) were used. The trial took place in nine long-term care facilities in the United States over 3 winter seasons. The study was conducted over multiple influenza seasons, therefore some participants were randomised more than once<BR/>Study duration: 3 winter seasons<BR/>Co-interventions and other potential confounders were not observed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>There were 231 participants in the rimantadine group and 226 in the zanamivir group (intention-to-treat population) of both sexes (29% female in rimantadine group and 30% female in zanamivir group). More than 75% of the participants were 65 years of age or older (90% in rimantadine group and 89% in zanamivir group)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-10-08 11:15:39 +1000" MODIFIED_BY="[Empty name]">
<P>Upon an influenza outbreak participants were randomised (1:1) to inhaled zanamivir plus PB or inhaled PB plus zanamivir 100 mg tablets for 14 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>The outcome of interest was laboratory-proven infection cases</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hall-1987">
<CHAR_METHODS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel, double-blind comparison of rimantadine with acetaminophen<BR/>Study duration: 7 days<BR/>1 patient dropped out, due to AE<BR/>Co-interventions and other potential confounders were not observed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>69 children were included, 40 females and 29 males<BR/>Inclusion criteria: clinical illness and viral isolation<BR/>Exclusion criteria: previously unhealthy aged 1 to 15 years<BR/>Disease stage: clinical illness and laboratory-confirmed infection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Rimantadine: 6.6 mg/kg/d, max: 150 mg/d (&lt; 9 years) and 200 mg/d (&gt;= 9 years), 2 x/d; by oral route, for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean symptom score of: fever, conjunctivitis, eye symptoms (pain on movement, fever up to 3rd day, conjunctivitis up to 3rd day, eyes symptoms (pain on movement and visual distortion); cough up to 7th day; malaise up to 6th day; CNS symptoms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kitamoto-1968">
<CHAR_METHODS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel, double-blind comparison of amantadine with PB. This trial took place during an outbreak of influenza in Japan<BR/>Study duration: 7 days<BR/>Patient, provider and outcome assessor method of blinding is unclear<BR/>Dropouts: none <BR/>Co-interventions and other potential confounders were not observed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>There were 355 participants. Although the proportions are not cited, it is stated that the groups are comparable in the following criteria: sex, age, influenza vaccination history, distribution and geometric mean of HI and CF titre in acute sera, interval between onset of symptoms and start of treatment and maximum body temperature before the treatment<BR/>158 participants of both genders met the age criteria. 91 children were cases of clinical influenza with serological confirmation. The proportion of males and females was not stated<BR/>Inclusion criteria: respiratory symptoms evident within the 2nd day of illness<BR/>Disease stage: clinical symptoms within 2nd day of illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Amantadine: 50 mg/d (1 to 2 years old); 100 mg/d (3 to 5 years old); 150 mg/d (6 to 10 years old), by oral route, for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Fever up to 4th day. AE: nausea/vomiting; diarrhoea; exanthema; malaise; muscular, limb pain; headache; dyspnoea; cyanosis; stimulation/insomnia; dizziness; arrhythmia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kitamoto-1971">
<CHAR_METHODS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel, double-blind comparison of amantadine with PB. The trial took place during an outbreak of influenza in the winter of 1968 to 1969 in Japan<BR/>Study duration: at least 7 days<BR/>Patient, provider and outcome assessor method of blinding was unclear<BR/>Dropouts were not stated<BR/>Co-interventions and other potential confounders: concomitant administration of antipyretics. An analyses with patients who received concomitant antipyretics was also performed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Of the 737 participants, 155 participants of both genders met the inclusion criteria. Although the proportions are not cited, it is stated that the groups are comparable in the following criteria: sex, age, influenza vaccination history, distribution and geometric mean of HI and CF titre in acute sera, interval between onset of symptoms and start of treatment and maximum body temperature before the treatment<BR/>Inclusion criteria: respiratory symptoms evident within the 2nd day of illness<BR/>Disease stage: clinical symptoms within 2nd day of illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Amantadine: 50 mg/d (1 to 2 years old); 100 mg/d (3 to 5 years old); 150 mg/d (6 to 10 years old), by oral route, for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-22 03:34:52 +1000" MODIFIED_BY="Liz Dooley">
<P>Fever up to 4th day. AE: nausea/vomiting; diarrhoea; exanthema; malaise; muscular, limb pain; headache; stimulation/insomnia; dizziness; arrhythmia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Monto-1995">
<CHAR_METHODS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel, double-blind comparison of 2 different doses of rimantadine with PB. The trial took place during an outbreak of influenza A/H3N2 during 1993<BR/>Study duration: 8 weeks<BR/>Dropouts: 62% withdrew because of side effects, death, discharge, hospitalisation, physician's request and refusal to continue participation<BR/>Co-interventions and other potential confounders were not observed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>A total of 328 participants, 275 females and 53 males were included<BR/>Inclusion criteria: residents of 10 nursing homes who agreed to participate in the study<BR/>Exclusion criteria: patients with significant renal or hepatic disease<BR/>Disease stage: rimantadine was administered as prophylaxis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Rimantadine: 100 mg/d; rimantadine: 200 mg/d; PB. Ratio: 2:2:1. Duration: up to 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Death. AEs: dry mouth, drowsiness/fatigue, headache, irritability, dizziness/light headedness, nausea/vomiting, abdominal pain, body weakness or disability, confusion, depression, impaired concentration, insomnia or sleeplessness, loss of appetite, rash or allergic reaction, seizure or clonic twitching</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>3 groups: rimantadine 100 amantadine 200 and PB</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patriarca-1984">
<CHAR_METHODS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel, double-blind comparison of rimantadine with PB. The trial took place during an outbreak of influenza A (H3N2). Viruses were isolated from patients in the community. The study was conducted from early January to 6 April 1983<BR/>Patient, provider and outcome assessor method of blinding is unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>35 participants, 68 to 102 years old, of non-specified gender, all of whom had been vaccinated the previous autumn<BR/>Inclusion criteria: residents of 3 nursing homes who agreed to participate in the study<BR/>Exclusion criteria: patients with medical conditions that might increase the severity of side effects or require careful adjustments in the dosage of rimantadine, which include: significant renal impairment (SCr &gt; 2 mg/d) or liver disease, acute congestive heart failure, seizure disorders, psychosis, severe pitting oedema, orthostatic hypotension and conditions requiring central nervous system stimulants<BR/>Disease stage: rimantadine was administered as prophylaxis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Rimantadine: 100 mg twice a day; PB. Duration: 80 (+/- 4.9) days prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Adverse reactions: anxiety, confusion, insomnia, anorexia, fatigue, dizziness, nausea and vomiting</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Payler-1984">
<CHAR_METHODS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel trial; blinding is not stated. Amantadine used as prophylaxis in naturally occurring acute respiratory illness. Amantadine was compared to no specific treatment. The trial took place in the autumn of 1982<BR/>Study duration: 14 days<BR/>Patients excluded from analysis were similar in the 2 groups and the reasons were: students were day boys from whom samples were not available; students infected before the start of amantadine; compliance failures</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>There were 604 randomised students and 536 were analysed. All of them were male, from 13 to 19 years of age. The participants were students of a boarding school. Once the influenza A outbreak had been detected, samples were taken from all boys who were sufficiently unwell to be absent from lessons even if they did not have a fever. Nasopharyngeal aspirates were examined for viruses by rapid immunofluorescent microscopy and tissue culture. Once outbreaks had been identified, only culture methods were used</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Amantadine: 100 mg/ dose, 1 x/d, during the 14 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical and laboratory-proven influenza A</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>13 to 19 years old</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schilling-1998">
<CHAR_METHODS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel, unblinded trial. Rimantadine and zanamivir were compared for prophylaxis of influenza A. The trial began in November 1996. The participants were volunteer residents of a nursing home for veterans and their spouses<BR/>Drug administration: 14 days<BR/>The number of respiratory illness was monitored until January 1997<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>65 volunteers of both sexes received zanamivir and 23 rimantadine<BR/>Age range: 50 to 95 years old and 75% older than 65 years of age<BR/>The participants were volunteers residents of a nursing home for veterans and their spouses<BR/>Inclusion criteria: volunteers living in a unit of the nursing home where outbreak of influenza was declared<BR/>Exclusion criteria: symptoms of new respiratory illness within the previous 7 days of the declared outbreak<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Rimantadine: 100 mg/dose, 1 x/day, during 14 days. Zanamivir: 10 mg inhaled bid and 4.4 mg intranasally bid</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical and laboratory-proven influenza A</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ACM: acetaminophen<BR/>AE: adverse effects<BR/>bid: twice a day<BR/>CF: complement fixation<BR/>CNS: central nervous system<BR/>d: day<BR/>GI: gastrointestinal<BR/>HI: haemagglutination inhibition<BR/>NC: not clear<BR/>PB: placebo<BR/>SCr: serum creatinine<BR/>STGO: aspartate aminotransferase<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-11-05 23:34:30 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-AAPCID-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:41 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Allen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:41 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:42 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Article about oseltamivir and vaccination</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anton-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aoky-1985a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Pharmacokinetics study of amantadine and rimantadine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aoky-1985b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aoky-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 23:34:18 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Atiee-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 23:34:18 +1000" MODIFIED_BY="[Empty name]">
<P>Open-label study of the pharmacokinetic interactions of peramivir with oseltamivir or rimantadine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Atmar-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 23:33:09 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bacosi-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 23:33:09 +1000" MODIFIED_BY="[Empty name]">
<P>Article about the treatment of hepatitis C</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Baker-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range (participants were aged between 17 to 57 years old)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-13 10:45:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bantia-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-13 10:45:27 +1000" MODIFIED_BY="[Empty name]">
<P>Non-human trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barr-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:42 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barr-2007b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:42 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bauer-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-human trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Belenky-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range (participants were aged between 17 to 57 years old)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bloomfield-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boltz-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Review article about other antiviral drugs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:45:50 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brady-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:45:50 +1000" MODIFIED_BY="[Empty name]">
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-01 06:32:53 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brammer-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-01 06:32:53 +1000" MODIFIED_BY="[Empty name]">
<P>Article focusing influenza surveillance</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bricaire-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Analyses by age subgroups of interest were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bryson-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Insufficient data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 23:33:28 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burch-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 23:33:28 +1000" MODIFIED_BY="[Empty name]">
<P>Systematic review about the use of other antivirals</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cady-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:42 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Callmander-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range (participants were 20 to 60 years old)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 23:33:31 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carter-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 23:33:31 +1000" MODIFIED_BY="[Empty name]">
<P>Review of the use of the influenza vaccine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cayley-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Article about neuraminidase inhibitors in healthy adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 23:33:33 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cayley-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 23:33:33 +1000" MODIFIED_BY="[Empty name]">
<P>Review about neuraminidase inhibitors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:46:20 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chawla-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:46:20 +1000" MODIFIED_BY="[Empty name]">
<P>Article about strategies for pandemic preparedness</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:43 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chemaly-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:43 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:46:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:46:52 +1000" MODIFIED_BY="[Empty name]">
<P>Article about Chinese medical herbs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cheng-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>The authors studied other antivirals, included other viral infections and the ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:16:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cheng-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:16:11 +1000" MODIFIED_BY="[Empty name]">
<P>Review study with different objectives</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cheng-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 23:33:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Choi-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 23:33:37 +1000" MODIFIED_BY="[Empty name]">
<P>Trial conducted in influenza isolates</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:47:15 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chou-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:47:15 +1000" MODIFIED_BY="[Empty name]">
<P>Article about chronic hepatitis C</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cohen-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range (participants were aged between 20 to 39 years old)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 23:33:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 23:33:40 +1000" MODIFIED_BY="[Empty name]">
<P>Study that compared patient access to pharmaceuticals in the UK and US</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cowling-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Preliminary findings of non-pharmaceutical intervention trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-13 11:42:18 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Curran-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-13 11:42:18 +1000" MODIFIED_BY="[Empty name]">
<P>Article about an influenza vaccine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dawkins-1968">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Study assessing the prophylactic efficacy of an analogue of amantadine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:47:39 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-la-Camara-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:47:39 +1000" MODIFIED_BY="[Empty name]">
<P>Review study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Vincenzo-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-13 10:53:03 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DeLaney-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-13 10:53:03 +1000" MODIFIED_BY="[Empty name]">
<P>Review study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Denys-1963">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of human participants were outside protocol age range (participants were aged between 19 to 21 years old). Animals were also studied</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dolamore-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case-control study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dolin-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range (participants were aged between 18 to 45 years old)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Doyle-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range (participants were aged between 18 to 50 years old)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Drinevskii-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomisation was not stated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Drinka-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Groups characteristics not stated. Analyses by age subgroup of interest not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Enger-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Article about oseltamivir</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 23:33:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Escuret-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 23:33:59 +1000" MODIFIED_BY="[Empty name]">
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:48:15 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Falagas-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:48:15 +1000" MODIFIED_BY="[Empty name]">
<P>Review study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:17:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Farlow-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:17:42 +1000" MODIFIED_BY="[Empty name]">
<P>Article about Alzheimer's</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-01 07:20:36 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fiore-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-01 07:20:36 +1000" MODIFIED_BY="[Empty name]">
<P>Article about Glycyrrhiza species</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Furuta-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Study of the mechanism of action of T-705 against influenza virus</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Galabov-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-human trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Galbraith-1969a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Analyses by age subgroups of interest were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Galbraith-1969b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcomes of interest were not studied</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Galbraith-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Analyses by age subgroups of interest were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Galbraith-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Insufficient data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Garman-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial about drugs that inhibit the virus's neuramidase</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gatwood-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Review study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:43 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gerth-1966">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:43 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Griffin-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pharmacological study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:49:33 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guo-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:49:33 +1000" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 23:34:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hay-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 23:34:30 +1000" MODIFIED_BY="[Empty name]">
<P>Study about the molecular basis for resistance of influenza A to amantadine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hayden-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hayden-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hayden-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hayden-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hayden-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pharmacokinetics study in which ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hayden-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hayden-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Analysis by age subgroups of interest was not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hayden-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Analysis by age subgroups of interest was not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hayden-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>The drug studied was zanamivir</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:43 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hayden-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:43 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hayden-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Review study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hornick-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:43 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hota-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:43 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hout-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Study about the human immunodeficiency virus</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hout-2006b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Study about the human immunodeficiency virus</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hsu-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hurt-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:44 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ilyushina-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:44 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ilyushina-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Study of whether combined therapy with 2 classes of anti-influenza drugs could affect the emergence of resistant virus variants in vitro</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ilyushina-2007a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-human trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ilyushina-2007b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-human trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ison-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ison-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Review about pharmacokinetics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ito-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ito-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study about influenza vaccination</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jefferson-2006a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Systematic review about antivirals for influenza in healthy adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jiang-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Article about Chinese medicinal herbs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jones-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Trial in which a 20-amino-acid peptide was used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:51:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kalia-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:51:44 +1000" MODIFIED_BY="[Empty name]">
<P>Article about neurological diseases</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kantor-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range (participants were aged between 17 to 53 years old)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kawai-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:44 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Khakoo-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Amantadine and/or rimantadine were not tested in this trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-13 10:58:07 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-13 10:58:07 +1000" MODIFIED_BY="[Empty name]">
<P>Article about the effect of corticosteroids treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kirkby-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:44 +1000" MODIFIED_BY="[Empty name]">
<P>Article about complementary and alternative medicine. Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kiso-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Descriptive study to investigate oseltamivir resistance in children treated for influenza</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kitamoto-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicated results</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Knight-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Knight-1970a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Knight-1970b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Knight-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ribavirin study in which ages of participants were outside protocol age range (participants were aged between 22 to 42 years old)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:53:01 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Korenke-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:53:01 +1000" MODIFIED_BY="[Empty name]">
<P>Article about multiple sclerosis treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Krylov-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Analysis by age subgroups of interest was not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kulichenko-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Langlet-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Article about the use of antivirals for chronic hepatitis C</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Le-Tissier-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-human trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leeming-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Insufficient data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leone-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Article about the use of amantadine for traumatic brain injury</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leung-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcomes of interest were not studied</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lim-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Study about an influenza-like illness</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Study about neurologic manifestations in children with influenza B</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Linder-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>The authors measured the rates of antiviral and antibiotic prescribing for patients with influenza</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lipatov-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study was conducted in influenza viruses isolated from poultry</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Little-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Analyses by age subgroups of interest were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Little-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Article is about hyperreactivity and airway dysfunction in influenza infection and not about treatment or prevention of influenza</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lopez_x002d_Medrano-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Louie-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Article about an intravenous neuraminidase inhibitor drug for influenza A</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lutz-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Study of a method for detecting and quantifying influenza A virus replication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:45 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lynd-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:45 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Machado-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Article was about the use of oseltamivir to control influenza complications after bone marrow transplantation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:45 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mallia-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:45 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:45 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maricich-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:45 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mase-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study was conducted in influenza viruses isolated from poultry</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mate-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mate-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:56:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matheson-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:56:11 +1000" MODIFIED_BY="[Empty name]">
<P>Systematic review of the use of neuraminidase inhibitors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matsuya-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Study of the synthesis and evaluation of dihydrofuran-fused perhydrophenanthrenes as a new anti-influenza agent</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Matthews-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article about treatment of viral hepatitis and oncological conditions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McCullers-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-human trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McKay-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-human trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Michiels-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Article about oseltamivir and zanamivir</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mishin-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-13 11:02:28 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miyachi-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-13 11:02:28 +1000" MODIFIED_BY="[Empty name]">
<P>Insufficient data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:56:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moffat-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:56:42 +1000" MODIFIED_BY="[Empty name]">
<P>Article about biophysical aspects of the influenza virus</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Monto-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside were outside protocol age (participants were aged between 18 to 24 years old)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:23:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morrison-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:23:17 +1000" MODIFIED_BY="[Empty name]">
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Muldoon-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nafta-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>A wider age range was considered. Analysis by age subgroups of interest was not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Natsina-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomisation was not stated. Additional information not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-16 03:16:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nuesch-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-16 03:16:05 +1000" MODIFIED_BY="[Empty name]">
<P>Review study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-O_x0027_Donoghute-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Analysis by age subgroups of interest was not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Obrosova_x002d_Serova-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study about effectiveness of midantan and interferon inducers as means of non-specific prevention of influenza</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oker_x002d_Blom-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range (participants were aged between 20 to 28 years old)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:45 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ong-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:45 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pachucki-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Article about a diagnostic test</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peiris-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>The aim of the authors was not to study amantadine and rimantadine to prevent or treat influenza</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pemberton-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Article about amantadine resistance in clinical influenza A and virus isolates</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Petterson-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Insufficient data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pritchard-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Article about the treatment of juvenile chronic arthritis with antivirals</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Quarles-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Quilligan-1966">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:46 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rabinovich-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reis-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Article about neurologic effects of amantadine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reuman-1989a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range (participants were aged between 18 to 40 years old)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reuman-1989b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range (participants were aged between 18 to 55 years old)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Risenbrough-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:46 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rose-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:46 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rothberg-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:46 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saito-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:46 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sampaio-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Article about the efficacy and safety of pardoprunox in patients with early Parkinson's disease</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Santesso-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sato-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Article about oseltamivir treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:47 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sauerbrei-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:47 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schapira-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Analysis by age subgroups of interest was not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schmidt-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sears-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range (participants were aged between 18 to 40 years old)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Semlitsch-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>The purpose of this article was to study the acute effects of amantadine infusions on event-related potentials</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Serkedjieva-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-human trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shah-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shuler-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case-control study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shvetsova-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>The trial authors studied different populations. No information was available about clinical outcomes and confirmation of influenza diagnosis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 09:03:06 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simeonova-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 09:03:06 +1000" MODIFIED_BY="[Empty name]">
<P>Non-human article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Singer-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Skoner-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range (participants were aged between 18 to 50 years old)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smorodintsev-1970a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smorodintsev-1970b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smorodintsev-1970c">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range (participants were aged between 18 to 30 years old)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Somani-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomisation was not stated. The groups were not similar at baseline</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tajima-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Study of aetiology and treatment in hospitalised children with pneumonia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Takemura-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a study about influenza A</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 09:07:09 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tappenden-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 09:07:09 +1000" MODIFIED_BY="[Empty name]">
<P>Systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Terabayashi-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Article about the inhibition of influenza-virus-induced cytopathy by sialyglycoconjugates</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 09:07:28 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thomas-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 09:07:28 +1000" MODIFIED_BY="[Empty name]">
<P>Article about multiple sclerosis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thompson-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Insufficient data presented</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Togo-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Togo-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Togo-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>The drug studied was cyclooctylamine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:47 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Townsend-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:47 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:47 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-der-Wouden-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:47 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Voris-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Voris-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Study about 4 antibody techniques to assess influenza infection</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 09:11:25 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wailoo-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 09:11:25 +1000" MODIFIED_BY="[Empty name]">
<P>Article about the use of neuraminidase inhibitors in adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Webster-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-human trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:48 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Welton-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:48 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wendel-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range (participants were aged between 17 to 54 years old)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:48 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Whitley-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:48 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wingfield-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:48 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wong-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:48 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wright-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Analysis by age subgroups of interest was not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wultzler-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yamaura-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>The antiviral studied was oseltamivir</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Younkin-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ages of participants were outside protocol age range (participants were aged between 17 to 20 years old)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 20:11:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yuen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 20:11:49 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yuen-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zeuzem-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>The purpose of the authors was to study treatment for chronic hepatitis C</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>PB: placebo<BR/>RCT: randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-06-26 08:10:23 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-11-02 10:03:33 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-11-05 23:32:24 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-11-05 23:32:18 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 23:31:03 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clover-1986">
<DESCRIPTION>
<P>It is reported that "children ... received either rimantadine or PB in a double-blind, random assignment". Nevertheless, the randomisation method is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 23:31:14 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clover-1991">
<DESCRIPTION>
<P>Authors stated it was a randomised study and that randomisation is described in another article (<LINK REF="STD-Hayden-1989" TYPE="STUDY">Hayden 1989</LINK>): "all eligible family members ... randomly assigned as a block to receive either rimantadine or PB". The method used is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 23:31:30 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Crawford-1988">
<DESCRIPTION>
<P>Authors stated it was a "a randomised ... clinical trial" although randomisation methods are not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 23:31:36 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Finklea-1967">
<DESCRIPTION>
<P>Authors stated "volunteers were assigned to amantadine or the PB group by randomisation", although randomisation method is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 23:31:45 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gravenstein-2005">
<DESCRIPTION>
<P>The authors describe the trial as "a randomised, parallel comparison of rimantadine with zanamivir" but randomisation methods are not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hall-1987">
<DESCRIPTION>
<P>It is stated in the published study that "Patients were assigned to the rimantadine or acetaminophen treatment group under a double-blind, randomised allocation". The investigators also reported in their correspondence to the review authors that a computer random system was used to randomise participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 23:31:56 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kitamoto-1968">
<DESCRIPTION>
<P>It was stated that "amantadine or PB was given to the patient at random", although randomisation method is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 23:32:05 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kitamoto-1971">
<DESCRIPTION>
<P>The author states "patients were given amantadine or PB according to randomly distributed individual code of the double-blind method", although the randomisation method is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Monto-1995">
<DESCRIPTION>
<P>Although the authors state that the participants were randomly assigned to receive active medication (100 or 200 mg of rimantadine per day) or placebo, the randomisation method is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 23:32:18 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patriarca-1984">
<DESCRIPTION>
<P>The authors stated that "participants ... were randomly assigned to receive either rimantadine or PB". Nevertheless, randomisation method is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Payler-1984">
<DESCRIPTION>
<P>In correspondence with the review authors, the study authors reported that randomisation had been carried out by the statistical department of a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schilling-1998">
<DESCRIPTION>
<P>The authors stated that it was a "randomised unblinded study" but the randomisation method is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-11-05 23:31:33 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-05 08:11:33 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clover-1986">
<DESCRIPTION>
<P>Concealment is not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-19 17:42:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clover-1991">
<DESCRIPTION>
<P>Randomisation was carried out in one of the centres where this multicentric trial was conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 23:31:33 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Crawford-1988">
<DESCRIPTION>
<P>The authors state that their "study design has been previously reported" (<LINK REF="STD-Clover-1986" TYPE="STUDY">Clover 1986</LINK>) but even in that trial, the method of concealment is not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-05 09:50:51 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Finklea-1967">
<DESCRIPTION>
<P>Concealment is not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-05 10:08:37 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gravenstein-2005">
<DESCRIPTION>
<P>Concealment is not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hall-1987">
<DESCRIPTION>
<P>Participants and investigators enrolling participants could not foresee assignment because a pharmaceutical-controlled randomisation was used to conceal allocation, as stated in the authors' correspondence to the review authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-05 10:52:16 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kitamoto-1968">
<DESCRIPTION>
<P>Concealment is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-05 11:21:25 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kitamoto-1971">
<DESCRIPTION>
<P>Concealment is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-05 11:46:05 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Monto-1995">
<DESCRIPTION>
<P>Concealment is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-05 12:27:25 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patriarca-1984">
<DESCRIPTION>
<P>Concealment is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Payler-1984">
<DESCRIPTION>
<P>Participants and investigators enrolling participants could not foresee assignment because a pharmaceutical company-controlled randomisation was used to conceal allocation. They kept the key to the randomisation and only when the study was analysed was the code broken, as stated in the study authors' correspondence with the review authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-05 13:13:06 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schilling-1998">
<DESCRIPTION>
<P>Concealment is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-06-04 11:09:13 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-11-05 23:32:13 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-11 05:42:50 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clover-1986">
<DESCRIPTION>
<P>Reasons for missing outcome data are unlikely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-11 05:44:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clover-1991">
<DESCRIPTION>
<P>Reasons for missing outcome data are unlikely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-05 12:23:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Crawford-1988">
<DESCRIPTION>
<P>Reasons for missing outcome data unlikely to be related to outcome </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-05 23:31:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Finklea-1967">
<DESCRIPTION>
<P>It is stated that "The rate of withdrawal ... (the same for the two groups) was small. The reason for withdrawal was discharge from school"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-11 05:50:02 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gravenstein-2005">
<DESCRIPTION>
<P>Reasons for missing outcome data are unlikely to be related to the true outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hall-1987">
<DESCRIPTION>
<P>1 "child receiving rimantadine complained of nausea and vomiting and withdrew from the study on the second day". The proportion of missing outcomes compared with observed event risk is not enough to have a clinically relevant impact on the intervention effect estimate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-05 23:31:59 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kitamoto-1968">
<DESCRIPTION>
<P>There were no missing patients, although "four cases were shown to be influenza B and were excluded from statistical analysis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-05 23:32:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kitamoto-1971">
<DESCRIPTION>
<P>Although there were no missing outcome data, the author states that "only patients with Hong Kong influenza in whom medication was started within 2 days were included in statistical analysis". "In order to exclude the possible influence of concomitantly administered antipyretics on the defervescent effect of amantadine the same analysis was performed with 134 Hong Kong influenza patients who had received no concomitant antipyretics"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-05 23:32:13 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Monto-1995">
<DESCRIPTION>
<P>Authors stated that an "increased risk of withdrawal from the study only on the basis of perceived side effects was demonstrated among participants in both groups receiving active medication, especially the 200 mg/day group, compared with the placebo group; however, these associations were not statistically significant". The reasons for missing outcome data are likely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Patriarca-1984">
<DESCRIPTION>
<P>It was cited that 2 participants from the intervention group withdrew because of side effects. 1 suffered a generalised convulsion of undetermined aetiology (a participant with an underlying idiopathic seizure disorder). 3 later withdrew for no described reasons. 2 participants from the PB group also withdrew. Reasons for missing outcome data are likely to be related to the true outcome, with imbalance in reasons for missing data across intervention and control groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-05 13:02:26 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Payler-1984">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schilling-1998">
<DESCRIPTION>
<P>There is insufficient reporting of exclusions. It is stated that "six volunteers receiving zanamivir withdrew. One withdrew due to mild adverse effects". The other reasons for withdrawal are not clear. It is also unclear if there were withdrawals among the rimantadine group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-06-04 10:27:11 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-11-05 23:32:21 +1000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1" REF_IDS="CMP-001.01 CMP-006.01 CMP-006.02 CMP-006.14 CMP-006.03 CMP-006.04 CMP-006.06 CMP-006.05 CMP-006.15 CMP-006.16">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-05 23:31:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clover-1986">
<DESCRIPTION>
<P>It is stated that "children ... received either rimantadine or PB in a double-blind, random assignment" but the specific people who were blinded are not listed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-05 23:31:18 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clover-1991">
<DESCRIPTION>
<P>Authors stated it was a double-blinded trial as described in the other article (<LINK REF="STD-Hayden-1989" TYPE="STUDY">Hayden 1989</LINK>): "the study was double-blind ... trial". Nevertheless, the specific people who were blinded are not listed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-06-05 09:49:10 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Crawford-1988">
<DESCRIPTION>
<P>Authors stated it was "a double-blind PB controlled clinical trial". Nevertheless, the specific people who are blinded are not listed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-07-19 17:48:03 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Finklea-1967">
<DESCRIPTION>
<P>Although it was "a double-blind study", the specific people who are blinded are not listed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-05 23:31:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gravenstein-2005">
<DESCRIPTION>
<P>The trial is described as a "double-blind comparison of rimantadine with zanamivir. Identical PB (inhaled or tablets) were used". Nevertheless, the specific people who are blinded are not listed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-05 23:31:52 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hall-1987">
<DESCRIPTION>
<P>Although "patients were assigned to the rimantadine or acetaminophen treatment group under a double-blind, randomised allocation", the specific people who are blinded are not listed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-05 23:32:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kitamoto-1968">
<DESCRIPTION>
<P>Although "amantadine or PB was given to the patient at random by double-blind method" the specific people who are blinded are not listed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-05 23:32:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kitamoto-1971">
<DESCRIPTION>
<P>The author states "patients were given amantadine or PB according to randomly distributed individual code of the double-blind method". Nevertheless, the specific people who are blinded are not listed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-05 23:32:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Monto-1995">
<DESCRIPTION>
<P>It is stated that "staff and residents were blinded to group assignment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-05 23:32:21 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patriarca-1984">
<DESCRIPTION>
<P>It is stated that "a double-blind, placebo-control trial" was conducted. Nevertheless, the specific people who were blinded are not listed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Payler-1984">
<DESCRIPTION>
<P>Although there was no blinding stated, the review authors judge that the outcome is not likely to be influenced by the lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schilling-1998">
<DESCRIPTION>
<P>Although it was a "randomised unblinded study", the review authors judge that the outcome is not likely to be influenced by the lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-11-05 23:32:24 +1000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1" REF_IDS="CMP-001.01 CMP-006.01 CMP-006.02 CMP-006.14 CMP-006.03 CMP-006.04 CMP-006.06 CMP-006.05 CMP-006.15 CMP-006.16">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-05 23:31:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clover-1986">
<DESCRIPTION>
<P>It is stated that "children ... received either rimantadine or PB in a double-blind, random assignment" but the specific people who were blinded are not listed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-05 23:31:22 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clover-1991">
<DESCRIPTION>
<P>Authors stated it was a double-blinded trial as described in the other article (<LINK REF="STD-Hayden-1989" TYPE="STUDY">Hayden 1989</LINK>): "the study was double-blind ... trial". Nevertheless, the specific people who were blinded are not listed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-06-05 09:49:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Crawford-1988">
<DESCRIPTION>
<P>Authors stated it was "a double-blind PB controlled clinical trial". Nevertheless, the specific people who are blinded are not listed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-06-11 05:49:12 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Finklea-1967">
<DESCRIPTION>
<P>Although the trial is described as "a double-blind study", the specific people who are blinded are not listed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-05 23:31:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gravenstein-2005">
<DESCRIPTION>
<P>The trial is described as a "double-blind comparison of rimantadine with zanamivir. Identical PB (inhaled or tablets) were used". Nevertheless, the specific people who are blinded are not listed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-05 23:31:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hall-1987">
<DESCRIPTION>
<P>Although "patients were assigned to the rimantadine or acetaminophen treatment group under a double-blind, randomised allocation", the specific people who are blinded are not listed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-05 23:32:03 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kitamoto-1968">
<DESCRIPTION>
<P>Although "amantadine or PB was given to the patient at random by double-blind method" the specific people who are blinded are not listed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-05 23:32:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kitamoto-1971">
<DESCRIPTION>
<P>The author states "patients were given amantadine or PB according to randomly distributed individual code of the double-blind method". Nevertheless, the specific people who are blinded are not listed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-07-19 17:54:25 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Monto-1995">
<DESCRIPTION>
<P>No blinding is stated. The outcome is likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-05 23:32:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patriarca-1984">
<DESCRIPTION>
<P>It is stated that "a double-blind, placebo-control trial" was conducted. Nevertheless, the specific people who were blinded are not listed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Payler-1984">
<DESCRIPTION>
<P>Although there was no blinding stated, the review authors judge that the outcome is not likely to be influenced by the lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schilling-1998">
<DESCRIPTION>
<P>Although it was a "randomised unblinded study", the review authors judge that the outcome is not likely to be influenced by the lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-11-18 14:32:13 +1000" MODIFIED_BY="Liz  Dooley">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-06-24 10:51:15 +1000" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="18">
<TR>
<TD COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Amantadine compared with placebo for prevention and treatment of influenza A in children</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Patient or population: </B>children with no influenza A infection (prevention) or with influenza A infection (treatment)</P>
<P>
<B>Settings: </B>all</P>
<P>
<B>Intervention: </B>amantadine</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Amantadine</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Cases of influenza A during prophylaxis</B>
</P>
<P>(follow-up:14 to 18 weeks)</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.11</B> (0.04 to 0.3)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>773<BR/>(2)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>1,2</SUP>
</B>
</P>
<P/>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>10 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>1 per 100</B>
<BR/>(0 to 3)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Fever after initiation of treatment</B>
</P>
<P>(follow-up: 3 days)</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.37</B> (0.08 to 1.75)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>104<BR/>(2)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>3,4</SUP>
</B>
</P>
<P/>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>23 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>9 per 100</B>
<BR/>(2 to 40)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Cough after initiation of treatment</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
<P>(0)</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>No selected trial</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Dizziness </B>
</P>
<P>(follow-up: 7 days)</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 6.63</B> (0.32 to 137.33)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>599<BR/>(2)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>3,4</SUP>
</B>
</P>
<P/>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>0 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 100</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Nausea/vomiting </B>
</P>
<P>(follow-up: 7 days)</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.54</B> (0.15 to 2)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>599<BR/>(2)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>3,4,5</SUP>
</B>
</P>
<P/>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>13 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>7 per 100</B>
<BR/>(2 to 27)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Stimulation/insomnia</B>
</P>
<P>(follow-up: 7 days)</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.46 </B>(0.12 to 1.74)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>599<BR/>(2)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>3,4</SUP>
</B>
</P>
<P/>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>3 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>7 per 100</B>
<BR/>(2 to 27)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate.</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*The basis for the <B>assumed risk </B>(e.g. median control group risk across studies) was calculated on the basis of control event rate. The <B>corresponding risk </B>(and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect </B>of the intervention (and its 95% CI).</P>
<P>
<SUP>1</SUP>Allocation concealment not used or unclear.</P>
<P>
<SUP>2</SUP>Sparse data.</P>
<P>
<SUP>3</SUP>Allocation concealment unclear.</P>
<P>
<SUP>4</SUP>Sparse data, confidence intervals do not rule out potential for null effect or harm.</P>
<P>
<SUP>5</SUP>High heterogeneity unexplained.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-06-27 06:36:17 +1000" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="18">
<TR>
<TD COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Rimantadine compared with placebo for prevention and treatment of influenza A in children</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Patient or population:</B> children with no influenza A infection (prevention) or with influenza A infection (treatment)</P>
<P>
<B>Settings: </B>any</P>
<P>
<B>Intervention: </B>rimantadine</P>
<P>
<B>Comparison: </B>control (placebo or acetaminophen)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Rimantadine</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Cases of influenza A during prophylaxis </B>(follow-up: 1 to 35 days)</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.49</B> (0.21 to 1.15)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>178<BR/>(3)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>1,2</SUP>
</B>
</P>
<P/>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>24 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>12 per 100</B>
<BR/>(5 to28)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Fever after initiation of treatment</B>
</P>
<P>(follow-up: 3 days)</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.36</B> (0.14 to 0.91)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>69<BR/>(1)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
<P/>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>38 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>14 per 100</B>
<BR/>(5 to 34)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Cough after initiation of treatment</B>
</P>
<P>(follow-up: 7 days)</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.83</B> (0.63 to 1.1)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>69<BR/>(1)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>81 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>67 per 100</B>
<BR/>(51 to 89)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Dizziness</B>
</P>
<P>(follow-up: 35 days)</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 3.21</B> (0.14 to 75.68)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>56<BR/>(1)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1,2</SUP>
</B>
</P>
<P/>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>0 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 100</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Nausea/vomiting </B>
</P>
<P>(follow-up: 7 to 35 days)</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.96</B> (0.1 to 9.01)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>125<BR/>(2)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>2</SUP>
</B>
</P>
<P/>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>2 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>2 per 100</B>
<BR/>(0 to 15)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Stimulation/insomnia</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>No selected trial</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*The basis for the <B>assumed risk </B>(e.g. median control group risk across studies) was calculated on the basis of control event rate. The <B>corresponding risk </B>(and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect </B>of the intervention (and its 95% CI).</P>
<P>
<SUP>1</SUP>Allocation concealment unclear.</P>
<P>
<SUP>2</SUP>Sparse data and confidence intervals do not rule out the potential for no effect or harm</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-06-27 07:47:18 +1000" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Amantadine compared with placebo for prevention and treatment of influenza A in the elderly</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Patient or population: </B>elderly people with no influenza A infection (prevention) or with influenza A infection (treatment)</P>
<P>
<B>Settings: </B>any</P>
<P>
<B>Intervention:</B> amantadine</P>
<P>
<B>Comparison: </B>control</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Amantadine</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Cases of influenza A during prophylaxis</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>No selected trial</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Fever after initiation of treatment</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>No selected trial</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Cough after initiation of treatment</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>No selected trial</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dizziness</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>No selected trial</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Nausea </B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>No selected trial</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Vomiting</B>
</P>
<P/>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>No selected trial</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Stimulation/insomnia </B>
</P>
<P/>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>No selected trial</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2014-11-18 14:32:13 +1000" MODIFIED_BY="Liz  Dooley" NO="4">
<TITLE MODIFIED="2011-06-27 08:05:01 +1000" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="18">
<TR>
<TD COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Patient or population: </B>elderly people with no influenza A infection (prevention) or with influenza A infection (treatment)</P>
<P>
<B>Settings: </B>any</P>
<P>
<B>Intervention: </B>rimantadine</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Control</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Rimantadine</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Cases of influenza A during prophylaxis</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.45</B> (0.14 to 1.41)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>103<BR/>(2)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1,2</SUP>
</B>
</P>
<P/>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>17per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>7 per 100</B>
<BR/>(2 to 23)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Fever after initiation of treatment</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>No selected trial</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Cough after initiation of treatment</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>No selected trial</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Dizziness</B>
</P>
<P>(follow-up: 12 weeks)</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>12 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>11 per 100 (2 to 70)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.94</B>
<BR/>(0.15 to 5.97)</P>
</TD>
<TD VALIGN="TOP">
<P>35</P>
<P>(1)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>2,3</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Nausea </B>
</P>
<P>(follow-up: 8 to 12 weeks)</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.99</B> (0.45 to 8.75)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>233<BR/>(2)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1,2,4</SUP>
</B>
</P>
<P>
<BR/>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>8 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>15 per 100</B>
<BR/>(3 to 66)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Vomiting </B>
</P>
<P>(follow-up: 8 to 12 weeks)</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.99</B> (0.38 to 2.6)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>233<BR/>(2)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>1,2</SUP>
</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>7 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>7 per 100</B>
<BR/>(3 to 17)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Stimulation/insomnia </B>(follow-up: 8 to 12 weeks)</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.61</B> (0.43 to 6.02)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>233<BR/>(2)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>1,2</SUP>
</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>7 per 100</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>11 per 100</B>
<BR/>(3 to 40)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*The basis for the <B>assumed risk </B>(e.g. median control group risk across studies) was calculated on the basis of control event rate. The <B>corresponding risk </B>(and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect </B>of the intervention (and its 95% CI).</P>
<P>
<SUP>1</SUP>Allocation concealment unclear and 1 study had high withdrawal rate.</P>
<P>
<SUP>2</SUP>Sparse data and confidence interval do not rule out no effect or harm.</P>
<P>
<SUP>3</SUP>Allocation concealment unclear</P>
<P>
<SUP>4</SUP>High heterogeneity unexplained.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2011-06-24 10:29:34 +1000" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-11-18 14:37:13 +1000" MODIFIED_BY="Liz  Dooley">
<COMPARISON ID="CMP-001" MODIFIED="2014-11-18 14:37:13 +1000" MODIFIED_BY="Liz  Dooley" NO="1">
<NAME>Amantadine or rimantadine compared to placebo or acetaminophen in the treatment of influenza A in children</NAME>
<DICH_OUTCOME CHI2="1.826533672164114" CI_END="0.8066433420531623" CI_START="0.1636682225940896" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.36334815543937654" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.09331844646326858" LOG_CI_START="-0.7860356339155408" LOG_EFFECT_SIZE="-0.4396770401894047" METHOD="MH" MODIFIED="2014-11-18 14:36:06 +1000" MODIFIED_BY="Liz  Dooley" NO="1" P_CHI2="0.4012114375848439" P_Q="0.9729930347977739" P_Z="0.012845227996098942" Q="0.0011461393698331997" RANDOM="YES" SCALE="505.19" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="88" TOTAL_2="85" WEIGHT="200.0" Z="2.4880317082063947">
<NAME>Fever day 3</NAME>
<GROUP_LABEL_1>AMTor RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or acetaminophen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or acetaminophen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.7803375242775474" CI_END="1.7539238517925482" CI_START="0.07881300478145517" DF="1" EFFECT_SIZE="0.37179565478584387" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" I2="43.830875529863626" ID="CMP-001.01.01" LOG_CI_END="0.2440107341473586" LOG_CI_START="-1.1034021145050668" LOG_EFFECT_SIZE="-0.42969569017885406" NO="1" P_CHI2="0.18210801684661326" P_Z="0.21126972564905144" STUDIES="2" TAU2="0.5910803390063372" TOTAL_1="51" TOTAL_2="53" WEIGHT="100.0" Z="1.2500817071841412">
<NAME>AMT</NAME>
<DICH_DATA CI_END="2.320055998106646" CI_START="0.19549571933322923" EFFECT_SIZE="0.673469387755102" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.3654984673802164" LOG_CI_START="-0.7088627476814688" LOG_EFFECT_SIZE="-0.1716821401506262" ORDER="11279" O_E="0.0" SE="0.6310850959010189" STUDY_ID="STD-Kitamoto-1968" TOTAL_1="21" TOTAL_2="33" VAR="0.3982683982683982" WEIGHT="63.317997150763155"/>
<DICH_DATA CI_END="1.0578504152276476" CI_START="0.016805568653061438" EFFECT_SIZE="0.13333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.024424260861660756" LOG_CI_START="-1.7745467876450607" LOG_EFFECT_SIZE="-0.8750612633917001" ORDER="11280" O_E="0.0" SE="1.0567244989431572" STUDY_ID="STD-Kitamoto-1971" TOTAL_1="30" TOTAL_2="20" VAR="1.1166666666666665" WEIGHT="36.682002849236845"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9131620903888716" CI_START="0.1422086951329176" DF="0" EFFECT_SIZE="0.36036036036036034" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-0.039452126394096176" LOG_CI_START="-0.8470738485232939" LOG_EFFECT_SIZE="-0.4432629874586951" NO="2" P_CHI2="1.0" P_Z="0.031440578387535965" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="32" WEIGHT="100.0" Z="2.1514515206654896">
<NAME>RMT</NAME>
<DICH_DATA CI_END="0.9131620903888716" CI_START="0.1422086951329176" EFFECT_SIZE="0.36036036036036034" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.039452126394096176" LOG_CI_START="-0.8470738485232939" LOG_EFFECT_SIZE="-0.4432629874586951" ORDER="11281" O_E="0.0" SE="0.4744009973706909" STUDY_ID="STD-Hall-1987" TOTAL_1="37" TOTAL_2="32" VAR="0.2250563063063063" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7036333395168466" CI_START="0.6322413119441463" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.037837837837838" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.23137613047808991" LOG_CI_START="-0.1991171298770182" LOG_EFFECT_SIZE="0.01612950030053583" METHOD="MH" MODIFIED="2014-11-18 14:35:02 +1000" MODIFIED_BY="Liz  Dooley" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.8832347523042086" Q="0.0" RANDOM="YES" SCALE="853.72" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="37" TOTAL_2="32" WEIGHT="100.0" Z="0.14686984716834298">
<NAME>Malaise day 6</NAME>
<GROUP_LABEL_1>AMTor RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or acetaminophen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or acetaminophen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7036333395168466" CI_START="0.6322413119441463" DF="0" EFFECT_SIZE="1.037837837837838" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.23137613047808991" LOG_CI_START="-0.1991171298770182" LOG_EFFECT_SIZE="0.01612950030053583" MODIFIED="2008-06-12 10:59:12 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.8832347523042086" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="32" WEIGHT="100.0" Z="0.14686984716834298">
<NAME>RMT</NAME>
<DICH_DATA CI_END="1.7036333395168466" CI_START="0.6322413119441463" EFFECT_SIZE="1.037837837837838" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.23137613047808991" LOG_CI_START="-0.1991171298770182" LOG_EFFECT_SIZE="0.01612950030053583" ORDER="11283" O_E="0.0" SE="0.25287387210859724" STUDY_ID="STD-Hall-1987" TOTAL_1="37" TOTAL_2="32" VAR="0.06394519519519519" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.098618720398613" CI_START="0.6294813025471433" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8316008316008316" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.04084699510091221" LOG_CI_START="-0.2010171651926509" LOG_EFFECT_SIZE="-0.08008508504586935" METHOD="MH" MODIFIED="2014-11-05 21:53:32 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.19430426416467297" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="32" WEIGHT="99.99999999999999" Z="1.2979507356378557">
<NAME>Cough day 7</NAME>
<GROUP_LABEL_1>AMTor RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or acetaminophen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or acetaminophen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.098618720398613" CI_START="0.6294813025471433" DF="0" EFFECT_SIZE="0.8316008316008316" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.04084699510091221" LOG_CI_START="-0.2010171651926509" LOG_EFFECT_SIZE="-0.08008508504586935" MODIFIED="2008-06-12 10:59:53 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.19430426416467297" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="32" WEIGHT="99.99999999999999" Z="1.2979507356378557">
<NAME>RMT</NAME>
<DICH_DATA CI_END="1.098618720398613" CI_START="0.6294813025471433" EFFECT_SIZE="0.8316008316008316" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" LOG_CI_END="0.04084699510091221" LOG_CI_START="-0.2010171651926509" LOG_EFFECT_SIZE="-0.08008508504586935" ORDER="11282" O_E="0.0" SE="0.14207220500334133" STUDY_ID="STD-Hall-1987" TOTAL_1="37" TOTAL_2="32" VAR="0.020184511434511443" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.489704940077031" CI_START="0.008644342574556948" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.17368421052631577" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.5427887082446919" LOG_CI_START="-2.0632680303945747" LOG_EFFECT_SIZE="-0.7602396610749416" METHOD="MH" MODIFIED="2014-11-18 14:36:58 +1000" MODIFIED_BY="Liz  Dooley" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.2528217067438375" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="37" TOTAL_2="32" WEIGHT="100.0" Z="1.1435225743425965">
<NAME>Conjunctivitis day 5</NAME>
<GROUP_LABEL_1>AMTor RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or acetaminophen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or acetaminophen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.489704940077031" CI_START="0.008644342574556948" DF="0" EFFECT_SIZE="0.17368421052631577" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.5427887082446919" LOG_CI_START="-2.0632680303945747" LOG_EFFECT_SIZE="-0.7602396610749416" MODIFIED="2008-06-12 10:59:48 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.2528217067438375" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="32" WEIGHT="100.0" Z="1.1435225743425965">
<NAME>RMT</NAME>
<DICH_DATA CI_END="3.489704940077031" CI_START="0.008644342574556948" EFFECT_SIZE="0.1736842105263158" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5427887082446919" LOG_CI_START="-2.0632680303945747" LOG_EFFECT_SIZE="-0.7602396610749415" ORDER="11284" O_E="0.0" SE="1.530810628465613" STUDY_ID="STD-Hall-1987" TOTAL_1="37" TOTAL_2="32" VAR="2.3433811802232856" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.237663432368693" CI_START="0.10267915600280582" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5765765765765766" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.5102317001733027" LOG_CI_START="-0.9885177097788433" LOG_EFFECT_SIZE="-0.23914300480277026" METHOD="MH" MODIFIED="2014-11-18 14:37:13 +1000" MODIFIED_BY="Liz  Dooley" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.5316623906433258" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="37" TOTAL_2="32" WEIGHT="100.0" Z="0.6254703734403266">
<NAME>Eye symptoms day 5 (pain on movement and visual distortion)</NAME>
<GROUP_LABEL_1>AMTor RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or acetaminophen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or acetaminophen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.237663432368693" CI_START="0.10267915600280582" DF="0" EFFECT_SIZE="0.5765765765765766" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.5102317001733027" LOG_CI_START="-0.9885177097788433" LOG_EFFECT_SIZE="-0.23914300480277026" MODIFIED="2008-06-12 10:59:41 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.5316623906433258" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="32" WEIGHT="100.0" Z="0.6254703734403266">
<NAME>RMT</NAME>
<DICH_DATA CI_END="3.237663432368693" CI_START="0.10267915600280582" EFFECT_SIZE="0.5765765765765766" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5102317001733027" LOG_CI_START="-0.9885177097788433" LOG_EFFECT_SIZE="-0.23914300480277026" ORDER="11285" O_E="0.0" SE="0.8803728223351208" STUDY_ID="STD-Hall-1987" TOTAL_1="37" TOTAL_2="32" VAR="0.7750563063063063" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-11-05 21:53:32 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Amantadine and rimantadine compared to placebo and to specific treatment in the prophylaxis of influenza A in children</NAME>
<DICH_OUTCOME CHI2="9.265959777061946" CI_END="0.66439915459641" CI_START="0.09221327690004974" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.24752055109618212" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="62" I2="56.83123932933452" I2_Q="80.16956903190986" ID="CMP-002.01" LOG_CI_END="-0.17757092883104006" LOG_CI_START="-1.035206544572108" LOG_EFFECT_SIZE="-0.606388736701574" METHOD="MH" MODIFIED="2014-11-05 21:53:32 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.05478497167938445" P_Q="0.024729165938670694" P_Z="0.005578607163778132" Q="5.042754752073396" RANDOM="YES" SCALE="626.4708135378553" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.6697682789664774" TOTALS="YES" TOTAL_1="455" TOTAL_2="496" WEIGHT="100.00000000000003" Z="2.7715735278527696">
<NAME>Infection</NAME>
<GROUP_LABEL_1>AMT or RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or specific treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or specific treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.008331771765705757" CI_END="0.2965031821294856" CI_START="0.03870351495806811" DF="1" EFFECT_SIZE="0.10712476531905843" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="40" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-0.5279706413423478" LOG_CI_START="-1.4122495916329414" LOG_EFFECT_SIZE="-0.9701101164876446" NO="1" P_CHI2="0.9272712702235575" P_Z="1.704826270642059E-5" STUDIES="2" TAU2="0.0" TOTAL_1="371" TOTAL_2="402" WEIGHT="39.19345914441435" Z="4.300409703813269">
<NAME>AMT</NAME>
<DICH_DATA CI_END="0.8860681680132486" CI_START="0.015254012509413224" EFFECT_SIZE="0.11625874125874126" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.05253286518612716" LOG_CI_START="-1.8166159017937118" LOG_EFFECT_SIZE="-0.9345743834899196" ORDER="11286" O_E="0.0" SE="1.03623110805516" STUDY_ID="STD-Finklea-1967" TOTAL_1="104" TOTAL_2="133" VAR="1.073774909301225" WEIGHT="14.556203234249974"/>
<DICH_DATA CI_END="0.33801482537127414" CI_START="0.032136072759439256" EFFECT_SIZE="0.1042231693142193" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="29" LOG_CI_END="-0.47106425109590716" LOG_CI_START="-1.4930071979870148" LOG_EFFECT_SIZE="-0.9820357245414609" ORDER="11287" O_E="0.0" SE="0.6002943457030092" STUDY_ID="STD-Payler-1984" TOTAL_1="267" TOTAL_2="269" VAR="0.36035330148300393" WEIGHT="24.63725591016437"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.4050609789843453" CI_END="1.1456016310235886" CI_START="0.20924686866155562" DF="2" EFFECT_SIZE="0.48960550857323565" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="22" I2="16.842025317603472" ID="CMP-002.01.02" LOG_CI_END="0.05903362328085448" LOG_CI_START="-0.6793410324180134" LOG_EFFECT_SIZE="-0.31015370456857944" NO="2" P_CHI2="0.3004330701898008" P_Z="0.09964795847914097" STUDIES="3" TAU2="0.10659853614707242" TOTAL_1="84" TOTAL_2="94" WEIGHT="60.80654085558568" Z="1.6465627197096222">
<NAME>RMT</NAME>
<DICH_DATA CI_END="1.3151975833774827" CI_START="0.004599599932744944" EFFECT_SIZE="0.07777777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.11899100219811301" LOG_CI_START="-2.337279941048249" LOG_EFFECT_SIZE="-1.109144469425068" ORDER="11288" O_E="0.0" SE="1.4428257108001756" STUDY_ID="STD-Clover-1986" TOTAL_1="35" TOTAL_2="41" VAR="2.081746031746032" WEIGHT="9.22378229955301"/>
<DICH_DATA CI_END="1.7734688581076357" CI_START="0.2621281061308813" EFFECT_SIZE="0.6818181818181818" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.24882356671788225" LOG_CI_START="-0.5814864102509323" LOG_EFFECT_SIZE="-0.16633142176652502" ORDER="11289" O_E="0.0" SE="0.48772819057215455" STUDY_ID="STD-Clover-1991" TOTAL_1="22" TOTAL_2="24" VAR="0.23787878787878788" WEIGHT="27.96171543233058"/>
<DICH_DATA CI_END="1.6015426573601381" CI_START="0.13230503933150534" EFFECT_SIZE="0.4603174603174603" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.2045385106610324" LOG_CI_START="-0.8784236137702837" LOG_EFFECT_SIZE="-0.33694255155462566" ORDER="11290" O_E="0.0" SE="0.636137312639928" STUDY_ID="STD-Crawford-1988" TOTAL_1="27" TOTAL_2="29" VAR="0.40467068053274946" WEIGHT="23.62104312370209"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-11-12 09:16:42 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Amantadine and rimantadine compared to placebo in the prophylaxis of influenza A in the elderly</NAME>
<DICH_OUTCOME CHI2="3.277596193265389" CI_END="4.074038537453695" CI_START="0.13380705905305007" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7383326588777367" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="38.97967040267249" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.61002513279481" LOG_CI_START="-0.8735209745583357" LOG_EFFECT_SIZE="-0.13174792088176282" METHOD="MH" MODIFIED="2014-11-05 21:53:32 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.19421350156080452" P_Q="1.0" P_Z="0.7277549811625403" Q="0.0" RANDOM="YES" SCALE="820.58" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.9610417587145816" TOTALS="YES" TOTAL_1="95" TOTAL_2="96" WEIGHT="99.99999999999999" Z="0.3481134542248781">
<NAME>RMT (proved and clinical infection)</NAME>
<GROUP_LABEL_1>RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.819006963786754" CI_START="0.14780672058942068" EFFECT_SIZE="0.5185185185185185" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.25983436169590324" LOG_CI_START="-0.8303058186574018" LOG_EFFECT_SIZE="-0.2852357284807493" ORDER="11320" O_E="0.0" SE="0.6403537382204543" STUDY_ID="STD-Monto-1995" TOTAL_1="54" TOTAL_2="14" VAR="0.4100529100529101" WEIGHT="55.387257117554235"/>
<DICH_DATA CI_END="3.682649011147799" CI_START="0.0097484927017579" EFFECT_SIZE="0.18947368421052632" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5661603287420783" LOG_CI_START="-2.0110625291131616" LOG_EFFECT_SIZE="-0.7224511001855417" ORDER="11321" O_E="0.0" SE="1.513873464163064" STUDY_ID="STD-Patriarca-1984" TOTAL_1="18" TOTAL_2="17" VAR="2.291812865497076" WEIGHT="23.346008882870866"/>
<DICH_DATA CI_END="195.69161214987366" CI_START="0.34780489185133384" EFFECT_SIZE="8.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.2915722110688663" LOG_CI_START="-0.4586643139690165" LOG_EFFECT_SIZE="0.9164539485499251" ORDER="11322" O_E="0.0" SE="1.6155025486976133" STUDY_ID="STD-Schilling-1998" TOTAL_1="23" TOTAL_2="65" VAR="2.609848484848485" WEIGHT="21.266733999574893"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.403014602952618" CI_END="1.4138941736092923" CI_START="0.14008843408694469" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.44505080692610866" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.15041690483749373" LOG_CI_START="-0.8535977192436054" LOG_EFFECT_SIZE="-0.35159040720305584" METHOD="MH" MODIFIED="2014-11-12 09:16:42 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.525536496284581" P_Q="1.0" P_Z="0.16984618790361541" Q="0.0" RANDOM="YES" SCALE="746.11" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="31" WEIGHT="99.99999999999999" Z="1.372698203591304">
<NAME>RMT Monto (100 + 200) and Patriarca</NAME>
<GROUP_LABEL_1>RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.819006963786754" CI_START="0.14780672058942068" EFFECT_SIZE="0.5185185185185185" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.25983436169590324" LOG_CI_START="-0.8303058186574018" LOG_EFFECT_SIZE="-0.2852357284807493" ORDER="11327" O_E="0.0" SE="0.6403537382204543" STUDY_ID="STD-Monto-1995" TOTAL_1="54" TOTAL_2="14" VAR="0.4100529100529101" WEIGHT="84.82334267810025"/>
<DICH_DATA CI_END="3.682649011147799" CI_START="0.0097484927017579" EFFECT_SIZE="0.18947368421052632" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5661603287420783" LOG_CI_START="-2.0110625291131616" LOG_EFFECT_SIZE="-0.7224511001855417" ORDER="11328" O_E="0.0" SE="1.513873464163064" STUDY_ID="STD-Patriarca-1984" TOTAL_1="18" TOTAL_2="17" VAR="2.291812865497076" WEIGHT="15.176657321899736"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.40240250940083877" CI_END="1.6300315023244063" CI_START="0.11824766780341772" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4390300941802991" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.21219599774963405" LOG_CI_START="-0.9272074160877799" LOG_EFFECT_SIZE="-0.357505709169073" METHOD="MH" MODIFIED="2014-11-12 09:16:42 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5258511155067943" P_Q="1.0" P_Z="0.21871999370328732" Q="0.0" RANDOM="YES" SCALE="569.39" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="31" WEIGHT="100.0" Z="1.2299389412551285">
<NAME>RMT 200</NAME>
<GROUP_LABEL_1>RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3243400844355033" CI_START="0.12474113850374131" EFFECT_SIZE="0.5384615384615384" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.36629967190594764" LOG_CI_START="-0.9039902964911074" LOG_EFFECT_SIZE="-0.26884531229257996" ORDER="11323" O_E="0.0" SE="0.7461746154731859" STUDY_ID="STD-Monto-1995" TOTAL_1="26" TOTAL_2="14" VAR="0.5567765567765568" WEIGHT="80.45430652718778"/>
<DICH_DATA CI_END="3.682649011147799" CI_START="0.0097484927017579" EFFECT_SIZE="0.18947368421052632" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5661603287420783" LOG_CI_START="-2.0110625291131616" LOG_EFFECT_SIZE="-0.7224511001855417" ORDER="11324" O_E="0.0" SE="1.513873464163064" STUDY_ID="STD-Patriarca-1984" TOTAL_1="18" TOTAL_2="17" VAR="2.291812865497076" WEIGHT="19.54569347281222"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.551897758051313" CI_END="21.097549164348536" CI_START="0.09606252005892292" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4236164300099738" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="60.81347707426874" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="1.3242320076095326" LOG_CI_START="-1.0174460244706507" LOG_EFFECT_SIZE="0.1533929915694409" METHOD="MH" MODIFIED="2014-11-12 09:16:37 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.1101622016853756" P_Q="1.0" P_Z="0.7973507887273078" Q="0.0" RANDOM="YES" SCALE="909.51" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.459270879033153" TOTALS="YES" TOTAL_1="51" TOTAL_2="79" WEIGHT="100.0" Z="0.25677717844915554">
<NAME>RMT 100</NAME>
<GROUP_LABEL_1>RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1661076187476573" CI_START="0.11541439485104547" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.3356800298826486" LOG_CI_START="-0.9377400212106111" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="11325" O_E="0.0" SE="0.7480132415430957" STUDY_ID="STD-Monto-1995" TOTAL_1="28" TOTAL_2="14" VAR="0.5595238095238095" WEIGHT="62.67523778091138"/>
<DICH_DATA CI_END="195.69161214987366" CI_START="0.34780489185133384" EFFECT_SIZE="8.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.2915722110688663" LOG_CI_START="-0.4586643139690165" LOG_EFFECT_SIZE="0.9164539485499251" ORDER="11326" O_E="0.0" SE="1.6155025486976133" STUDY_ID="STD-Schilling-1998" TOTAL_1="23" TOTAL_2="65" VAR="2.609848484848485" WEIGHT="37.324762219088626"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2014-11-12 08:59:39 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Use of different doses of rimantadine for prophylaxis and treatment of influenza A in the elderly</NAME>
<DICH_OUTCOME CHI2="2.0803615448738043E-32" CI_END="4.197728181253358" CI_START="0.20540751109371128" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="100.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.623014312949637" LOG_CI_START="-0.6873836796924396" LOG_EFFECT_SIZE="-0.03218468337140124" METHOD="MH" MODIFIED="2014-11-05 21:54:34 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.9233003030229848" Q="0.0" RANDOM="YES" SCALE="853.72" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="0.09627734568577222">
<NAME>Clinical and laboratory infection</NAME>
<GROUP_LABEL_1>RMT 200 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>RMT 100 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RMT 200 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RMT 100 mg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0803615448738043E-32" CI_END="4.197728181253358" CI_START="0.20540751109371128" DF="0" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="100.0" ID="CMP-004.01.01" LOG_CI_END="0.623014312949637" LOG_CI_START="-0.6873836796924396" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2008-06-12 11:06:19 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="0.0" P_Z="0.9233003030229848" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="0.09627734568577222">
<NAME>RMT</NAME>
<DICH_DATA CI_END="4.197728181253358" CI_START="0.20540751109371128" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.623014312949637" LOG_CI_START="-0.6873836796924396" LOG_EFFECT_SIZE="-0.03218468337140124" ORDER="11350" O_E="0.0" SE="0.7697342674526336" STUDY_ID="STD-Monto-1995" TOTAL_1="28" TOTAL_2="26" VAR="0.5924908424908425" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2014-11-12 09:01:20 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Rimantadine compared to zanamivir in the elderly</NAME>
<DICH_OUTCOME CHI2="0.1478427253446519" CI_END="14.722593036699347" CI_START="1.4579864673143526" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="4.633070408625814" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="1.1679843074439036" LOG_CI_START="0.16375349298197148" LOG_EFFECT_SIZE="0.6658689002129374" METHOD="MH" MODIFIED="2014-11-05 21:51:24 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7006056565973585" P_Q="1.0" P_Z="0.009345178023751333" Q="0.0" RANDOM="YES" SCALE="391.09" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="254" TOTAL_2="291" WEIGHT="100.0" Z="2.599161555387873">
<NAME>RMT and zanamivir</NAME>
<GROUP_LABEL_1>RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>Zanamivir</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours zanamivir</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.678304830792374" CI_START="1.2245068277095266" EFFECT_SIZE="4.2395382395382395" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" LOG_CI_END="1.1666759026411933" LOG_CI_START="0.0879612110436684" LOG_EFFECT_SIZE="0.627318556842431" ORDER="11362" O_E="0.0" SE="0.6336423495682276" STUDY_ID="STD-Gravenstein-2005" TOTAL_1="231" TOTAL_2="226" VAR="0.40150262716634394" WEIGHT="86.66702711734908"/>
<DICH_DATA CI_END="195.69161214987366" CI_START="0.34780489185133384" EFFECT_SIZE="8.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.2915722110688663" LOG_CI_START="-0.4586643139690165" LOG_EFFECT_SIZE="0.9164539485499251" ORDER="11363" O_E="0.0" SE="1.6155025486976133" STUDY_ID="STD-Schilling-1998" TOTAL_1="23" TOTAL_2="65" VAR="2.609848484848485" WEIGHT="13.332972882650914"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2014-11-12 09:51:31 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Adverse effects of amantadine and rimantadine compared to placebo or acetaminophen in children</NAME>
<DICH_OUTCOME CHI2="0.5010316486330866" CI_END="1.466397035169497" CI_START="0.42424618176484263" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7887416200010906" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.16625157387803582" LOG_CI_START="-0.3723820576630186" LOG_EFFECT_SIZE="-0.10306524189249137" METHOD="MH" MODIFIED="2014-11-05 21:53:32 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7783991721530943" P_Q="0.6161277817636409" P_Z="0.4532176999892391" Q="0.2513476545105571" RANDOM="YES" SCALE="616.5810605723578" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="291" TOTAL_2="364" WEIGHT="100.00000000000001" Z="0.7500614530483333">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>AMT or RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or acetaminophen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or acetaminophen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.24851328820585275" CI_END="1.5324562163783941" CI_START="0.4325791843004002" DF="1" EFFECT_SIZE="0.8141920289815194" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="0.1853880751924781" LOG_CI_START="-0.3639343826338099" LOG_EFFECT_SIZE="-0.08927315372066588" NO="1" P_CHI2="0.6181239004040819" P_Z="0.524094104884842" STUDIES="2" TAU2="0.0" TOTAL_1="264" TOTAL_2="335" WEIGHT="96.14622214174416" Z="0.6370471972734983">
<NAME>AMT</NAME>
<DICH_DATA CI_END="2.5733395788618387" CI_START="0.37321152944174385" EFFECT_SIZE="0.98" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.4104970996556883" LOG_CI_START="-0.42804494827069867" LOG_EFFECT_SIZE="-0.00877392430750515" ORDER="11291" O_E="0.0" SE="0.492563749802041" STUDY_ID="STD-Kitamoto-1968" TOTAL_1="75" TOTAL_2="84" VAR="0.24261904761904762" WEIGHT="41.260761956399726"/>
<DICH_DATA CI_END="1.6358221757983287" CI_START="0.3066798196163658" EFFECT_SIZE="0.708289241622575" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.21373609134815746" LOG_CI_START="-0.5133148008600447" LOG_EFFECT_SIZE="-0.14978935475594363" ORDER="11292" O_E="0.0" SE="0.4270732930430577" STUDY_ID="STD-Kitamoto-1971" TOTAL_1="189" TOTAL_2="251" VAR="0.18239159763064144" WEIGHT="54.885460185344435"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.408811719288554" CI_START="0.015168733070283916" DF="0" EFFECT_SIZE="0.3571428571428572" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="0.9247346283522918" LOG_CI_START="-1.8190506910367303" LOG_EFFECT_SIZE="-0.44715803134221915" NO="2" P_CHI2="1.0" P_Z="0.5229300009088108" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="29" WEIGHT="3.8537778582558495" Z="0.6388354297512895">
<NAME>RMT</NAME>
<DICH_DATA CI_END="8.408811719288554" CI_START="0.015168733070283916" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9247346283522918" LOG_CI_START="-1.8190506910367303" LOG_EFFECT_SIZE="-0.4471580313422192" ORDER="11293" O_E="0.0" SE="1.6117130785654894" STUDY_ID="STD-Crawford-1988" TOTAL_1="27" TOTAL_2="29" VAR="2.5976190476190477" WEIGHT="3.8537778582558495"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.13548791658897846" CI_END="2.343445205373948" CI_START="0.20544714882011753" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6938689615916339" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.3698548032661108" LOG_CI_START="-0.6872998814660282" LOG_EFFECT_SIZE="-0.1587225390999587" METHOD="MH" MODIFIED="2014-11-05 21:53:32 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7128085876079264" P_Q="1.0" P_Z="0.556167927355823" Q="0.0" RANDOM="YES" SCALE="651.883314254875" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="264" TOTAL_2="335" WEIGHT="100.0" Z="0.5885429344703581">
<NAME>Exanthema</NAME>
<GROUP_LABEL_1>AMT or RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or acetaminophen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or acetaminophen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.13548791658897846" CI_END="2.343445205373948" CI_START="0.20544714882011753" DF="1" EFFECT_SIZE="0.6938689615916339" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="0.3698548032661108" LOG_CI_START="-0.6872998814660282" LOG_EFFECT_SIZE="-0.1587225390999587" NO="1" P_CHI2="0.7128085876079264" P_Z="0.556167927355823" STUDIES="2" TAU2="0.0" TOTAL_1="264" TOTAL_2="335" WEIGHT="100.0" Z="0.5885429344703581">
<NAME>AMT</NAME>
<DICH_DATA CI_END="2.970578303905017" CI_START="0.10556866977307164" EFFECT_SIZE="0.56" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4728410047873221" LOG_CI_START="-0.9764649507749213" LOG_EFFECT_SIZE="-0.25181197299379954" ORDER="11294" O_E="0.0" SE="0.8513294924774455" STUDY_ID="STD-Kitamoto-1968" TOTAL_1="75" TOTAL_2="84" VAR="0.7247619047619048" WEIGHT="53.20554837543593"/>
<DICH_DATA CI_END="5.2459175233632545" CI_START="0.14942382801841414" EFFECT_SIZE="0.8853615520282186" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.7198214583035535" LOG_CI_START="-0.8255801417993281" LOG_EFFECT_SIZE="-0.05287934174788727" ORDER="11295" O_E="0.0" SE="0.9077765497617285" STUDY_ID="STD-Kitamoto-1971" TOTAL_1="189" TOTAL_2="251" VAR="0.824058264297308" WEIGHT="46.794451624564076"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7607744620810669" CI_END="1.5858292744411766" CI_START="0.4577071178301809" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8519655782807178" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.2002564306744631" LOG_CI_START="-0.33941233378127683" LOG_EFFECT_SIZE="-0.06957795155340687" METHOD="MH" MODIFIED="2014-11-12 09:39:40 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.38308630159128276" P_Q="1.0" P_Z="0.6132883763372625" Q="0.0" RANDOM="YES" SCALE="245.20894396900957" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="264" TOTAL_2="335" WEIGHT="100.0" Z="0.505385110810631">
<NAME>Muscular, limb pain</NAME>
<GROUP_LABEL_1>AMT or RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or acetaminophen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or acetaminophen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7607744620810669" CI_END="1.5858292744411766" CI_START="0.4577071178301809" DF="1" EFFECT_SIZE="0.8519655782807178" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="24" I2="0.0" ID="CMP-006.03.01" LOG_CI_END="0.2002564306744631" LOG_CI_START="-0.33941233378127683" LOG_EFFECT_SIZE="-0.06957795155340687" NO="1" P_CHI2="0.38308630159128276" P_Z="0.6132883763372625" STUDIES="2" TAU2="0.0" TOTAL_1="264" TOTAL_2="335" WEIGHT="100.0" Z="0.505385110810631">
<NAME>AMT</NAME>
<DICH_DATA CI_END="5.022131615983939" CI_START="0.39027252765775944" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.7008880901663392" LOG_CI_START="-0.40863201880986316" LOG_EFFECT_SIZE="0.146128035678238" ORDER="11298" O_E="0.0" SE="0.651737604225738" STUDY_ID="STD-Kitamoto-1968" TOTAL_1="75" TOTAL_2="84" VAR="0.4247619047619048" WEIGHT="23.658336729597526"/>
<DICH_DATA CI_END="1.4873133317108882" CI_START="0.3587126916764667" EFFECT_SIZE="0.7304232804232804" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="20" LOG_CI_END="0.17240247080726936" LOG_CI_START="-0.4452532572031936" LOG_EFFECT_SIZE="-0.13642539319796215" ORDER="11299" O_E="0.0" SE="0.3628140320785095" STUDY_ID="STD-Kitamoto-1971" TOTAL_1="189" TOTAL_2="251" VAR="0.13163402187306572" WEIGHT="76.34166327040248"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.21501835643431771" CI_END="1.0291324384897775" CI_START="0.5176252399906158" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7298663750683401" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="72" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.01247126747789256" LOG_CI_START="-0.28598455513419047" LOG_EFFECT_SIZE="-0.13675664382814892" METHOD="MH" MODIFIED="2014-11-12 09:40:53 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6428621972105224" P_Q="1.0" P_Z="0.07246812457197944" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="264" TOTAL_2="335" WEIGHT="100.0" Z="1.7961659732678457">
<NAME>Headache</NAME>
<GROUP_LABEL_1>AMT or RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or acetaminophen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or acetaminophen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.21501835643431771" CI_END="1.0291324384897775" CI_START="0.5176252399906158" DF="1" EFFECT_SIZE="0.7298663750683401" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="72" I2="0.0" ID="CMP-006.04.01" LOG_CI_END="0.01247126747789256" LOG_CI_START="-0.28598455513419047" LOG_EFFECT_SIZE="-0.13675664382814892" NO="1" P_CHI2="0.6428621972105224" P_Z="0.07246812457197944" STUDIES="2" TAU2="0.0" TOTAL_1="264" TOTAL_2="335" WEIGHT="100.0" Z="1.7961659732678457">
<NAME>AMT</NAME>
<DICH_DATA CI_END="1.167984179227966" CI_START="0.3654539607947322" EFFECT_SIZE="0.6533333333333333" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="24" LOG_CI_END="0.06743696013894243" LOG_CI_START="-0.4371673268653151" LOG_EFFECT_SIZE="-0.18486518336318639" ORDER="11300" O_E="0.0" SE="0.2964070560178061" STUDY_ID="STD-Kitamoto-1968" TOTAL_1="75" TOTAL_2="84" VAR="0.08785714285714284" WEIGHT="34.98309587480067"/>
<DICH_DATA CI_END="1.1863124590679266" CI_START="0.5058926049463137" EFFECT_SIZE="0.7746913580246914" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="48" LOG_CI_END="0.07419909153815529" LOG_CI_START="-0.2959416689893033" LOG_EFFECT_SIZE="-0.110871288725574" ORDER="11301" O_E="0.0" SE="0.21742251496014353" STUDY_ID="STD-Kitamoto-1971" TOTAL_1="189" TOTAL_2="251" VAR="0.047272550011593834" WEIGHT="65.01690412519933"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.14019526920090247" CI_END="1.7386742107860238" CI_START="0.12266519197947401" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.46181685315266274" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="0.24021821241503313" LOG_CI_START="-0.9112786571251669" LOG_EFFECT_SIZE="-0.33553022235506685" METHOD="MH" MODIFIED="2014-11-12 09:41:17 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.7080870807523769" P_Q="1.0" P_Z="0.2533656537903245" Q="0.0" RANDOM="YES" SCALE="349.5359185082996" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="264" TOTAL_2="335" WEIGHT="100.0" Z="1.142212660644474">
<NAME>Stimulation/insomnia</NAME>
<GROUP_LABEL_1>AMT or RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or acetaminophen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or acetaminophen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.14019526920090247" CI_END="1.7386742107860238" CI_START="0.12266519197947401" DF="1" EFFECT_SIZE="0.46181685315266274" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" I2="0.0" ID="CMP-006.05.01" LOG_CI_END="0.24021821241503313" LOG_CI_START="-0.9112786571251669" LOG_EFFECT_SIZE="-0.33553022235506685" NO="1" P_CHI2="0.7080870807523769" P_Z="0.2533656537903245" STUDIES="2" TAU2="0.0" TOTAL_1="264" TOTAL_2="335" WEIGHT="100.0" Z="1.142212660644474">
<NAME>AMT</NAME>
<DICH_DATA CI_END="2.970578303905017" CI_START="0.10556866977307164" EFFECT_SIZE="0.56" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4728410047873221" LOG_CI_START="-0.9764649507749213" LOG_EFFECT_SIZE="-0.25181197299379954" ORDER="11309" O_E="0.0" SE="0.8513294924774455" STUDY_ID="STD-Kitamoto-1968" TOTAL_1="75" TOTAL_2="84" VAR="0.7247619047619048" WEIGHT="63.12557827464457"/>
<DICH_DATA CI_END="2.94636724815795" CI_START="0.0374125210073256" EFFECT_SIZE="0.33201058201058203" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.4692868782527312" LOG_CI_START="-1.4269830262930678" LOG_EFFECT_SIZE="-0.4788480740201684" ORDER="11310" O_E="0.0" SE="1.1138783286176164" STUDY_ID="STD-Kitamoto-1971" TOTAL_1="189" TOTAL_2="251" VAR="1.2407249309639747" WEIGHT="36.87442172535543"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.10581651695206606" CI_END="41.74657875801735" CI_START="0.5261663383306849" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="4.6867520185027445" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.06" LOG_CI_END="1.6206208897023429" LOG_CI_START="-0.2788769394978556" LOG_EFFECT_SIZE="0.6708719751022437" METHOD="MH" MODIFIED="2014-11-12 09:42:15 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.744958219985042" P_Q="0.7457368839738425" P_Z="0.16621908907615549" Q="0.10514827282105414" RANDOM="YES" SCALE="853.7200649751705" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="291" TOTAL_2="364" WEIGHT="100.0" Z="1.3844552904714762">
<NAME>Dizziness</NAME>
<GROUP_LABEL_1>AMT or RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or acetaminophen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or acetaminophen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="137.3264425344251" CI_START="0.320243053876209" DF="0" EFFECT_SIZE="6.6315789473684195" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-006.06.01" LOG_CI_END="2.1377541697283524" LOG_CI_START="-0.49452028139888504" LOG_EFFECT_SIZE="0.8216169441647339" NO="1" P_CHI2="1.0" P_Z="0.22112781370913304" STUDIES="2" TAU2="0.0" TOTAL_1="264" TOTAL_2="335" WEIGHT="52.07331982381805" Z="1.2235347411901731">
<NAME>AMT</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11304" O_E="0.0" SE="0.0" STUDY_ID="STD-Kitamoto-1968" TOTAL_1="75" TOTAL_2="84" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="137.3264425344252" CI_START="0.32024305387620905" EFFECT_SIZE="6.631578947368421" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.137754169728353" LOG_CI_START="-0.494520281398885" LOG_EFFECT_SIZE="0.821616944164734" ORDER="11305" O_E="0.0" SE="1.5462110425608173" STUDY_ID="STD-Kitamoto-1971" TOTAL_1="189" TOTAL_2="251" VAR="2.3907685881370093" WEIGHT="52.07331982381805"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="75.67930547359703" CI_START="0.13651859763255525" DF="0" EFFECT_SIZE="3.2142857142857144" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-006.06.02" LOG_CI_END="1.878977137791617" LOG_CI_START="-0.8648081815974054" LOG_EFFECT_SIZE="0.5070844780971057" NO="2" P_CHI2="1.0" P_Z="0.4687896629539118" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="29" WEIGHT="47.92668017618194" Z="0.7244497644669435">
<NAME>RMT</NAME>
<DICH_DATA CI_END="75.67930547359703" CI_START="0.13651859763255525" EFFECT_SIZE="3.2142857142857144" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.878977137791617" LOG_CI_START="-0.8648081815974054" LOG_EFFECT_SIZE="0.5070844780971057" ORDER="11306" O_E="0.0" SE="1.6117130785654894" STUDY_ID="STD-Crawford-1988" TOTAL_1="27" TOTAL_2="29" VAR="2.5976190476190477" WEIGHT="47.92668017618194"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.015288888322758" CI_START="0.015416596633965994" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3728070175438597" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.07" LOG_CI_END="0.9549796479296643" LOG_CI_START="-1.8120114905019864" LOG_EFFECT_SIZE="-0.428515921286161" METHOD="MH" MODIFIED="2014-11-12 09:43:03 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.5438058443353301" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="84" WEIGHT="100.0" Z="0.6070679163786001">
<NAME>Dyspnoea</NAME>
<GROUP_LABEL_1>AMT or RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or acetaminophen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or acetaminophen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.015288888322758" CI_START="0.015416596633965994" DF="0" EFFECT_SIZE="0.3728070175438597" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-006.07.01" LOG_CI_END="0.9549796479296643" LOG_CI_START="-1.8120114905019864" LOG_EFFECT_SIZE="-0.428515921286161" NO="1" P_CHI2="1.0" P_Z="0.5438058443353301" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="84" WEIGHT="100.0" Z="0.6070679163786001">
<NAME>AMT</NAME>
<DICH_DATA CI_END="9.015288888322758" CI_START="0.015416596633965994" EFFECT_SIZE="0.37280701754385964" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9549796479296643" LOG_CI_START="-1.8120114905019864" LOG_EFFECT_SIZE="-0.42851592128616106" ORDER="11302" O_E="0.0" SE="1.6253442915417864" STUDY_ID="STD-Kitamoto-1968" TOTAL_1="75" TOTAL_2="84" VAR="2.6417440660474716" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.7033065183403835" CI_START="0.011575780619897981" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2333333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-006.08" LOG_CI_END="0.6724032829957057" LOG_CI_START="-1.9364497124065168" LOG_EFFECT_SIZE="-0.6320232147054055" METHOD="MH" MODIFIED="2014-11-12 09:44:47 +1000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.34229242845532426" Q="0.0" RANDOM="YES" SCALE="746.1117432302848" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="41" WEIGHT="100.0" Z="0.9496454881888325">
<NAME>Central nervous system symptoms</NAME>
<GROUP_LABEL_1>AMT or RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or acetaminophen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or acetaminophen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.7033065183403835" CI_START="0.011575780619897981" DF="0" EFFECT_SIZE="0.2333333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-006.08.01" LOG_CI_END="0.6724032829957057" LOG_CI_START="-1.9364497124065168" LOG_EFFECT_SIZE="-0.6320232147054055" MODIFIED="2008-06-12 11:02:45 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.34229242845532426" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="41" WEIGHT="100.0" Z="0.9496454881888325">
<NAME>RMT</NAME>
<DICH_DATA CI_END="4.703306518340383" CI_START="0.011575780619897981" EFFECT_SIZE="0.23333333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6724032829957056" LOG_CI_START="-1.9364497124065168" LOG_EFFECT_SIZE="-0.6320232147054056" ORDER="11307" O_E="0.0" SE="1.5324531635298675" STUDY_ID="STD-Clover-1986" TOTAL_1="35" TOTAL_2="41" VAR="2.3484126984126985" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.7033065183403835" CI_START="0.011575780619897981" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2333333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-006.09" LOG_CI_END="0.6724032829957057" LOG_CI_START="-1.9364497124065168" LOG_EFFECT_SIZE="-0.6320232147054055" METHOD="MH" MODIFIED="2014-11-12 09:47:16 +1000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.34229242845532426" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="41" WEIGHT="100.0" Z="0.9496454881888325">
<NAME>Change in behaviour</NAME>
<GROUP_LABEL_1>AMT or RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or acetaminophen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or acetaminophen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.7033065183403835" CI_START="0.011575780619897981" DF="0" EFFECT_SIZE="0.2333333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-006.09.01" LOG_CI_END="0.6724032829957057" LOG_CI_START="-1.9364497124065168" LOG_EFFECT_SIZE="-0.6320232147054055" MODIFIED="2008-06-12 11:02:49 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.34229242845532426" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="41" WEIGHT="100.0" Z="0.9496454881888325">
<NAME>RMT</NAME>
<DICH_DATA CI_END="4.703306518340383" CI_START="0.011575780619897981" EFFECT_SIZE="0.23333333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6724032829957056" LOG_CI_START="-1.9364497124065168" LOG_EFFECT_SIZE="-0.6320232147054056" ORDER="11308" O_E="0.0" SE="1.5324531635298675" STUDY_ID="STD-Clover-1986" TOTAL_1="35" TOTAL_2="41" VAR="2.3484126984126985" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="18.048914231489825" CI_START="0.07602922150103836" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1714285714285715" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.10" LOG_CI_END="1.2564510811748832" LOG_CI_START="-1.1190194564359637" LOG_EFFECT_SIZE="0.06871581236945988" METHOD="MH" MODIFIED="2014-11-12 09:48:43 +1000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.9097192213515057" Q="0.0" RANDOM="YES" SCALE="764.0789999822534" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="41" WEIGHT="100.0" Z="0.11339270707016187">
<NAME>Gastrointestinal symptoms</NAME>
<GROUP_LABEL_1>AMT or RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or acetaminophen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or acetaminophen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="18.048914231489825" CI_START="0.07602922150103836" DF="0" EFFECT_SIZE="1.1714285714285715" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-006.10.01" LOG_CI_END="1.2564510811748832" LOG_CI_START="-1.1190194564359637" LOG_EFFECT_SIZE="0.06871581236945988" MODIFIED="2008-06-12 11:02:38 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.9097192213515057" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="41" WEIGHT="100.0" Z="0.11339270707016187">
<NAME>RMT</NAME>
<DICH_DATA CI_END="18.048914231489825" CI_START="0.07602922150103836" EFFECT_SIZE="1.1714285714285715" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2564510811748832" LOG_CI_START="-1.1190194564359637" LOG_EFFECT_SIZE="0.06871581236945988" ORDER="11303" O_E="0.0" SE="1.3953631525614156" STUDY_ID="STD-Clover-1986" TOTAL_1="35" TOTAL_2="41" VAR="1.9470383275261325" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.408811719288554" CI_START="0.015168733070283916" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3571428571428572" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.11" LOG_CI_END="0.9247346283522918" LOG_CI_START="-1.8190506910367303" LOG_EFFECT_SIZE="-0.44715803134221915" METHOD="MH" MODIFIED="2014-11-12 09:49:20 +1000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.5229300009088108" Q="0.0" RANDOM="YES" SCALE="459.0097854089981" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="29" WEIGHT="100.0" Z="0.6388354297512895">
<NAME>Hyperreactivity</NAME>
<GROUP_LABEL_1>AMT or RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or acetaminophen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or acetaminophen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.408811719288554" CI_START="0.015168733070283916" DF="0" EFFECT_SIZE="0.3571428571428572" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-006.11.01" LOG_CI_END="0.9247346283522918" LOG_CI_START="-1.8190506910367303" LOG_EFFECT_SIZE="-0.44715803134221915" MODIFIED="2008-06-12 11:03:00 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.5229300009088108" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="29" WEIGHT="100.0" Z="0.6388354297512895">
<NAME>RMT</NAME>
<DICH_DATA CI_END="8.408811719288554" CI_START="0.015168733070283916" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9247346283522918" LOG_CI_START="-1.8190506910367303" LOG_EFFECT_SIZE="-0.4471580313422192" ORDER="11312" O_E="0.0" SE="1.6117130785654894" STUDY_ID="STD-Crawford-1988" TOTAL_1="27" TOTAL_2="29" VAR="2.5976190476190477" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="75.67930547359703" CI_START="0.13651859763255525" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.2142857142857144" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.12" LOG_CI_END="1.878977137791617" LOG_CI_START="-0.8648081815974054" LOG_EFFECT_SIZE="0.5070844780971057" METHOD="MH" MODIFIED="2014-11-12 09:51:31 +1000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.4687896629539118" Q="0.0" RANDOM="YES" SCALE="459.0097854089981" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="29" WEIGHT="100.0" Z="0.7244497644669435">
<NAME>Tinnitus</NAME>
<GROUP_LABEL_1>AMT or RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or acetaminophen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or acetaminophen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="75.67930547359703" CI_START="0.13651859763255525" DF="0" EFFECT_SIZE="3.2142857142857144" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-006.12.01" LOG_CI_END="1.878977137791617" LOG_CI_START="-0.8648081815974054" LOG_EFFECT_SIZE="0.5070844780971057" MODIFIED="2008-06-12 11:03:05 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.4687896629539118" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="29" WEIGHT="100.0" Z="0.7244497644669435">
<NAME>RMT</NAME>
<DICH_DATA CI_END="75.67930547359703" CI_START="0.13651859763255525" EFFECT_SIZE="3.2142857142857144" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.878977137791617" LOG_CI_START="-0.8648081815974054" LOG_EFFECT_SIZE="0.5070844780971057" ORDER="11313" O_E="0.0" SE="1.6117130785654894" STUDY_ID="STD-Crawford-1988" TOTAL_1="27" TOTAL_2="29" VAR="2.5976190476190477" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="61.80482499275749" CI_START="0.10981984210260329" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6052631578947367" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.13" LOG_CI_END="1.791022381010061" LOG_CI_START="-0.9593191850485815" LOG_EFFECT_SIZE="0.41585159798073973" METHOD="MH" MODIFIED="2014-11-12 09:51:31 +1000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.5533866017524547" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="32" WEIGHT="100.00000000000001" Z="0.5926930422127075">
<NAME>Cerebellar ataxia</NAME>
<GROUP_LABEL_1>AMT or RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or acetaminophen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or acetaminophen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="61.80482499275749" CI_START="0.10981984210260329" DF="0" EFFECT_SIZE="2.6052631578947367" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-006.13.01" LOG_CI_END="1.791022381010061" LOG_CI_START="-0.9593191850485815" LOG_EFFECT_SIZE="0.41585159798073973" MODIFIED="2008-06-12 11:02:55 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.5533866017524547" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="32" WEIGHT="100.00000000000001" Z="0.5926930422127075">
<NAME>RMT</NAME>
<DICH_DATA CI_END="61.80482499275749" CI_START="0.10981984210260329" EFFECT_SIZE="2.6052631578947367" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.791022381010061" LOG_CI_START="-0.9593191850485815" LOG_EFFECT_SIZE="0.41585159798073973" ORDER="11311" O_E="0.0" SE="1.615564250313169" STUDY_ID="STD-Hall-1987" TOTAL_1="37" TOTAL_2="32" VAR="2.610047846889952" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.7501931141575087" CI_END="1.962069168914115" CI_START="0.40741884484168944" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8940827446598454" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="76" I2="73.33470651884942" I2_Q="0.0" ID="CMP-006.14" LOG_CI_END="0.2927143135170276" LOG_CI_START="-0.389958886917892" LOG_EFFECT_SIZE="-0.04862228670043222" METHOD="MH" MODIFIED="2014-11-12 09:51:28 +1000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.05280167956750381" P_Q="1.0" P_Z="0.7800986460531905" Q="0.0" RANDOM="YES" SCALE="602.0338365646401" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.24128431229901512" TOTALS="YES" TOTAL_1="264" TOTAL_2="335" WEIGHT="100.0" Z="0.27919048446054506">
<NAME>Malaise</NAME>
<GROUP_LABEL_1>AMT or RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or acetaminophen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or acetaminophen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.7501931141575087" CI_END="1.962069168914115" CI_START="0.40741884484168944" DF="1" EFFECT_SIZE="0.8940827446598454" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="76" I2="73.33470651884942" ID="CMP-006.14.01" LOG_CI_END="0.2927143135170276" LOG_CI_START="-0.389958886917892" LOG_EFFECT_SIZE="-0.04862228670043222" NO="1" P_CHI2="0.05280167956750381" P_Z="0.7800986460531905" STUDIES="2" TAU2="0.24128431229901512" TOTAL_1="264" TOTAL_2="335" WEIGHT="100.0" Z="0.27919048446054506">
<NAME>AMT</NAME>
<DICH_DATA CI_END="2.9452856206066524" CI_START="0.6898891730366383" EFFECT_SIZE="1.4254545454545455" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.4691274170988771" LOG_CI_START="-0.16122067071848775" LOG_EFFECT_SIZE="0.15395337319019461" ORDER="11296" O_E="0.0" SE="0.3702695870572779" STUDY_ID="STD-Kitamoto-1968" TOTAL_1="75" TOTAL_2="84" VAR="0.1370995670995671" WEIGHT="42.49797990850977"/>
<DICH_DATA CI_END="0.9298023727510059" CI_START="0.4314493895789612" EFFECT_SIZE="0.6333740333740334" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="65" LOG_CI_END="-0.031609349880879725" LOG_CI_START="-0.365070141120698" LOG_EFFECT_SIZE="-0.19833974550078887" ORDER="11297" O_E="0.0" SE="0.19587651943180737" STUDY_ID="STD-Kitamoto-1971" TOTAL_1="189" TOTAL_2="251" VAR="0.03836761086471921" WEIGHT="57.50202009149022"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.123360293146248" CI_END="1.5759548052481505" CI_START="0.2351342250644964" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6087371451363004" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="34" I2="41.44468028115773" I2_Q="0.0" ID="CMP-006.15" LOG_CI_END="0.19754375876725666" LOG_CI_START="-0.628684152351663" LOG_EFFECT_SIZE="-0.2155701967922031" METHOD="MH" MODIFIED="2014-11-05 21:53:32 +1000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.16298400781504319" P_Q="0.663074128058381" P_Z="0.30642891312240683" Q="0.18981081587936116" RANDOM="YES" SCALE="441.01595167099435" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3595523230132576" TOTALS="YES" TOTAL_1="328" TOTAL_2="396" WEIGHT="100.0" Z="1.0227440060230981">
<NAME>Nausea/vomiting</NAME>
<GROUP_LABEL_1>AMT or RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or acetaminophen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or acetaminophen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.264086213851163" CI_END="1.9997813937230728" CI_START="0.1463893297427173" DF="1" EFFECT_SIZE="0.5410606785371468" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="33" I2="76.54831657128157" ID="CMP-006.15.01" LOG_CI_END="0.3009825233196064" LOG_CI_START="-0.834490577667932" LOG_EFFECT_SIZE="-0.2667540271741628" NO="1" P_CHI2="0.03892634507338877" P_Z="0.3571029282894357" STUDIES="2" TAU2="0.685692627007779" TOTAL_1="264" TOTAL_2="335" WEIGHT="84.10287305165" Z="0.920899465672355">
<NAME>AMT</NAME>
<DICH_DATA CI_END="0.748371498621107" CI_START="0.0927984977955616" EFFECT_SIZE="0.2635294117647059" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="17" LOG_CI_END="-0.12588276075952354" LOG_CI_START="-1.0324590540007361" LOG_EFFECT_SIZE="-0.5791709073801299" ORDER="11314" O_E="0.0" SE="0.5325274022749154" STUDY_ID="STD-Kitamoto-1968" TOTAL_1="75" TOTAL_2="84" VAR="0.2835854341736695" WEIGHT="36.62443394865241"/>
<DICH_DATA CI_END="2.0550595778211433" CI_START="0.4827496242979441" EFFECT_SIZE="0.996031746031746" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.31282441693904867" LOG_CI_START="-0.3162780555400606" LOG_EFFECT_SIZE="-0.0017268193005059503" ORDER="11315" O_E="0.0" SE="0.3695379064416912" STUDY_ID="STD-Kitamoto-1971" TOTAL_1="189" TOTAL_2="251" VAR="0.1365582642973081" WEIGHT="47.478439102997584"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7582640326319022" CI_END="9.006342501127282" CI_START="0.10282185131643667" DF="1" EFFECT_SIZE="0.9623142987381065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-006.15.02" LOG_CI_END="0.9545484586741336" LOG_CI_START="-0.9879145808884123" LOG_EFFECT_SIZE="-0.016683061107139414" NO="2" P_CHI2="0.3838723711333327" P_Z="0.9731429016723312" STUDIES="2" TAU2="0.0" TOTAL_1="64" TOTAL_2="61" WEIGHT="15.897126948350008" Z="0.033666739861612026">
<NAME>RMT</NAME>
<DICH_DATA CI_END="8.408811719288554" CI_START="0.015168733070283916" EFFECT_SIZE="0.35714285714285715" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9247346283522918" LOG_CI_START="-1.8190506910367303" LOG_EFFECT_SIZE="-0.4471580313422192" ORDER="11316" O_E="0.0" SE="1.6117130785654894" STUDY_ID="STD-Crawford-1988" TOTAL_1="27" TOTAL_2="29" VAR="2.5976190476190477" WEIGHT="7.96523209371549"/>
<DICH_DATA CI_END="61.80482499275749" CI_START="0.10981984210260329" EFFECT_SIZE="2.6052631578947367" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.791022381010061" LOG_CI_START="-0.9593191850485815" LOG_EFFECT_SIZE="0.41585159798073973" ORDER="11317" O_E="0.0" SE="1.615564250313169" STUDY_ID="STD-Hall-1987" TOTAL_1="37" TOTAL_2="32" VAR="2.610047846889952" WEIGHT="7.9318948546345185"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-11-05 21:53:32 +1000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="441.02" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="264" TOTAL_2="335" WEIGHT="0.0" Z="0.0">
<NAME>Arrhythmia</NAME>
<GROUP_LABEL_1>AMT or RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo or acetaminophen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AMT or RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo or acetaminophen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.16.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="264" TOTAL_2="335" WEIGHT="0.0" Z="0.0">
<NAME>AMT</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11318" O_E="0.0" SE="0.0" STUDY_ID="STD-Kitamoto-1968" TOTAL_1="75" TOTAL_2="84" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11319" O_E="0.0" SE="0.0" STUDY_ID="STD-Kitamoto-1971" TOTAL_1="189" TOTAL_2="251" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2014-11-12 09:36:59 +1000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Adverse effects of rimantadine compared to placebo in the elderly</NAME>
<DICH_OUTCOME CHI2="0.062236349921086925" CI_END="6.0217972007501945" CI_START="0.4299880620313492" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.609130482060538" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.7797261254580133" LOG_CI_START="-0.3665436017829268" LOG_EFFECT_SIZE="0.20659126183754326" METHOD="MH" MODIFIED="2014-11-12 09:27:10 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8029955899045176" P_Q="1.0" P_Z="0.4798863130801988" Q="0.0" RANDOM="YES" SCALE="485.42" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="83" WEIGHT="100.0" Z="0.706485433750199">
<NAME>Stimulation/insomnia</NAME>
<GROUP_LABEL_1>Rimantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.062236349921086925" CI_END="6.0217972007501945" CI_START="0.4299880620313492" DF="1" EFFECT_SIZE="1.609130482060538" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="0.7797261254580133" LOG_CI_START="-0.3665436017829268" LOG_EFFECT_SIZE="0.20659126183754326" MODIFIED="2008-06-12 11:01:03 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="0.8029955899045176" P_Z="0.4798863130801988" STUDIES="2" TAU2="0.0" TOTAL_1="150" TOTAL_2="83" WEIGHT="100.0" Z="0.706485433750199">
<NAME>RMT</NAME>
<DICH_DATA CI_END="17.53924922902106" CI_START="0.22805993276961137" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.244010999368011" LOG_CI_START="-0.6419510080400486" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11330" O_E="0.0" SE="1.1078234188139946" STUDY_ID="STD-Monto-1995" TOTAL_1="132" TOTAL_2="66" VAR="1.2272727272727273" WEIGHT="36.94092504961074"/>
<DICH_DATA CI_END="7.464683896091129" CI_START="0.2688585976822646" EFFECT_SIZE="1.4166666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8730114215600387" LOG_CI_START="-0.5704760708987405" LOG_EFFECT_SIZE="0.15126767533064914" ORDER="11331" O_E="0.0" SE="0.8479116984486138" STUDY_ID="STD-Patriarca-1984" TOTAL_1="18" TOTAL_2="17" VAR="0.718954248366013" WEIGHT="63.05907495038925"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5089949202035534" CI_END="1.5609359602630752" CI_START="0.3971111052422679" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7873150604379866" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.19338508584596792" LOG_CI_START="-0.4010879676880699" LOG_EFFECT_SIZE="-0.10385144092105103" METHOD="MH" MODIFIED="2014-11-12 09:27:57 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4755743301803482" P_Q="1.0" P_Z="0.4934754260843316" Q="0.0" RANDOM="YES" SCALE="174.45" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="83" WEIGHT="100.0" Z="0.6847916242386747">
<NAME>Confusion</NAME>
<GROUP_LABEL_1>Rimantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5089949202035534" CI_END="1.5609359602630752" CI_START="0.3971111052422679" DF="1" EFFECT_SIZE="0.7873150604379866" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" I2="0.0" ID="CMP-007.02.01" LOG_CI_END="0.19338508584596792" LOG_CI_START="-0.4010879676880699" LOG_EFFECT_SIZE="-0.10385144092105103" MODIFIED="2008-06-12 11:01:12 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="0.4755743301803482" P_Z="0.4934754260843316" STUDIES="2" TAU2="0.0" TOTAL_1="150" TOTAL_2="83" WEIGHT="100.0" Z="0.6847916242386747">
<NAME>RMT</NAME>
<DICH_DATA CI_END="1.9032079275844953" CI_START="0.4151535128339491" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" LOG_CI_END="0.27948623803458533" LOG_CI_START="-0.38179128292934794" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="11334" O_E="0.0" SE="0.38843768919073546" STUDY_ID="STD-Monto-1995" TOTAL_1="132" TOTAL_2="66" VAR="0.1508838383838384" WEIGHT="80.8159025449738"/>
<DICH_DATA CI_END="2.2530663376550586" CI_START="0.09897348490527838" EFFECT_SIZE="0.4722222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3527739789645759" LOG_CI_START="-1.0044811377426026" LOG_EFFECT_SIZE="-0.3258535793890133" ORDER="11335" O_E="0.0" SE="0.7972583740749793" STUDY_ID="STD-Patriarca-1984" TOTAL_1="18" TOTAL_2="17" VAR="0.6356209150326797" WEIGHT="19.184097455026208"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2539389361089592" CI_END="1.5959033412283608" CI_START="0.4088613738279458" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8077767219914402" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="0.20300658398064245" LOG_CI_START="-0.3884239164100806" LOG_EFFECT_SIZE="-0.09270866621471908" METHOD="MH" MODIFIED="2014-11-12 09:28:30 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6143151431840266" P_Q="1.0" P_Z="0.538910386382476" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="83" WEIGHT="100.0" Z="0.6144615359388891">
<NAME>Fatigue</NAME>
<GROUP_LABEL_1>Rimantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2539389361089592" CI_END="1.5959033412283608" CI_START="0.4088613738279458" DF="1" EFFECT_SIZE="0.8077767219914402" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" I2="0.0" ID="CMP-007.03.01" LOG_CI_END="0.20300658398064245" LOG_CI_START="-0.3884239164100806" LOG_EFFECT_SIZE="-0.09270866621471908" MODIFIED="2008-06-12 11:01:14 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="0.6143151431840266" P_Z="0.538910386382476" STUDIES="2" TAU2="0.0" TOTAL_1="150" TOTAL_2="83" WEIGHT="100.0" Z="0.6144615359388891">
<NAME>RMT</NAME>
<DICH_DATA CI_END="1.8421987048414588" CI_START="0.24125760336081317" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.26533647263711463" LOG_CI_START="-0.6175189907484772" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="11336" O_E="0.0" SE="0.5185936693977221" STUDY_ID="STD-Monto-1995" TOTAL_1="132" TOTAL_2="66" VAR="0.2689393939393939" WEIGHT="44.877454711523825"/>
<DICH_DATA CI_END="2.3630630047043937" CI_START="0.37746573276557915" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.3734753010782742" LOG_CI_START="-0.42312246852833857" LOG_EFFECT_SIZE="-0.024823583725032152" ORDER="11337" O_E="0.0" SE="0.46792547308947935" STUDY_ID="STD-Patriarca-1984" TOTAL_1="18" TOTAL_2="17" VAR="0.21895424836601307" WEIGHT="55.122545288476175"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0015105811445911593" CI_END="2.6020633025162554" CI_START="0.3787194504035749" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9926993421193888" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="0.4153178577901671" LOG_CI_START="-0.4216823896612638" LOG_EFFECT_SIZE="-0.0031822659355483546" METHOD="MH" MODIFIED="2014-11-12 09:29:28 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.9689970730747495" P_Q="1.0" P_Z="0.9881091485174132" Q="0.0" RANDOM="YES" SCALE="459.01" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="83" WEIGHT="99.99999999999999" Z="0.014903523964048324">
<NAME>Vomiting</NAME>
<GROUP_LABEL_1>Rimantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0015105811445911593" CI_END="2.6020633025162554" CI_START="0.3787194504035749" DF="1" EFFECT_SIZE="0.9926993421193888" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" I2="0.0" ID="CMP-007.04.01" LOG_CI_END="0.4153178577901671" LOG_CI_START="-0.4216823896612638" LOG_EFFECT_SIZE="-0.0031822659355483546" MODIFIED="2008-06-12 11:01:34 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="0.9689970730747495" P_Z="0.9881091485174132" STUDIES="2" TAU2="0.0" TOTAL_1="150" TOTAL_2="83" WEIGHT="99.99999999999999" Z="0.014903523964048324">
<NAME>RMT</NAME>
<DICH_DATA CI_END="2.8068201121546563" CI_START="0.35627505862224623" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.4482145797872655" LOG_CI_START="-0.44821457978726553" LOG_EFFECT_SIZE="0.0" ORDER="11348" O_E="0.0" SE="0.5265669257299848" STUDY_ID="STD-Monto-1995" TOTAL_1="132" TOTAL_2="66" VAR="0.27727272727272734" WEIGHT="87.1804733321429"/>
<DICH_DATA CI_END="13.932485776128214" CI_START="0.06402126102796939" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.144028608351085" LOG_CI_START="-1.1936757758011494" LOG_EFFECT_SIZE="-0.024823583725032152" ORDER="11349" O_E="0.0" SE="1.373179127074352" STUDY_ID="STD-Patriarca-1984" TOTAL_1="18" TOTAL_2="17" VAR="1.8856209150326797" WEIGHT="12.819526667857094"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.3811101905535055" CI_START="0.20538947425749535" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-007.05" LOG_CI_END="0.5290593246757175" LOG_CI_START="-0.6874218167709671" LOG_EFFECT_SIZE="-0.0791812460476248" METHOD="MH" MODIFIED="2014-11-12 09:29:28 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.7986074902961251" Q="0.0" RANDOM="YES" SCALE="717.09" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="66" WEIGHT="100.0" Z="0.25514968578927344">
<NAME>Headache</NAME>
<GROUP_LABEL_1>Rimantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.3811101905535055" CI_START="0.20538947425749535" DF="0" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-007.05.01" LOG_CI_END="0.5290593246757175" LOG_CI_START="-0.6874218167709671" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2008-06-12 11:00:58 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.7986074902961251" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="66" WEIGHT="100.0" Z="0.25514968578927344">
<NAME>RMT</NAME>
<DICH_DATA CI_END="3.3811101905535055" CI_START="0.20538947425749535" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5290593246757175" LOG_CI_START="-0.6874218167709671" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="11329" O_E="0.0" SE="0.7145670441645491" STUDY_ID="STD-Monto-1995" TOTAL_1="132" TOTAL_2="66" VAR="0.5106060606060606" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.4100374164416394" CI_START="0.10373282933055819" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-007.06" LOG_CI_END="0.3820237851590987" LOG_CI_START="-0.9840837764870611" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" MODIFIED="2014-11-12 09:31:08 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.3877089626917306" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="66" WEIGHT="100.0" Z="0.8637796412702556">
<NAME>Impaired concentration</NAME>
<GROUP_LABEL_1>Rimantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4100374164416394" CI_START="0.10373282933055819" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-007.06.01" LOG_CI_END="0.3820237851590987" LOG_CI_START="-0.9840837764870611" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2008-06-12 11:01:23 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.3877089626917306" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="66" WEIGHT="100.0" Z="0.8637796412702556">
<NAME>RMT</NAME>
<DICH_DATA CI_END="2.4100374164416394" CI_START="0.10373282933055819" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.3820237851590987" LOG_CI_START="-0.9840837764870611" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="11342" O_E="0.0" SE="0.8024583440524461" STUDY_ID="STD-Monto-1995" TOTAL_1="132" TOTAL_2="66" VAR="0.6439393939393939" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.178432270931809E-32" CI_END="67.27956304744613" CI_START="0.1848243728682098" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.5263157894736836" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="100.0" I2_Q="0.0" ID="CMP-007.07" LOG_CI_END="1.8278831622384404" LOG_CI_START="-0.7332407587424454" LOG_EFFECT_SIZE="0.5473212017479974" METHOD="MH" MODIFIED="2014-11-12 09:34:47 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="1.0" P_Z="0.4021978665063266" Q="0.0" RANDOM="YES" SCALE="689.17" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="66" WEIGHT="100.0" Z="0.8377024122990587">
<NAME>Rash or allergic reaction</NAME>
<GROUP_LABEL_1>Rimantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.178432270931809E-32" CI_END="67.27956304744613" CI_START="0.1848243728682098" DF="0" EFFECT_SIZE="3.5263157894736836" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="100.0" ID="CMP-007.07.01" LOG_CI_END="1.8278831622384404" LOG_CI_START="-0.7332407587424454" LOG_EFFECT_SIZE="0.5473212017479974" MODIFIED="2008-06-12 11:01:27 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="0.0" P_Z="0.4021978665063266" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="66" WEIGHT="100.0" Z="0.8377024122990587">
<NAME>RMT</NAME>
<DICH_DATA CI_END="67.27956304744613" CI_START="0.1848243728682098" EFFECT_SIZE="3.526315789473684" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8278831622384404" LOG_CI_START="-0.7332407587424454" LOG_EFFECT_SIZE="0.5473212017479975" ORDER="11345" O_E="0.0" SE="1.5044168689520456" STUDY_ID="STD-Monto-1995" TOTAL_1="132" TOTAL_2="66" VAR="2.2632701155874764" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="17.53924922902106" CI_START="0.22805993276961137" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-007.08" LOG_CI_END="1.244010999368011" LOG_CI_START="-0.6419510080400486" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" MODIFIED="2014-11-12 09:35:46 +1000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.5315223562728779" Q="0.0" RANDOM="YES" SCALE="807.68" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="66" WEIGHT="100.0" Z="0.6256838127704591">
<NAME>Seizures or clonic twitching</NAME>
<GROUP_LABEL_1>Rimantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.53924922902106" CI_START="0.22805993276961137" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-007.08.01" LOG_CI_END="1.244010999368011" LOG_CI_START="-0.6419510080400486" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-06-12 11:01:29 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.5315223562728779" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="66" WEIGHT="100.0" Z="0.6256838127704591">
<NAME>RMT</NAME>
<DICH_DATA CI_END="17.53924922902106" CI_START="0.22805993276961137" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.244010999368011" LOG_CI_START="-0.6419510080400486" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="11346" O_E="0.0" SE="1.1078234188139946" STUDY_ID="STD-Monto-1995" TOTAL_1="132" TOTAL_2="66" VAR="1.2272727272727273" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.66316885329236E-32" CI_END="2.1218175941712154" CI_START="0.23093408280997618" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="100.0" I2_Q="0.0" ID="CMP-007.09" LOG_CI_END="0.3267080462713246" LOG_CI_START="-0.636511966242811" LOG_EFFECT_SIZE="-0.1549019599857432" METHOD="MH" MODIFIED="2014-11-12 09:36:59 +1000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="1.0" P_Z="0.5284392777769542" Q="0.0" RANDOM="YES" SCALE="641.6" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="66" WEIGHT="100.00000000000001" Z="0.6303902717184581">
<NAME>Dry mouth</NAME>
<GROUP_LABEL_1>Rimantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.66316885329236E-32" CI_END="2.1218175941712154" CI_START="0.23093408280997618" DF="0" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="100.0" ID="CMP-007.09.01" LOG_CI_END="0.3267080462713246" LOG_CI_START="-0.636511966242811" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2008-06-12 11:01:32 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="0.0" P_Z="0.5284392777769542" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="66" WEIGHT="100.00000000000001" Z="0.6303902717184581">
<NAME>RMT</NAME>
<DICH_DATA CI_END="2.1218175941712154" CI_START="0.23093408280997618" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.3267080462713246" LOG_CI_START="-0.636511966242811" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="11347" O_E="0.0" SE="0.5658002033667628" STUDY_ID="STD-Monto-1995" TOTAL_1="132" TOTAL_2="66" VAR="0.32012987012987015" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.973382805578824" CI_START="0.14932498680796374" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-007.10" LOG_CI_END="0.7762203474983387" LOG_CI_START="-0.8258675149484029" LOG_EFFECT_SIZE="-0.024823583725032152" METHOD="MH" MODIFIED="2014-11-12 09:36:59 +1000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.9515683413816378" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="17" WEIGHT="99.99999999999999" Z="0.060737405492821465">
<NAME>Dizziness</NAME>
<GROUP_LABEL_1>Rimantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.973382805578824" CI_START="0.14932498680796374" DF="0" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-007.10.01" LOG_CI_END="0.7762203474983387" LOG_CI_START="-0.8258675149484029" LOG_EFFECT_SIZE="-0.024823583725032152" MODIFIED="2008-06-12 11:01:06 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.9515683413816378" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="99.99999999999999" Z="0.060737405492821465">
<NAME>RMT</NAME>
<DICH_DATA CI_END="5.973382805578824" CI_START="0.14932498680796374" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7762203474983387" LOG_CI_START="-0.8258675149484029" LOG_EFFECT_SIZE="-0.024823583725032152" ORDER="11332" O_E="0.0" SE="0.941074340864036" STUDY_ID="STD-Patriarca-1984" TOTAL_1="18" TOTAL_2="17" VAR="0.8856209150326797" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.73623184247016" CI_START="0.9189062198134079" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.833333333333334" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-007.11" LOG_CI_END="0.9413241508379308" LOG_CI_START="-0.036728808848670115" LOG_EFFECT_SIZE="0.45229767099463036" METHOD="MH" MODIFIED="2014-11-12 09:36:56 +1000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.06986900240366789" Q="0.0" RANDOM="YES" SCALE="400.61" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="1.8127589854129795">
<NAME>Anxiety</NAME>
<GROUP_LABEL_1>Rimantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.73623184247016" CI_START="0.9189062198134079" DF="0" EFFECT_SIZE="2.833333333333334" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" ID="CMP-007.11.01" LOG_CI_END="0.9413241508379308" LOG_CI_START="-0.036728808848670115" LOG_EFFECT_SIZE="0.45229767099463036" MODIFIED="2008-06-12 11:01:09 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.06986900240366789" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="1.8127589854129795">
<NAME>RMT</NAME>
<DICH_DATA CI_END="8.73623184247016" CI_START="0.9189062198134079" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9413241508379308" LOG_CI_START="-0.036728808848670115" LOG_EFFECT_SIZE="0.4522976709946303" ORDER="11333" O_E="0.0" SE="0.5745131499601416" STUDY_ID="STD-Patriarca-1984" TOTAL_1="18" TOTAL_2="17" VAR="0.3300653594771241" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.0216890188761982" CI_END="8.750720483960764" CI_START="0.45090333664002114" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9863859303322928" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="7" I2="50.536408386099225" I2_Q="0.0" ID="CMP-007.12" LOG_CI_END="0.9420438118025215" LOG_CI_START="-0.3459165509453972" LOG_EFFECT_SIZE="0.29806363042856215" METHOD="MH" MODIFIED="2014-11-12 09:36:53 +1000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.15506696798129616" P_Q="1.0" P_Z="0.36432144828171975" Q="0.0" RANDOM="YES" SCALE="667.61" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.6475748760780861" TOTALS="YES" TOTAL_1="150" TOTAL_2="83" WEIGHT="100.0" Z="0.9071614276930633">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Rimantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0216890188761982" CI_END="8.750720483960764" CI_START="0.45090333664002114" DF="1" EFFECT_SIZE="1.9863859303322928" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="7" I2="50.536408386099225" ID="CMP-007.12.01" LOG_CI_END="0.9420438118025215" LOG_CI_START="-0.3459165509453972" LOG_EFFECT_SIZE="0.29806363042856215" MODIFIED="2008-06-12 11:01:17 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="0.15506696798129616" P_Z="0.36432144828171975" STUDIES="2" TAU2="0.6475748760780861" TOTAL_1="150" TOTAL_2="83" WEIGHT="100.0" Z="0.9071614276930633">
<NAME>RMT</NAME>
<DICH_DATA CI_END="2.8971455205287056" CI_START="0.46981109559961615" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.46197030990013416" LOG_CI_START="-0.3280767306389077" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="11338" O_E="0.0" SE="0.4640775424085563" STUDY_ID="STD-Monto-1995" TOTAL_1="132" TOTAL_2="66" VAR="0.21536796536796537" WEIGHT="66.32819349532646"/>
<DICH_DATA CI_END="42.315484050713096" CI_START="0.7588501427190926" EFFECT_SIZE="5.666666666666667" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6264993131739753" LOG_CI_START="-0.1198439798567522" LOG_EFFECT_SIZE="0.7533276666586115" ORDER="11339" O_E="0.0" SE="1.025810694864967" STUDY_ID="STD-Patriarca-1984" TOTAL_1="18" TOTAL_2="17" VAR="1.0522875816993464" WEIGHT="33.67180650467355"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8741436095064561" CI_END="4.978777762829771" CI_START="0.5345701639449894" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6314122853900477" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-007.13" LOG_CI_END="0.6971227411517865" LOG_CI_START="-0.2719952842544712" LOG_EFFECT_SIZE="0.21256372844865767" METHOD="MH" MODIFIED="2014-11-12 09:36:50 +1000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.3498108284904963" P_Q="1.0" P_Z="0.3899068027853356" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="83" WEIGHT="99.99999999999997" Z="0.859786406313666">
<NAME>Depression</NAME>
<GROUP_LABEL_1>Rimantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8741436095064561" CI_END="4.978777762829771" CI_START="0.5345701639449894" DF="1" EFFECT_SIZE="1.6314122853900477" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" I2="0.0" ID="CMP-007.13.01" LOG_CI_END="0.6971227411517865" LOG_CI_START="-0.2719952842544712" LOG_EFFECT_SIZE="0.21256372844865767" MODIFIED="2008-06-12 11:01:19 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="0.3498108284904963" P_Z="0.3899068027853356" STUDIES="2" TAU2="0.0" TOTAL_1="150" TOTAL_2="83" WEIGHT="99.99999999999997" Z="0.859786406313666">
<NAME>RMT</NAME>
<DICH_DATA CI_END="4.36659743591832" CI_START="0.3117097765676816" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.6401431554161788" LOG_CI_START="-0.5062495761549525" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="11340" O_E="0.0" SE="0.6733967652604247" STUDY_ID="STD-Monto-1995" TOTAL_1="132" TOTAL_2="66" VAR="0.45346320346320346" WEIGHT="71.46386410982318"/>
<DICH_DATA CI_END="30.5016773206036" CI_START="0.4678957418722434" EFFECT_SIZE="3.7777777777777777" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.48432372233213" LOG_CI_START="-0.3298509071262696" LOG_EFFECT_SIZE="0.5772364076029303" ORDER="11341" O_E="0.0" SE="1.0656551576531124" STUDY_ID="STD-Patriarca-1984" TOTAL_1="18" TOTAL_2="17" VAR="1.1356209150326797" WEIGHT="28.5361358901768"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.004387707151824252" CI_END="2.1677843388647413" CI_START="0.5646797582502527" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1063923067379067" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-007.14" LOG_CI_END="0.3360160744070621" LOG_CI_START="-0.24819777988801586" LOG_EFFECT_SIZE="0.04390914725952315" METHOD="MH" MODIFIED="2014-11-12 09:36:46 +1000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.9471869343135599" P_Q="1.0" P_Z="0.7682846943120311" Q="0.0" RANDOM="YES" SCALE="314.85" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="83" WEIGHT="100.0" Z="0.29461933019158804">
<NAME>Loss of appetite</NAME>
<GROUP_LABEL_1>Rimantadine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimantadine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.004387707151824252" CI_END="2.1677843388647413" CI_START="0.5646797582502527" DF="1" EFFECT_SIZE="1.1063923067379067" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" I2="0.0" ID="CMP-007.14.01" LOG_CI_END="0.3360160744070621" LOG_CI_START="-0.24819777988801586" LOG_EFFECT_SIZE="0.04390914725952315" MODIFIED="2008-06-12 11:01:25 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="0.9471869343135599" P_Z="0.7682846943120311" STUDIES="2" TAU2="0.0" TOTAL_1="150" TOTAL_2="83" WEIGHT="100.0" Z="0.29461933019158804">
<NAME>RMT</NAME>
<DICH_DATA CI_END="2.7214029187101576" CI_START="0.43125224237922055" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.43479284623329056" LOG_CI_START="-0.3652686337148667" LOG_EFFECT_SIZE="0.03476210625921191" ORDER="11343" O_E="0.0" SE="0.4699600736897453" STUDY_ID="STD-Monto-1995" TOTAL_1="132" TOTAL_2="66" VAR="0.22086247086247085" WEIGHT="53.32083983365613"/>
<DICH_DATA CI_END="3.0332010168202537" CI_START="0.42346169519320065" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.48190119290312816" LOG_CI_START="-0.37318586825794275" LOG_EFFECT_SIZE="0.054357662322592676" ORDER="11344" O_E="0.0" SE="0.5022823724752307" STUDY_ID="STD-Patriarca-1984" TOTAL_1="18" TOTAL_2="17" VAR="0.2522875816993464" WEIGHT="46.67916016634386"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2014-11-12 09:01:13 +1000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Adverse effects related to different doses of rimantadine in the elderly</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6458120383703472" CI_START="0.4135496545972177" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.825" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.21638023466741227" LOG_CI_START="-0.38347233756756216" LOG_EFFECT_SIZE="-0.08354605145007493" METHOD="MH" MODIFIED="2014-11-05 21:45:54 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5850945890997172" Q="0.0" RANDOM="YES" SCALE="116.97" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="0.5459583220009404">
<NAME>Confusion</NAME>
<GROUP_LABEL_1>RMT 100 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>RMT 200 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RMT 100 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RMT 200 mg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6458120383703472" CI_START="0.4135496545972177" DF="0" EFFECT_SIZE="0.825" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" I2="0.0" ID="CMP-008.01.01" LOG_CI_END="0.21638023466741227" LOG_CI_START="-0.38347233756756216" LOG_EFFECT_SIZE="-0.08354605145007493" MODIFIED="2008-06-12 11:03:54 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.5850945890997172" STUDIES="1" TAU2="0.0" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="0.5459583220009404">
<NAME>RMT</NAME>
<DICH_DATA CI_END="1.6458120383703472" CI_START="0.4135496545972177" EFFECT_SIZE="0.825" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.21638023466741227" LOG_CI_START="-0.38347233756756216" LOG_EFFECT_SIZE="-0.08354605145007493" ORDER="11351" O_E="0.0" SE="0.35235637024894506" STUDY_ID="STD-Monto-1995" TOTAL_1="130" TOTAL_2="132" VAR="0.12415501165501167" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6464377092360873" CI_START="0.11501706545090075" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4351648351648352" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.2165453044091276" LOG_CI_START="-0.9392377172002901" LOG_EFFECT_SIZE="-0.3613462063955813" METHOD="MH" MODIFIED="2014-11-05 21:46:07 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.22037420489603066" Q="0.0" RANDOM="YES" SCALE="592.52" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="1.2255337502696977">
<NAME>Depression</NAME>
<GROUP_LABEL_1>RMT 100 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>RMT 200 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RMT 100 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RMT 200 mg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6464377092360873" CI_START="0.11501706545090075" DF="0" EFFECT_SIZE="0.4351648351648352" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" ID="CMP-008.02.01" LOG_CI_END="0.2165453044091276" LOG_CI_START="-0.9392377172002901" LOG_EFFECT_SIZE="-0.3613462063955813" MODIFIED="2008-06-12 11:03:59 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.22037420489603066" STUDIES="1" TAU2="0.0" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="1.2255337502696977">
<NAME>RMT</NAME>
<DICH_DATA CI_END="1.6464377092360873" CI_START="0.11501706545090075" EFFECT_SIZE="0.4351648351648352" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.2165453044091276" LOG_CI_START="-0.9392377172002901" LOG_EFFECT_SIZE="-0.3613462063955813" ORDER="11352" O_E="0.0" SE="0.6789126681115996" STUDY_ID="STD-Monto-1995" TOTAL_1="130" TOTAL_2="132" VAR="0.46092241092241093" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.39011962514506E-32" CI_END="3.984971724650996" CI_START="0.11498823171979651" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.676923076923077" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="99.99999999999999" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="0.6004252442085146" LOG_CI_START="-0.9393466045218509" LOG_EFFECT_SIZE="-0.16946068015666813" METHOD="MH" MODIFIED="2014-11-05 21:47:10 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="1.0" P_Z="0.666169957115408" Q="0.0" RANDOM="YES" SCALE="961.27" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="0.4314104458742998">
<NAME>Impaired concentration</NAME>
<GROUP_LABEL_1>RMT 100 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>RMT 200 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RMT 100 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RMT 200 mg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.39011962514506E-32" CI_END="3.984971724650996" CI_START="0.11498823171979651" DF="0" EFFECT_SIZE="0.676923076923077" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="99.99999999999999" ID="CMP-008.03.01" LOG_CI_END="0.6004252442085146" LOG_CI_START="-0.9393466045218509" LOG_EFFECT_SIZE="-0.16946068015666813" MODIFIED="2008-06-12 11:04:03 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="0.0" P_Z="0.666169957115408" STUDIES="1" TAU2="0.0" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="0.4314104458742998">
<NAME>RMT</NAME>
<DICH_DATA CI_END="3.984971724650996" CI_START="0.11498823171979657" EFFECT_SIZE="0.676923076923077" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6004252442085146" LOG_CI_START="-0.9393466045218507" LOG_EFFECT_SIZE="-0.16946068015666813" ORDER="11353" O_E="0.0" SE="0.9044696059377938" STUDY_ID="STD-Monto-1995" TOTAL_1="130" TOTAL_2="132" VAR="0.818065268065268" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.974294210829392" CI_START="0.25941861937408084" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0153846153846153" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-008.04" LOG_CI_END="0.5992600141100177" LOG_CI_START="-0.5859988563119917" LOG_EFFECT_SIZE="0.006630578899013076" METHOD="MH" MODIFIED="2014-11-05 21:47:48 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.9825046926910611" Q="0.0" RANDOM="YES" SCALE="477.73" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="0.021928873367705368">
<NAME>Insomnia or sleeplessness</NAME>
<GROUP_LABEL_1>RMT 100 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>RMT 200 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RMT 100 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RMT 200 mg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.974294210829392" CI_START="0.25941861937408084" DF="0" EFFECT_SIZE="1.0153846153846153" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-008.04.01" LOG_CI_END="0.5992600141100177" LOG_CI_START="-0.5859988563119917" LOG_EFFECT_SIZE="0.006630578899013076" MODIFIED="2008-06-12 11:04:08 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.9825046926910611" STUDIES="1" TAU2="0.0" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="0.021928873367705368">
<NAME>RMT</NAME>
<DICH_DATA CI_END="3.974294210829392" CI_START="0.25941861937408084" EFFECT_SIZE="1.0153846153846153" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5992600141100177" LOG_CI_START="-0.5859988563119917" LOG_EFFECT_SIZE="0.006630578899013076" ORDER="11354" O_E="0.0" SE="0.6962269276119207" STUDY_ID="STD-Monto-1995" TOTAL_1="130" TOTAL_2="132" VAR="0.48473193473193477" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4572257311978531" CI_START="0.2679338569731666" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6248520710059171" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-008.05" LOG_CI_END="0.16352683126228726" LOG_CI_START="-0.5719724040940475" LOG_EFFECT_SIZE="-0.20422278641588013" METHOD="MH" MODIFIED="2014-11-05 21:47:59 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.27640583228694504" Q="0.0" RANDOM="YES" SCALE="400.61" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="1.0884288846435533">
<NAME>Loss of appetite</NAME>
<GROUP_LABEL_1>RMT 100 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>RMT 200 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RMT 100 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RMT 200 mg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4572257311978531" CI_START="0.2679338569731666" DF="0" EFFECT_SIZE="0.6248520710059171" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" I2="0.0" ID="CMP-008.05.01" LOG_CI_END="0.16352683126228726" LOG_CI_START="-0.5719724040940475" LOG_EFFECT_SIZE="-0.20422278641588013" MODIFIED="2008-06-12 11:04:11 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.27640583228694504" STUDIES="1" TAU2="0.0" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="1.0884288846435533">
<NAME>RMT</NAME>
<DICH_DATA CI_END="1.4572257311978534" CI_START="0.2679338569731665" EFFECT_SIZE="0.6248520710059171" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.16352683126228731" LOG_CI_START="-0.5719724040940476" LOG_EFFECT_SIZE="-0.20422278641588013" ORDER="11355" O_E="0.0" SE="0.43203589162824385" STUDY_ID="STD-Monto-1995" TOTAL_1="130" TOTAL_2="132" VAR="0.18665501165501167" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.740619510343687E-32" CI_END="3.2117999074653283" CI_START="0.0356672944511529" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3384615384615385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="100.0" I2_Q="0.0" ID="CMP-008.06" LOG_CI_END="0.5067484812546841" LOG_CI_START="-1.4477298328959827" LOG_EFFECT_SIZE="-0.4704906758206493" METHOD="MH" MODIFIED="2014-11-05 21:48:10 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="1.0" P_Z="0.3453626418478559" Q="0.0" RANDOM="YES" SCALE="909.51" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.00000000000001" Z="0.9436224213836906">
<NAME>Rash or allergic reaction</NAME>
<GROUP_LABEL_1>RMT 100 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>RMT 200 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RMT 100 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RMT 200 mg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.740619510343687E-32" CI_END="3.2117999074653283" CI_START="0.0356672944511529" DF="0" EFFECT_SIZE="0.3384615384615385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="100.0" ID="CMP-008.06.01" LOG_CI_END="0.5067484812546841" LOG_CI_START="-1.4477298328959827" LOG_EFFECT_SIZE="-0.4704906758206493" MODIFIED="2008-06-12 11:04:13 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="0.0" P_Z="0.3453626418478559" STUDIES="1" TAU2="0.0" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.00000000000001" Z="0.9436224213836906">
<NAME>RMT</NAME>
<DICH_DATA CI_END="3.2117999074653283" CI_START="0.0356672944511529" EFFECT_SIZE="0.3384615384615385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5067484812546841" LOG_CI_START="-1.4477298328959827" LOG_EFFECT_SIZE="-0.4704906758206493" ORDER="11356" O_E="0.0" SE="1.1480702365557902" STUDY_ID="STD-Monto-1995" TOTAL_1="130" TOTAL_2="132" VAR="1.318065268065268" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0744393747239998" CI_START="0.006134440021939989" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.11280746395250213" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-008.07" LOG_CI_END="0.3169007471391729" LOG_CI_START="-2.2122250753951795" LOG_EFFECT_SIZE="-0.9476621641280033" METHOD="MH" MODIFIED="2014-11-05 21:50:23 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.14188839422264043" Q="0.0" RANDOM="YES" SCALE="651.88" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="1.468795023682096">
<NAME>Seizure or clonic twitching</NAME>
<GROUP_LABEL_1>RMT 100mg</GROUP_LABEL_1>
<GROUP_LABEL_2>RMT 200 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RMT 100 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RMT 200 mg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0744393747239998" CI_START="0.006134440021939989" DF="0" EFFECT_SIZE="0.11280746395250213" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-008.07.01" LOG_CI_END="0.3169007471391729" LOG_CI_START="-2.2122250753951795" LOG_EFFECT_SIZE="-0.9476621641280033" MODIFIED="2008-06-12 11:04:16 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.14188839422264043" STUDIES="1" TAU2="0.0" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="1.468795023682096">
<NAME>RMT</NAME>
<DICH_DATA CI_END="2.0744393747239998" CI_START="0.006134440021939989" EFFECT_SIZE="0.11280746395250212" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3169007471391729" LOG_CI_START="-2.2122250753951795" LOG_EFFECT_SIZE="-0.9476621641280034" ORDER="11357" O_E="0.0" SE="1.48562102753141" STUDY_ID="STD-Monto-1995" TOTAL_1="130" TOTAL_2="132" VAR="2.207069837443482" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.107573775330989" CI_START="0.43333483636755543" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1604395604395605" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-008.08" LOG_CI_END="0.4924214478008331" LOG_CI_START="-0.36317639604743324" LOG_EFFECT_SIZE="0.0646225258766999" METHOD="MH" MODIFIED="2014-11-05 21:50:36 +1000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.7671777016940129" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="0.29606858927709334">
<NAME>Dry mouth</NAME>
<GROUP_LABEL_1>RMT 100 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>RMT 200 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RMT 100 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RMT 200 mg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.107573775330989" CI_START="0.43333483636755543" DF="0" EFFECT_SIZE="1.1604395604395605" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-008.08.01" LOG_CI_END="0.4924214478008331" LOG_CI_START="-0.36317639604743324" LOG_EFFECT_SIZE="0.0646225258766999" MODIFIED="2008-06-12 11:04:18 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.7671777016940129" STUDIES="1" TAU2="0.0" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="0.29606858927709334">
<NAME>RMT</NAME>
<DICH_DATA CI_END="3.107573775330989" CI_START="0.43333483636755543" EFFECT_SIZE="1.1604395604395605" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4924214478008331" LOG_CI_START="-0.36317639604743324" LOG_EFFECT_SIZE="0.0646225258766999" ORDER="11358" O_E="0.0" SE="0.5025824087541043" STUDY_ID="STD-Monto-1995" TOTAL_1="130" TOTAL_2="132" VAR="0.25258907758907756" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.86943406253205" CI_START="0.45474711579672367" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1423076923076922" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-008.09" LOG_CI_END="0.4577962494323414" LOG_CI_START="-0.34223004673955265" LOG_EFFECT_SIZE="0.05778310134639437" METHOD="MH" MODIFIED="2014-11-05 21:50:49 +1000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.7770827909820723" Q="0.0" RANDOM="YES" SCALE="485.42" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="0.28312268758132747">
<NAME>Fatigue and drowsiness</NAME>
<GROUP_LABEL_1>RMT 100 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>RMT 200 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RMT 100 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RMT 200 mg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.86943406253205" CI_START="0.45474711579672367" DF="0" EFFECT_SIZE="1.1423076923076922" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" ID="CMP-008.09.01" LOG_CI_END="0.4577962494323414" LOG_CI_START="-0.34223004673955265" LOG_EFFECT_SIZE="0.05778310134639437" MODIFIED="2008-06-12 11:04:20 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.7770827909820723" STUDIES="1" TAU2="0.0" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="0.28312268758132747">
<NAME>RMT</NAME>
<DICH_DATA CI_END="2.8694340625320502" CI_START="0.4547471157967236" EFFECT_SIZE="1.1423076923076922" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4577962494323415" LOG_CI_START="-0.3422300467395527" LOG_EFFECT_SIZE="0.05778310134639437" ORDER="11359" O_E="0.0" SE="0.4699394065654059" STUDY_ID="STD-Monto-1995" TOTAL_1="130" TOTAL_2="132" VAR="0.22084304584304584" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.424548679827601" CI_START="0.30106329725517766" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0153846153846153" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-008.10" LOG_CI_END="0.5346033440691299" LOG_CI_START="-0.5213421862711037" LOG_EFFECT_SIZE="0.006630578899013076" METHOD="MH" MODIFIED="2014-11-05 21:51:00 +1000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.9803625891257821" Q="0.0" RANDOM="YES" SCALE="820.58" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="0.024614329935237402">
<NAME>Headache</NAME>
<GROUP_LABEL_1>RMT 100 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>RMT 200 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RMT 100 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RMT 200 mg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.424548679827601" CI_START="0.30106329725517766" DF="0" EFFECT_SIZE="1.0153846153846153" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-008.10.01" LOG_CI_END="0.5346033440691299" LOG_CI_START="-0.5213421862711037" LOG_EFFECT_SIZE="0.006630578899013076" MODIFIED="2008-06-12 11:04:22 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.9803625891257821" STUDIES="1" TAU2="0.0" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="0.024614329935237402">
<NAME>RMT</NAME>
<DICH_DATA CI_END="3.4245486798276" CI_START="0.3010632972551777" EFFECT_SIZE="1.0153846153846153" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5346033440691298" LOG_CI_START="-0.5213421862711037" LOG_EFFECT_SIZE="0.006630578899013076" ORDER="11360" O_E="0.0" SE="0.6202676315365285" STUDY_ID="STD-Monto-1995" TOTAL_1="130" TOTAL_2="132" VAR="0.3847319347319348" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.1755304191120444" CI_START="0.38386721029635856" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9138461538461539" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-008.11" LOG_CI_END="0.33756516014546534" LOG_CI_START="-0.4158189834687894" LOG_EFFECT_SIZE="-0.03912691166166202" METHOD="MH" MODIFIED="2014-11-05 21:51:11 +1000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.8386809649213394" Q="0.0" RANDOM="YES" SCALE="517.44" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="0.20358097083180182">
<NAME>Body weakness or debility</NAME>
<GROUP_LABEL_1>RMT 100 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>RMT 200 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RMT 100 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RMT 200 mg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1755304191120444" CI_START="0.38386721029635856" DF="0" EFFECT_SIZE="0.9138461538461539" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" I2="0.0" ID="CMP-008.11.01" LOG_CI_END="0.33756516014546534" LOG_CI_START="-0.4158189834687894" LOG_EFFECT_SIZE="-0.03912691166166202" MODIFIED="2008-06-12 11:04:25 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.0" P_Z="0.8386809649213394" STUDIES="1" TAU2="0.0" TOTAL_1="130" TOTAL_2="132" WEIGHT="100.0" Z="0.20358097083180182">
<NAME>RMT</NAME>
<DICH_DATA CI_END="2.1755304191120444" CI_START="0.38386721029635856" EFFECT_SIZE="0.9138461538461539" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.33756516014546534" LOG_CI_START="-0.4158189834687894" LOG_EFFECT_SIZE="-0.03912691166166202" ORDER="11361" O_E="0.0" SE="0.44254157527066973" STUDY_ID="STD-Monto-1995" TOTAL_1="130" TOTAL_2="132" VAR="0.19584304584304585" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2014-11-05 21:53:32 +1000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Additional comparison: RMT compared to placebo in the prophylaxis of influenza A in children and the elderly</NAME>
<DICH_OUTCOME CHI2="2.8204755351896447" CI_END="0.9165318565250458" CI_START="0.2658375250522093" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.49360769885621186" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-0.03785243536886877" LOG_CI_START="-0.575383714992857" LOG_EFFECT_SIZE="-0.3066180751808629" METHOD="MH" MODIFIED="2014-11-05 21:53:32 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5883035009597282" P_Q="1.0" P_Z="0.025351670319588567" Q="0.0" RANDOM="YES" SCALE="667.6149728118739" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="156" TOTAL_2="125" WEIGHT="100.00000000000003" Z="2.2360015394224777">
<NAME>Infection</NAME>
<GROUP_LABEL_1>RMT</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>RMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.8204755351896447" CI_END="0.9165318565250458" CI_START="0.2658375250522093" DF="4" EFFECT_SIZE="0.49360769885621186" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="27" I2="0.0" ID="CMP-009.01.01" LOG_CI_END="-0.03785243536886877" LOG_CI_START="-0.575383714992857" LOG_EFFECT_SIZE="-0.3066180751808629" NO="1" P_CHI2="0.5883035009597282" P_Z="0.025351670319588567" STUDIES="5" TAU2="0.0" TOTAL_1="156" TOTAL_2="125" WEIGHT="100.00000000000003" Z="2.2360015394224777">
<NAME>RMT</NAME>
<DICH_DATA CI_END="1.3151975833774827" CI_START="0.004599599932744944" EFFECT_SIZE="0.07777777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.11899100219811301" LOG_CI_START="-2.337279941048249" LOG_EFFECT_SIZE="-1.109144469425068" ORDER="11364" O_E="0.0" SE="1.4428257108001756" STUDY_ID="STD-Clover-1986" TOTAL_1="35" TOTAL_2="41" VAR="2.081746031746032" WEIGHT="4.789111423874426"/>
<DICH_DATA CI_END="1.7734688581076357" CI_START="0.2621281061308813" EFFECT_SIZE="0.6818181818181818" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.24882356671788225" LOG_CI_START="-0.5814864102509323" LOG_EFFECT_SIZE="-0.16633142176652502" ORDER="11365" O_E="0.0" SE="0.48772819057215455" STUDY_ID="STD-Clover-1991" TOTAL_1="22" TOTAL_2="24" VAR="0.23787878787878788" WEIGHT="41.9108983661052"/>
<DICH_DATA CI_END="1.6015426573601381" CI_START="0.13230503933150534" EFFECT_SIZE="0.4603174603174603" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.2045385106610324" LOG_CI_START="-0.8784236137702837" LOG_EFFECT_SIZE="-0.33694255155462566" ORDER="11366" O_E="0.0" SE="0.636137312639928" STUDY_ID="STD-Crawford-1988" TOTAL_1="27" TOTAL_2="29" VAR="0.40467068053274946" WEIGHT="24.636609919737786"/>
<DICH_DATA CI_END="1.819006963786754" CI_START="0.14780672058942068" EFFECT_SIZE="0.5185185185185185" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.25983436169590324" LOG_CI_START="-0.8303058186574018" LOG_EFFECT_SIZE="-0.2852357284807493" ORDER="11367" O_E="0.0" SE="0.6403537382204543" STUDY_ID="STD-Monto-1995" TOTAL_1="54" TOTAL_2="14" VAR="0.4100529100529101" WEIGHT="24.31323728675346"/>
<DICH_DATA CI_END="3.682649011147799" CI_START="0.0097484927017579" EFFECT_SIZE="0.18947368421052632" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5661603287420783" LOG_CI_START="-2.0110625291131616" LOG_EFFECT_SIZE="-0.7224511001855417" ORDER="11368" O_E="0.0" SE="1.513873464163064" STUDY_ID="STD-Patriarca-1984" TOTAL_1="18" TOTAL_2="17" VAR="2.291812865497076" WEIGHT="4.350143003529141"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-11-05 23:32:25 +1000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-11-05 23:32:25 +1000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAADOCAMAAADYBvzeAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-11-05 23:32:25 +1000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAARAAAAK9CAIAAABjAqTvAAAdvklEQVR42u3dv47cRrrG4QYMGAoU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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2014-11-05 21:55:21 +1000" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2014-11-05 21:55:21 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-06-12 11:11:43 +1000" MODIFIED_BY="Liz Dooley">Amantadine and rimantadine for influenza A in children and the elderly</TITLE>
<DATE_SUBMITTED>
<DATE DAY="24" MONTH="1" YEAR="2008"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2008-06-12 11:13:12 +1000" MODIFIED_BY="Liz Dooley">
<P>A year ago CDC provided a recommendation not to use these drugs for 'flu supporting this recommendation by newly acquired resistance of the virus. I believe that this recommendation ought to be at least discussed in the review and better, addressed e.g. by analysis of RCTs data for time periods e.g. before 2000 and after etc.<BR/>Also it would be nice to have the abstract rich with data, not just a statement.<BR/>
<BR/>Submitter agrees with default conflict of interest statement:<BR/>I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.<BR/>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2014-11-05 21:55:21 +1000" MODIFIED_BY="[Empty name]">
<P>We do agree that the issue of viral resistance is of utmost importance. We have stressed this concern in the Background and in the Discussion sections. We expect, from what is written in the text, that readers would be aware of the problem.</P>
<P>
<I>
<B>Background:</B>
</I> ...<I>Both drug classes have shown partial effectiveness for prevention and treatment of influenza A viruses, although neuraminidase inhibitors are less likely to promote the development of drug-resistant influenza (</I>
<LINK REF="REF-Moscona-2005" TYPE="REFERENCE">Moscona 2005</LINK>
<I>)</I>. </P>
<P>
<I>
<B>Discussion</B>:</I> <I>Data on comparison to other antivirals was available just for </I>rimantadine<I> and zanamivir for prophylaxis of influenza A in the elderly group. This fact allowed a comparison of drugs of the two different classes of antivirals: M2 ion channel inhibitors and neuraminidase inhibitors. Zanamivir more effectively prevented influenza A in the elderly group</I> (<LINK REF="STD-Gravenstein-2005" TYPE="STUDY">Gravenstein 2005</LINK>; <LINK REF="STD-Schilling-1998" TYPE="STUDY">Schilling 1998</LINK>). <I>Although the M2 ion channel inhibitors are increasingly subject to viral resistance (</I>
<LINK REF="REF-Goodman-2006" TYPE="REFERENCE">Goodman 2006</LINK>
<I>) it does not mean that we should abandon </I>amantadine<I> and </I>rimantadine<I>. These antivirals proved effective for prophylaxis against influenza illness in the 1968 pandemic of &#8220;Hong Kong Influenza&#8221; and in 1977 pandemic-like event involving &#8220;Russian influenza&#8221;. Although the same resistance marker (Ser31Asn) was present in two isolates of influenza A (H5N1) obtained from patients in China in 2003 and in one lineage of avian and human H5N1 viruses in Thailand, Vietnam</I> and<I> Cambodia, most tested isolates from a second lineage that has been circulating in Indonesia, China, Mongolia, Russia</I> and<I> Turkey appear to be sensitive to amantadine (</I>
<LINK REF="REF-Hayden-2005" TYPE="REFERENCE">Hayden 2005</LINK>
<I>). Furthermore, the next pandemic virus may be one that, like H2N2, is susceptible to this class of drugs. If the circulating strain were known to be susceptible to M2 inhibitors, these drugs would offer a less costly alternative to other antivirals (neuraminidase inhibitors) for prophylaxis against illness.</I>
</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2008-06-12 11:12:14 +1000" MODIFIED_BY="Liz Dooley">
<P>Vasiliy Vlassov<BR/>Feedback comment added 12 June 2008</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-06-05 10:59:52 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-07-21 13:14:40 +1000" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-08 16:18:08 +1000" MODIFIED_BY="[Empty name]">
<P>We combined the MEDLINE search strategy with the Cochrane highly sensitive search strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximising version (2008 revision); Ovid format (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>).</P>
<P>
<B>MEDLINE (OVID) </B>
<BR/>1 exp Influenza, Human/<BR/>2 influenza*.tw.<BR/>3 flu.tw.<BR/>4 exp Influenzavirus A/<BR/>5 or/1-4<BR/>6 exp Amantadine/<BR/>7 amantadine.tw,nm.<BR/>8 symmetrel.tw,nm.<BR/>9 Rimantadine/<BR/>10 rimantadine.tw,nm.<BR/>11 flumadine.tw,nm.<BR/>12 or/6-11<BR/>13 5 and 12</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-06-05 10:59:55 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-07-21 13:16:39 +1000" MODIFIED_BY="[Empty name]">EMBASE.com search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-13 13:12:42 +1000" MODIFIED_BY="[Empty name]">
<P>#13. #9 AND #12 <BR/>#12. #10 OR #11 <BR/>#11. random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR 'cross over':ab,ti OR 'cross-over':ab,ti OR volunteer*:ab,ti OR allocat*:ab,ti OR assign*:ab,ti OR ((singl* OR doubl*) NEAR/2 (blind* OR mask*)):ab,ti <BR/>#10. 'randomized controlled trial'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp <BR/>#9. #3 AND #8 <BR/>#8. #4 OR #5 OR #6 OR #7 <BR/>#7. rimantadine:ab,ti OR flumadine:ab,ti <BR/>#6. 'rimantadine'/de <BR/>#5. amantadine:ab,ti OR symmetrel:ab,ti <BR/>#4. 'amantadine'/de <BR/>#3. #1 OR #2 <BR/>#2. influenza*:ab,ti OR flu:ab,ti <BR/>#1. 'influenza'/de OR 'influenza virus a'/exp </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-05-13 12:59:20 +1000" MODIFIED_BY="[Empty name]">Previous searches</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-05 21:58:42 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library </I>2007, Issue 3); MEDLINE (1966 to July 2007); and EMBASE (1980 to July 2007).</P>
<P>The MEDLINE and CENTRAL search strategies are shown below. We combined the MEDLINE search string with the Cochrane highly sensitive search strategy phases one and two as published in Appendix 5b of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (Higgins 2005). We adapted the search strategy to search EMBASE.</P>
<P>
<B>MEDLINE (OVID) </B>
<BR/>1 exp INFLUENZA/<BR/>2 influenza.mp.<BR/>3 or/1-2<BR/>4 exp AMANTADINE/<BR/>5 amantadine.mp.<BR/>6 exp RIMANTADINE/<BR/>7 rimantadine.mp.<BR/>8 or/4-7<BR/>9 3 and 8</P>
<P>
<B>EMBASE (Embase.com)</B>
<BR/>1 exp INFLUENZA/<BR/>2 influenza.ti. or influenza.ab.<BR/>3 or/1-2<BR/>4 exp AMANTADINE/<BR/>5 amantadine.ti. or amantadine.ab.<BR/>6 exp RIMANTADINE/<BR/>7 rimantadine.ti. or rimantadine.ab.<BR/>8 or/4-7<BR/>9 3 and 8<BR/>10 Randomized Controlled Trial/<BR/>11 Controlled Study/<BR/>12 exp RANDOMIZATION/<BR/>13 Single Blind Procedure/<BR/>14 Double Blind Procedure/<BR/>15 Crossover Procedure/<BR/>16 Phase 3 Clinical Trial/<BR/>17 Phase 4 Clinical Trial/<BR/>18 or/10-17<BR/>19 9 and 18</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>